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ABSTRACT 
Background 
New malaria vector control tools hold the promise of sustaining gains in malaria control 
achieved to date and achieving the goal of elimination set for 2030. However, 
insecticide resistance has the potential to derail these malaria control achievements. 
Access to innovative vector control tools is key to surmounting the threat of insecticide 
resistance and will play a major role if malaria elimination is to be achieved. The aim of 
this thesis is to gather new evidence and provide insight into strategies for accelerating 
access to new malaria vector control tools. This is done by examining access to new 
malaria vector control tools in two national settings (Nigeria and Burkina Faso) as well 
as at the global level. 
Methods 
Three retrospective policy analyses were carried out using an analytical framework to 
guide the selection of key informants (KI), data collection and analysis. Semi-structured 
interviews were carried out with KIs in Nigeria (2013), Burkina Faso (2014) and at the global 
level (2014). Interviews were conducted in English (French in Burkina Faso) audio recorded, 
transcribed and entered into NVivo10 for data management and analysis. Data were coded 
according to the framework themes and then analysed to provide a description of the key 
points and explain patterns in the data.  
Results  
A total of 40 interviews were conducted with policymakers, researchers, donors, 
multilaterals, Non-governmental organizations and private sector. The synthesized 
findings of the three case studies show that, in the context of insecticide resistance, the 
evidence required to facilitate policy change is nuanced and context specific; national 
policymaking may be well defined and appear to be evidence based, but can be open to 
being circumvented and hindered by inefficiencies in global policymaking and lack of 
donor funding; price rather than cost-effectiveness is the key financial variable at the 
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national level; and no readily identifiable policy champions exist to facilitate global and 
national adoption of new vector control tools.  
Conclusions 
This thesis has identified five areas that need to be strengthened in order to facilitate 
access to new malaria vector control tools by fostering their global and national 
adoption. The thesis demonstrates that, without a well-coordinated architecture to: 
facilitate the development of robust and appropriate evidence; support a transparent 
and timely global policymaking process; diversify the available funding base, and 
facilitate price reductions without stifling innovation, accelerating access to new vector 
control tools and achieving malaria elimination goals is unlikely. 
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1 Introduction, Context and Background 
  
1.1 Introduction 
This thesis aims to gather evidence and provide new insights into the available 
strategies to accelerate access to new malaria vector control tools. This introductory 
chapter sets out the global malaria context including the contribution of malaria vector 
control to malaria control achievements to date. The threat, scale, impact and options 
for addressing insecticide resistance are introduced. The chapter concludes by setting 
the context for the research, which conducts three retrospective health policy analysis 
case studies 2 at the national level (Nigeria and Burkina Faso) and 1 at the global level.  
 
 
1.2 Global Malaria Context 
Malaria control has been recognized as crucial to achieving key international health-
related targets. Indeed, its control forms part of Sustainable Development Goal (SDG) 3 
– Ensuring healthy lives and promoting well-being for all, at all ages (1). Significant 
progress in malaria control is also central to achieving SDG1 – Ending poverty; SDG2 – 
Ending hunger; SDG5 – Achieving gender equality; SDG8 – Promoting sustained 
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economic growth and decent work for all; and SDG10 – Reducing inequality within and 
among countries (1). Achieving effective malaria control is dependent on attaining and 
sustaining universal access to effective preventive measures and to appropriate case 
management (2). Indeed, the availability of vector control tools remains an important 
factor to achieving malaria elimination as well as the SDGs (3). Vector control is a core 
preventive measure considered “an essential component to malaria control and 
elimination” (4) and “remains the most generally effective measure to prevent malaria 
transmission” (5). The two core methods of vector control, as recommended by the 
World Health Organization (WHO), are indoor residual spraying (IRS) and the provision 
of LLINs to all people at risk of malaria (6).  
 
Progress in malaria control has been recorded over the past two decades. Between 
2000 and 2015, malaria mortality rates declined by 60% globally – resulting in an 
estimated 6.2 million malaria deaths being averted, particularly in children under the 
age of 5 (3). WHO’s Action and Investment to Defeat Malaria report on malaria showed 
that 55 countries were set to achieve a 75% reduction in malaria burden by the end of 
2015 (2). As of 2013, an estimated 198 million malaria cases occurred worldwide, 
resulting in over 500,000 deaths, mostly in children under the age of 5 (4). Indeed, 
malaria remains one of the most significant public health challenges of our day, and is a 
barrier to economic development. Sub-Saharan Africa carries most of the malaria 
burden, with two countries, the Democratic Republic of Congo and Nigeria, accounting 
for almost half of all malaria-related mortality (4).  
 
The global community has pledged to reduce malaria mortality and morbidity by 90% 
by 2030 (4) and progress in achieving malaria elimination goals has been made, with 
eight countries recording malaria elimination since 2000 (4). The rapid scale-up of 
vector control tools, such as IRS and LLINs, is recognised to have led to significant 
reductions in malaria transmission in a number of countries (4) and will be directly 
linked to the possibility of achieving malaria elimination (figure 1) (2).  
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Figure 1. Link between malaria elimination and vector control 
*IVM, Integrated Vector Management, adapted from AIM 2016-2030(2) 
 
The ability to sustain malaria control achievements and attain elimination is threatened 
by a number of challenges, including the availability of sustained funding and political 
commitment for malaria control, parasite resistance to antimalarial medicines, and 
vector resistance to insecticides (4). The Global Plan for Insecticide Resistance 
Management recognises that a collective strategy is required to tackle the issue of 
insecticide resistance, with the strategy being predicated on five pillars: i) implementing 
insecticide resistance management (IRM) strategies in malaria-endemic countries; ii) 
ensuring proper and timely entomological and resistance monitoring as well as effective 
data management; iii) developing and deploying new, innovative vector control tools; 
iv) filling gaps in knowledge on the mechanisms of insecticide resistance and the impact 
of current IRM strategies; and v) ensuring that enabling mechanisms (e.g., human and 
financial resources) are in place (5). 
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1.3 Malaria Vector Control Context 
Current malaria vector control efforts are based on two main interventions, namely 
Indoor residual spraying (IRS) and LLINs, with larval source management (LSM) as a 
supplemental intervention (7). IRS is the application of insecticides on the internal walls 
of houses in order to kill vectors that come into contact with the insecticide by resting 
on the wall surface following a blood meal. IRS reduces malaria transmission by killing 
mosquitoes, thereby reducing the density of adult vectors (8). Bednets act as a vector 
control tool by forming a physical barrier between humans and malaria-transmitting 
mosquito vectors. The addition of an insecticide to bednets kills mosquitoes that come 
into contact with the insecticide. Insecticide-treated nets (ITNs) provide personal 
protection for those that use them (9). LLINs are ITNs incorporated with long-lasting 
insecticides that last up to 4 years or 20 washes. LSM involves the management of 
water bodies that are potential breeding sites for malaria vectors (10) and includes 
temporary or permanent habitat modification (e.g., clearing drains or filling land) or the 
addition of chemicals to water bodies to prevent the development of adult vectors 
(larviciding). 
 
1.4 A Brief History of the Contribution of Vector Control to Malaria 
Control and Elimination  
Vector control has been the linchpin of malaria prevention since the late 19th century 
(11, 12). Vector control efforts have been recorded as far back as 1899, implemented by 
Ronald Ross in Sierra Leone; this early effort was documented to be relatively successful 
but not sustained due to a lack of funds (12). Several noteworthy vector control 
intervention programmes were also implemented in a few countries in the early 20th 
century (11).  
 
LSM is one of the earliest forms of vector control and is considered to have contributed 
to most successful malaria eradication efforts (13-15) before being largely abandoned 
for a single blanket approach to malaria eradication using IRS (16). By the mid-20th 
century, the discovery of the insecticidal properties of dichlorodiphenyltrichloroethane 
(DDT) as well as the establishment of the first expert committee, convened to deal with 
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the social and economic burden of malaria, revolutionised malaria control efforts (17). 
This led to the first malaria eradication objective articulated by WHO in 1956 (17) based 
on IRS using DDT and the mass administration of antimalarial drugs. The reliance on IRS 
using DDT for the eradication of malaria, while cited as a contributory factor for the 
failure of malaria eradication (due to insecticide resistance and the lack of funding and 
political will to sustain efforts), attests to the fundamentality of vector control in any 
malaria eradication effort. Vector control, notably IRS, was central to the success of 
malaria eradication efforts in Asia and America during the 1950s and 1960s (18). With 
the use of DDT, eradication was documented in most of Europe, the West Indies, the 
Middle East, North America, Australia, Japan, Singapore, Korea, Taiwan, and Sardinia 
(12, 19). Furthermore, vector control is recognised as the only approach that has led to 
lasting malaria eradication (20). However, by 1969, it was recognised that, in some 
areas and particularly sub-Saharan Africa, malaria control was a more feasible goal than 
malaria eradication. An important lesson learnt from the eradication era was the 
recognition that every available effective vector control method is required to tackle 
malaria, taking into account each context’s epidemiological and entomological diversity 
(21).  
 
In the 1980s, studies of ITNs showed that pyrethroids were safe and highly efficacious 
in reducing all cause childhood morbidity, and that ITNs had an impact on various 
measures of mosquito biting by both repelling and killing mosquitoes (22). In addition, 
researchers demonstrated the highly the cost-effective nature of ITNs (23, 24) and the 
optimal doses of various insecticides with different materials (25, 26). 
 
ITN use can reduce the incidence of uncomplicated malaria by 39% compared to 
untreated bednets and up to 50% compared to no nets (27, 28). The early forms of ITNs 
proved successful (29); however, the insecticides used had short lived residual effects 
and programmes promoting the retreatment of bednets resulted in relatively low 
uptake rates (29). Thus, over the in the late 1990s efforts focused on the development 
of bednets treated with long-lasting pyrethroid-based insecticides – LLINs. In some 
contexts, retreatment programmes are still important for untreated bednets, 
particularly in regions like South East Asia, where they represent a significant 
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proportion of bednets sold in the private sector. This thesis recognises the importance 
of retreatment of bednets in these contexts, but further discussion of this issue is 
beyond its scope.  
 
It took 20 years from the initial evaluation of insecticide treated bednets (30) to the 
landmark Cochrane review confirming that they led to a 20% and 50% reduction in child 
deaths and malaria episodes, respectively (28), and an additional 3 years for a WHO 
recommendation for universal coverage of LLINs for all populations at risk (31). In sub-
Saharan Africa, the percentage of people sleeping under an ITN increased from 2% to 
55% between 2000 and 2015 (32). 
 
In 2010, a systematic review reaffirmed the benefit of IRS for malaria vector control, 
particularly in areas of unstable malaria transmission (33). The efficacy of IRS for 
malaria control is dependent on the susceptibility of malaria vectors to the insecticide 
being used, the residual efficacy of the insecticide (i.e., the time-frame during which the 
insecticide continues to kill vectors following spraying), and the quality and 
sustainability of the IRS spraying programme (33). As of 2014, 3.4% of the global 
population at risk for malaria was covered with IRS – a decline of 5% from peak levels in 
2010 (32). 
 
Over the past decade, there have been significant advancements made towards 
achieving malaria control-related goals and the scale-up of interventions has resulted in 
declines in malaria mortality and morbidity (4). The scale-up of vector control, and in 
particular the increased coverage and use of LLINs, is considered a major contributor to 
these achievements. Bhatt et al. (34) estimated that 68% of the deaths averted 
between 2000 and 2015 were due to bednet use and 10% due to IRS. 
 
1.5 Insecticide Resistance 
There is global consensus that insecticide resistance has the potential to derail the 
malaria control achievements to date (35-40). Insecticide resistance in malaria vectors 
is defined, in simple terms, as a situation where “vectors are no longer killed by the 
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standard dose of insecticide [they are no longer susceptible to the insecticide] or 
manage to avoid coming into contact with the insecticide” (5). Insecticide resistance has 
been reported in 53 countries globally (5).  
 
An in-depth analysis of insecticide resistance is beyond the scope of this thesis, 
however, the main forms of insecticide resistance are described briefly below. For the 
purposes of this thesis, it is sufficient to consider that insecticide resistance is complex 
and can occur through various mechanisms and at low levels for many years.  
 
Target site resistance: This occurs due to changes in the site targeted by the insecticide  
as a result of mutations. For example it can, result in vectors being able to tolerate up 
to 1000 times the insecticide concentration that would kill susceptible mosquitoes, 
without being knocked down (5, 37, 40).  
 
Metabolic resistance: Occurs when changes in the vector result in it being able to more 
rapidly metabolise the insecticide, resulting in a lower dose of the insecticide reaching 
the targeted site (5). Metabolic and target site resistance are considered the main 
forms of resistance. However, as mentioned above, it is currently difficult to ascertain 
the impact this form of resistance has on malaria control failure (37).  
 
Cuticular resistance: This occurs when the tarsal cuticle (the most likely route of entry 
for the insecticide into the vector’s system) thickens, resulting in a reduction in the 
insecticide’s ability to penetrate it and, therefore, in less insecticide being taken up by 
the malaria vector (5).  
 
Behavioural resistance: This refers to changes in vector behaviour aimed at reducing 
contact or avoiding exposure to insecticides (5). To date, there is insufficient evidence 
to assess the extent of this form of resistance. However, it is recognised that genetic 
changes that lead to vectors shifting from indoor to outdoor feeding could have major 
implications for malaria control, particularly since the core vector control tools 
currently only tackle indoor biting mosquitoes (37).  
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Operational resistance: This refers to changes in vector sensitivity to insecticides as 
reflected by reduced effectiveness or complete failure of the vector control tool (37). 
Operational resistance can be conceptualised simply as the manifestation of the various 
forms of resistance described above on the effectiveness of vector control tools. 
 
1.5.1 The Scale and Impact of Insecticide Resistance 
There are major gaps in knowledge of the impact of resistance on vector control. For 
example, there is insufficient proof to show whether knock down resistance alone leads 
to operational failure of malaria vector control tools. Further, the extent to which 
behavioural resistance occurs remains unclear and there is limited evidence of the 
epidemiological impact of any of these forms of resistance, i.e., whether they lead to a 
loss of effectiveness of malaria control tools in field settings or to an increase in malaria 
cases and deaths (5, 41). However, when a tipping point is reached, resistance rises 
rapidly to a level that can lead to the failure of vector control tools (42). Ultimately, 
there is consensus that additional research is required to improve our understanding on 
how this growing trend affects the efficacy/effectiveness of malaria control 
interventions (37, 41).  
 
Currently, there are only four classes of insecticides approved by WHO for use in IRS 
(organochlorines, carbamates, organophosphates, and pyrethroids), with pyrethroids 
being the only insecticides recommended for use on LLINs and the cheapest and longest 
lasting for IRS (5). However, of the countries reporting insecticide resistance, 75% 
reported resistance to two or more classes, with the most common form of 
documented resistance being to pyrethroids, the most frequently used insecticide in 
malaria vector control (43). For example, Benin, Burkina Faso, Cameroon, Côte d’Ivoire, 
and Ghana reported widespread resistance to at least two classes of insecticide, 
whereas Ethiopia reported resistance to all four (5). Furthermore, resistance to one or 
more insecticide classes has been observed in all other regions of the world (5). 
Worryingly, these observations are likely an underestimation of the true incidence of 
resistance given that several countries and programmes do not perform sufficiently 
robust insecticide resistance monitoring (5). 
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More often, the mortality and feeding success of resistant vectors (entomological 
impact) is used as a proxy in defining the impact of insecticide resistance (5). In Benin, 
trials showed that IRS and LLIN efficacy was reduced when testing in resistant 
compared to susceptible areas (44). A recent study in Burkina Faso also demonstrated 
that insecticide resistance is compromising LLIN activity in the southwestern region of 
the country (45). The most compelling evidence to date of the epidemiological impact 
of insecticide resistance is the 90% decrease in malaria cases observed in Mozambique 
and South Africa following a change of insecticides (46-50). More recently, Senegal 
experienced a rise in malaria cases associated with a significant increase in resistance in 
the malaria vector population (51). 
 
It is argued that, without concerted effort to halt and reverse the growing trend of 
insecticide resistance, an increase in malaria cases and deaths will be observed (4). 
However, as mentioned above, establishing the link between insecticide resistance and 
epidemiological impact has not been easy to achieve (5).  
 
1.5.2 Insecticide Resistance Management  
The potential for insecticide resistance to reverse malaria control achievements and 
compromise the attainment of malaria elimination goals necessitates urgent action. 
Lessons of successful IRM strategies can be gleaned from past malaria eradication 
efforts, agriculture, and other disease vector control activities such as the 
onchocerciasis control programme in West Africa (5, 52-54). These IRM strategies 
include i) the annual rotation of two or more insecticides with different modes of 
action; ii) combining two or more insecticide-based vector control interventions in 
households; iii) spraying with a given insecticide class in a geographic area and a 
different one in neighbouring areas; and iv) mixing two or more insecticides from 
different classes to make a single product (the latter is not currently available for 
malaria vector control) (5).  
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1.5.2.1  Insecticide Resistance Management Options for Indoor 
Residual Spraying 
While all four classes of insecticide approved for public health use are appropriate for 
IRS, there is widespread resistance to pyrethroids, the cheapest and longest lasting (5). 
This widespread resistance limits the available options for IRM strategies such as 
rotation. While resistance to other classes of insecticide for IRS is relatively lower, their 
higher cost and shorter residual effect make them a less attractive option for national 
malaria control programmes (21, 55). With this in mind, a non-pyrethroid, long-lasting 
insecticide for use in IRS (Actellic 300CS®) has recently been developed.  
 
Actellic 300CS® provides an alternative to pyrethroid-based insecticides and extends the 
residual effect of IRS from 3 to 9 months compared to other non-pyrethroid-based 
formulations. While more expensive the longer residual effect of Actellic 300CS® which 
surpasses the average peak transmission season in most endemic countries potentially 
provides a balance against the relative high cost of the product (56, 57). The availability 
of this new formulation provides a viable option for national malaria control 
programmes seeking to rotate insecticides used for IRS as an IRM strategy aimed at 
delaying the emergence/spread of insecticide resistance (56). However, like other non-
pyrethroid-based IRS insecticides, Actellic 300CS® has a high cost. UNITAID has launched 
a US$ 65.1 million initiative to support countries in the implementation of next 
generation IRS insecticides such as Actellic 300CS® at lower prices (58). 
 
WHO Pesticide Evaluation Scheme (WHOPES) was set up in 1960 and its key mandate is 
to ‘collect, consolidate, evaluate and disseminate information on the use of pesticides 
for public health’ (59). WHOPES establishes the relevant testing guidelines for safety 
and efficacy, makes recommendations on use after their safety and efficacy 
assessment, and develops specifications for their quality control and international 
trade. Annex 1 provides a list of WHOPES approved insecticides for IRS. 
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1.5.2.2  Insecticide Resistance Management Options for Long Lasting 
Insecticidal Nets 
The increasingly widespread resistance to malaria vector insecticides, particularly to 
pyrethroids, is especially dangerous for LLINs, considering that, to date, only 
pyrethroids have been approved by WHOPES for use on LLINs. Annex 2 provides a list of 
the 16 LLINs approved by WHOPES as of April 2016. Combination LLINs that incorporate 
the use of non-pyrethroid-based insecticides need to be developed and approved, with 
WHOPES providing recommendation for their use in areas of insecticide resistance. 
 
Two next generation LLINs, PermaNet® 3.0 and Olyset® plus, are currently available on 
the market. Both of these products are treated with a pyrethroid and a synergist – 
piperonyl butoxide (PBO). PBO does not have insecticidal properties but inhibits the 
major enzyme families that detoxify insecticides in the vector, and thus can increase the 
potency of conventional LLINs. PermaNet® 3.0 and Olyset® plus received WHOPES 
interim approval as standard LLINs in 2008 and 2012, respectively (60, 61). In 2014, the 
Vector Control Advisory Group (VCAG) recognised that PermaNet® 3.0 has “increased 
bio-efficacy compared with pyrethroid-only LLINs in areas where malaria vectors have 
P450-based metabolic resistance mechanisms that reduce the efficacy of pyrethroid-
only LLINs” (62). In December 2015, the WHO Global Malaria Programme released 
recommendations on the conditions for use of LLINs treated with PBO (63). The 
recommendation is for pilot exploratory implementation with robust monitoring and 
evaluation and deployment where universal coverage of LLIN and/or IRS is not 
compromised (63). 
 
Two additional next generation LLINs treated with a combination of two insecticides are 
currently being tested in Phase III trials or are being considered by WHOPES. One of 
these, Interceptor 2.0, was submitted to WHOPES for approval in 2014, with potential 
first use anticipated between 2016 and 2018. The second, Olyset® Duo, contains an 
insect-sterilizing agent and thus has a different mode of action than conventional LLINs 
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(64). AvecNet is currently conducting a randomised control trial of Olyset® Duo in 
Burkina Faso1 (65). 
 
1.5.2.3  Insecticide Resistance Management and Larval Source 
Management 
The use of LSM to control malaria is significant, particularly in light of behavioural 
resistance and the over-reliance on pyrethroid-based insecticides. Unlike IRS and LLINs, 
LSM addresses the issue of outdoor biting vectors at the larval stage and is not 
dependent on pyrethroids, but rather a wider range and different set of insecticides 
than those used in IRS and LLINs (16). Annex 3 provides a list of WHOPES-recommended 
larvicides for vector control.  
 
In the context of growing insecticide resistance, the reliance of LSM on a different set of 
insecticides and its ability to tackle both indoor and outdoor biting are important 
considerations for its modern-day role in malaria elimination. Furthermore, non-
chemical biocontrol/bacterial pesticides, such as Bacillus thuringiensis israelensis and 
Bacillus sphaericus, which have been shown to be safe and effective at low cost and 
dosage, can effectively be used for LSM (66). A significant drawback for LSM use is that, 
in order to achieve significant impact, the implementation (logistics) of an LSM 
programme can be challenging in settings where there are widespread vector breeding 
areas, to the point of rendering LSM virtually ineffective (16). Thus, WHO recommends 
that, in sub-Saharan Africa, LSM should only be implemented as a supplement to LLINs 
and IRS in clearly defined habitats, particularly in urban areas where malaria vector 
breeding sites are few, fixed and findable (7, 67). The rise of insecticide resistance 
necessitates the development of new vector control tools. 
 
1.6  New Paradigms in Vector Control 
The Innovative Vector Control Consortium define a vector control paradigm as a mode 
of delivering an active ingredient to a vector by targeting vector behaviour or its 
                                                 
1 TRIAL REGISTRATION: ISRCTN21853394 - AvecNet, registered on 3 April 2013. 
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environment (e.g., ITNs) (68). Vontas et al. (64) note that paradigms are composed of a 
group of products categorised by the way in which they work. Product categories, in 
turn, possess a common target product profile.  
 
WHO states that a product or group of products is considered a new paradigm if they 
satisfy at least one of the following criteria:  
i) tackles a new kind of vector or works in a new setting, covers a new and 
different human population group, or works on a different mechanism;  
ii) is an existing intervention sufficiently changed to the point where entomological 
effect is not sufficient to imply an epidemiological effect based on current 
knowledge;  
iii) when a product is not adequately described by an existing target, product 
profile validation results in the development of a new target product profile 
(69).  
 
There are currently seven new malaria vector control paradigms with tools and 
prototypes at various stages of development – ITNs against resistant vector populations 
e.g next generation LLINs; insecticide-treated walls against resistant vector populations; 
attract and kill baits; spatial repellents interrupting human–vector contact; insecticide-
treated materials for specific risk groups; vector traps for disease management; and 
lethal house lures. Annex 4 provides a summary of the new paradigms and examples of 
product categories and prototypes, as well as the operational settings within which 
these tools operate as articulated by the VCAG (70).  
 
While the array of potential new vector control tools is cause for enthusiasm, the 
majority of new paradigms have products currently undergoing small-scale trials and 
which will need to be tested in large-scale trials expected to last 3 years prior to policy 
adoption and wide scale use (64), a process that for ITNs took two decades. 
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1.7 Research Context 
This PhD has been conducted as part of the African Vector Control: New Tools 
(AvecNet) consortium research project. AvecNet is a multi-partner, interdisciplinary 
consortium funded by the European Commission with the overarching objective of 
developing and assessing new tools for malaria vector control in Africa. AvecNet 
specifically aims to ensure the ‘sustainability of current intervention strategies by 
investing in the development and evaluation of new insecticides and approaches to 
overcome insecticide resistance, designing new tools and interventions that target 
mosquitoes that evade these current practices and increasing the knowledge base on 
the biology and behavior of mosquitoes and planning for vector control in a changing 
environment’(71)  Specifically activities include optimizing existing insecticide based 
vector control tools; developing new tools to detect insecticide; the testing of new 
insecticides and formulations; optimizing the delivery of insecticides, by observing the 
mosquito’s response to insecticide treated surfaces and the field evaluation of new 
tools, or improved methods of targeting existing vector control interventions. 
 
 
AvecNet emphasises the importance of ensuring a clear pathway for the transfer of a 
tool from basic science to epidemiological effectiveness and, ultimately, to its 
implementation (71). As part of this approach, AvecNet has assessed potential new 
vector control tools from the perspective of community and end-user acceptability via 
social research activities conducted alongside intervention trials (65, 72, 73). AvecNet 
also recognises that successful policy adoption is critical to accelerating access to new 
malaria vector control tools (64, 74). This in turn depends on perceptions and actions of 
policymakers and actors at the national and global levels, which are addressed in this 
thesis through the application of policy analysis. Policy analysis is a multidisciplinary 
endeavour that underpins this research. Policy analysis can be performed either 
prospectively or retrospectively, and is used to aid the understanding of interactions 
that bring about the success or failure of a given policy process(75). 
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1.8 Policy Analysis 
Walt et l define health policy analysis as a multi-disciplinary approach to public policy 
that seeks to explain the interaction between institutions, interests and ideas in the 
policy process (75). Parsons further states that policy analysis is the processes through 
which ideas, knowledge, interests, power and institutions influence decision-making.  
Gilson argues that a key attribute of policy analysis is the understanding that it is a 
process of continuing interactions between these three elements (76). Policy analysis is 
used to understand past policy outcomes (retrospective policy analysis) and plan for 
future policy implementation (prospective policy analysis)(75). Walt et al also recognize 
that health policies outcomes are influenced by both political and social factors, as well 
as state and non-state actors including the private sector and international 
organisations (75). Walt et al argue that policy analysis is central to a comprehensive 
approach in determining how low and middle income countries can achieve health 
reforms (77). Health policy analysis has been used in low and middle income countries 
to examine agenda setting (78), policy adoption and policy implementation (79). Within 
the context of this research policy analysis forms the lens through which access to new 
vector control tools are analysed in two national contexts and at the global level. 
 
1.9 Thesis Structure  
In Chapter 2, the thesis firstly examines the concept of health policy: its definitions, the 
main theoretical underpinnings and the frameworks used to understand how policies 
are made, including the role of evidence in the policy process. The concept of access as 
it pertains to the introduction of new health interventions is also presented, followed 
by outlining the foundation for the modified framework used to carry out the three 
case studies. The current literature regarding the adoption of new health interventions, 
particularly in relation to malaria and vector control tools is reviewed, highlighting the 
gaps in knowledge that this thesis aims to address. The chapter concludes by outlining 
the study’s research questions, aims and objectives. 
 
Chapter 3 provides a comparative overview of the methods used to answer the posed 
research questions, presenting the modified analytical framework, an overview of data 
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collection and analysis. The chapter concludes by setting out ethical considerations and 
the steps taken to ensure rigor in the research process. 
 
The first of the two national level case studies, in Nigeria, is presented in Chapter 4. The 
case study provides an analysis of a contentious decision of nationwide scale-up of 
larviciding in Nigeria using a product not universally accepted as appropriate for the 
Nigerian context. The analysis of the decision examines the actors, policy process, 
context, and evidence used to support the decision. This national level analysis provides 
valuable insight into the factors that influence vector control policymaking at the 
national level.  
 
The second national level policy analysis case study and the global policy analysis case 
study are presented in Chapters 5 and 6, respectively. The two case studies analyse the 
context, content, processes, actors, power, and evidence involved in malaria vector 
control policymaking in Burkina Faso and at the global level. The challenges and 
opportunities associated with the adoption of a next generation long-lasting insecticidal 
nets (LLINs) are analyzed as a means of identifying the potential challenges and 
opportunities for accelerating access to new vector control tools in Burkina Faso and at 
the global level. 
 
A synthesis of the results of three case studies (Chapters 4 to 6) is presented in Chapter 
7 along with a discussion on five areas that need strengthened in order to accelerate 
sustained access to new vector control tools. 
 
The concluding chapter (Chapter 8) reflects on the contribution this research has made 
to the knowledge gaps identified in Chapter 2, the implications of the research findings 
for theory and practice, and concludes by identifying areas for future research. 
 
 
1.10 Conclusions 
This introductory chapter has set out the general backdrop against which this thesis is 
set. The chapter outlined the thesis structure, the global malaria context including the 
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contribution of malaria vector control to malaria control achievements to date. The 
threat, scale, impact and options for addressing of insecticide resistance have been 
introduced. The chapter concluded by setting the context for the research, which 
conducts three retrospective health policy analysis. 
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2 Literature Review 
 
2.1 Introduction 
This chapter presents a critical summary of the existing literature on  the concept of 
health policy – its definitions and main theoretical underpinnings – as well as the 
frameworks used to understand how policies are made, including the role of evidence 
in the policy process. The definition of policy as employed in this thesis is outlined, as 
well as the concept of access as it pertains to the introduction of new health 
interventions and the foundations on which the modified framework used to perform 
the three case studies is based. The current literature regarding the adoption of new 
health interventions, particularly in relation to malaria and vector control tools is 
reviewed, highlighting the gaps in knowledge that this thesis aims to address. The 
chapter concludes by setting out the research questions, aims and objectives. 
 
2.2 Defining Health Policy 
WHO defines health policy as “decisions, plans, and actions that are undertaken to 
achieve specific health care goals within a society. An explicit health policy can achieve 
several things: it defines a vision for the future which in turn helps to establish targets 
and points of reference for the short and medium term. It outlines priorities and the 
expected roles of different groups; and it builds consensus and informs people” (80). 
 
Policies can be defined in a number of ways, broadly as a written or unwritten position 
that directs an organisation’s courses of action (and inaction) over time (81). Policies 
can clarify official positions, express an organisation’s intent, determine the allocation 
of resources and set standards (81). Baggott (82) specifically includes statements, 
documents or programmes of action in his definition of policy. A policy can also be 
narrowly defined as an individual item in a multi-component policy, a strategy or even a 
tool, in so far as these relate to the achievement of the organization’s goals (83). Some 
argue that policy should be evidenced by the organization’s actions (77). However, this 
definition fails to recognise that failure to adopt a policy (such as a tool) is in itself a 
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policy, and may result in the failure to analyse the impact of unwritten decisions or 
inactions.  
 
This mix of tangible (actions, documents and tools) and intangible (inaction and 
unwritten decisions) concepts makes policies difficult to analyse, but underscores 
Exworthy’s (84) argument on the importance of “policy being conceptualised as a 
process, as well as a product”. Therefore, policy analysts need to clearly define the 
object and scope of their analyses as well as consider the intangible factors. Over the 
course of this thesis, policy is conceptualised in two ways: as a decision to scale-up 
larviciding in the Nigerian case study, and as a tool (PBO LLIN) in the Burkina Faso and 
global studies. 
 
2.3 Theories and Frameworks on Policymaking 
 
Understanding the policy process is an important step in understanding the factors that 
influence policy adoption. Exworthy maintains that understanding and describing the 
processes by which policies are made is tricky, as often decisions emerge rather than 
take place at a point in time (84).  A number of models exist that identify elements of 
the policy making process and their interrelation (85). One of the best known public 
policy models is the stages heuristic, which divides the policy process into four stages: 
agenda setting, formulation, implementation and evaluation (86, 87). The stages model 
is underpinned by the theory of rationalism in decision-making, which postulates that 
decisions are (should be) made through a rational process. Alternatives should be 
weighed and the most optimal selected (88). March and Simon refine this argument by 
recognizing that policymakers seek to be rational but are bounded by their individual 
and collective capacity for logical economic or maximizing behaviors (89). 
 
Variants of the stages model have been developed by policy analysts and define the 
policymaking process as comprising of broadly similar stages that range in number from 
four stages  (86, 87, 90) to nine stages (91). Policy analysts including Sabatier have 
criticized these demarcation of policymaking into discrete stages as being flawed 
because they assume that policy making is a rational and well defined linear process 
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(92). They argue that it is naïve to assume that issues come to the attention of 
policymakers and rationality is employed to make the best policy response, resulting in 
that option being implemented and evaluated. Instead Sabatier asserts that the reality 
of policymaking is more muddled than the stages model represents (92). Furthermore, 
it has been cited that the stages frameworks fail to postulate a causal driver within and 
across identified stages thus they provide little insight for studies seeking to influence 
how policies are made (91). In order words, the stages model would fail to explain how 
new vector control tools reach the attention of the policymakers and what convinces 
them to adopt implement the vector control tools. 
 
John argues that the policy making process often has no start or end point. He argues 
that new policies are made within the context of existing constraints and opportunities 
(93). This is known as the incremental model of policy making which argues that 
policymaking focuses on small changes to existing policies (95). Greener defines a path 
dependency as the pre-existing context that creates parameters from which 
policymakers may find it difficult to diverge (94). It embraces the notion that few, if any, 
problems are solved once and for all (77). Lindblom describes the reality of the policy 
making process as muddled in contrast to rational models which he argues are 
concerned with what ought to happen (96).  The incremental model of policy is useful 
because it is recognized that there are several new paradigms of vector control tools in 
the pipeline and decisions around the adoption of new one will have to be made in the 
context of already existing tools. However, many analysts, most notably Dror, criticize 
the incremental model as being conservative. He argues that there are at least three 
instances where incrementalism would be inadequate: i) where present policies are 
wholly inadequate and warrant fundamental change; ii) where problems change so fast 
or so fundamentally that policies based on past experience would not suffice and iii) 
where the means for problem solving is expanding to new dimensions (97). In relation 
to new vector control tools the incremental model does not help prepare or explain 
how to gain policy adoption of a radically different or a truly novel vector control tool 
not based on an existing paradigm. 
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Baumgartner and Jones, in challenging the incremental model, argue that the policy is 
marked by long periods of little change, which is punctuated by fundamental policy 
change. They argue that policy monopolies maintain policies in a stable equilibrium 
over a long period of time until exogenous shocks bring about far reaching change (98). 
At least two examples of these exogenous shocks exist in the malaria vector control 
context:  the demonstration of the effectiveness of ITNs/LLINs which shifted the policy 
focus from IRS and the discovery of DDT which shifted the policy focus to IRS in the 
early 20th century. 
 
Walt argues that the dichotomy of rational versus incremental models is artificial as 
both models serve to explain different things. The rational model describes the way 
things ought to be and the incremental model the way things are (77). 
 
The mixed scanning model of policymaking  proposes a middle ground between the 
idealism of the rational approach and the realism of the incremental approach (81). 
Amitai Etzioni (99) describes the mixed scanning approach as one that involves a broad 
sweep of the problem with detailed analysis of components of it. He distinguishes 
between major and minor decisions that need to be made. He states that policymakers 
carry out broad analysis of a problem area, with detailed analysis being carried out on 
important steps which may flow from or lead to a fundamental (major) decision (99). 
Critics of the mixed scanning maintain that the approach fails to distinguish between 
major and minor decisions (81). 
 
A useful way to carry out analysis of the policymaking process is to examine theories 
that explain specific stages of the process. The literature on the agenda setting stage of 
the policy process provides critical insight into the policymaking process, as they seek to 
explain why some issues receive attention (77).  Kingdon argues that policy windows 
open (and close) as a result of interactions from three streams: problem, policies and 
politics. His theory asserts that these three relatively independent streams combine to 
make the potential for policy highly likely (90). The problem stream refers to issues that 
are recognised as significant problems. Major events, publication of evidence or 
feedback from existing policies can work to make an issue be recognised as a problem 
37 
 
(81). The emergency and spread of insecticide resistance threatening the utility of the 
best available malaria vector control tools arguably, constitutes a problem stream. 
 
The policy (solution) stream refers to the range of competing options available to 
address the identified problem. These options are proposed and considered by 
technical specialists for feasibility and acceptability (81).  The emergence of new vector 
control tool options such as the longer lasting insecticide solutions for IRS, next 
generation LLINs as well as the ongoing research and development across the new 
paradigms provides a modest range of options for consideration. However, the range of 
options are limited given that majority of the tools within the new paradigms still need 
to be proven to be safe and effective for public health use. 
 
The political (political will) stream refers to the political environment including the 
prevalent public opinion and the actions of stakeholders such as advocacy groups (81). 
Kingdon incorporates the role of policy entrepreneurs who attempt to orchestrate the 
coupling of the streams to bring about their preferred policy solution. Kingdon points 
out that solutions may need to be advocated for over a long period of time before the 
appropriate policy window opens (90). Critics of the Kingdon model argue that it fails to 
explain why some issues do not make it to the agenda. Bachrach and Baratz argue that 
the ability to keep things off the agenda is as important as the power to get things on to 
the policy agenda (100). Considering that policy is defined by both the actions and the 
inactions of decision makers, explaining why and how issues do not get on to the 
agenda is critical, albeit difficult task.  
 
Kingdon's multiple streams model concentrates on the timing and flow of policymaking, 
taking a bigger-picture perspective (77). The network model comprises of a set of 
theories that take into account the wide range of networks and relationships that shape 
the policy agenda. (101). Network theories are based on the premise that decisions 
makers, though autonomous, depend on each other within a given policy (93). 
Furthermore, Kickert et al state that policymaking takes place in ‘networks consisting of 
various actors (individuals, coalitions, bureaux, organizations)’ (102). These positions 
support the premise that the policy process operates through networks of stakeholders, 
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each with their own interests and motivations. Networks lobbying to raise the profile of 
a problem and promoting their preferred solution have become fairly common (84).  
 
A number of types of networks have been identified including policy communities (103), 
issue networks, advocacy coalition (104) and epistemic communities (101).  Bowen and 
Zwi argue that policy networks like epistemic communities can shape the way policies 
are formulated, by influencing the way is evidence gathered, synthesized, and 
disseminated during the policy process. (101).  
 
These theories and frameworks are useful for conceptualising, stages in the policy 
process as well as examining how actors engage and organise to influence policy 
outcomes. However, other frameworks, such as the Walt and Gilson policy triangle 
(105) (Figure 2), provide a more comprehensive analytical lens. Walt and Gilson (105) 
developed a seminal policy framework which incorporates the policy content, context, 
actors and process into policy analysis (81).  
 
Figure 2. Policy analysis triangle 
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Walt and Gilson (105) define context as the environment within which policies are 
mediated. The context is comprised of systemic factors (political, economic, cultural 
and social, local, regional, national, and international) that may affect policy (81, 106). 
International factors play an increasingly important role in national policies, particularly 
in an area like malaria where the health issue at hand necessitates regional and 
international cooperation (81). The relationship between the context and the policy is 
interactive in that the policy is shaped by the context and vice versa (84). Thus, in order 
to understand how health policies (in this case malaria vector control policies) may or 
may not change, the extent to which the national and global contexts will impact the 
policy outcomes needs to be understood (81). The content aspect of the policy triangle 
examines the details of the policy being analysed, which may be technical or 
institutional and explores the aims, objectives, intrinsic values, and impact of the policy 
in question (77).  
 
Actors within the Walt and Gilson framework are at the centre of the triangle and may 
denote individuals and/or institutions, including organizations such as WHO, private 
sector companies, the state/government, civil society organizations and 
interest/pressure groups who seek to influence, direct or change policy (77). A crucial 
element of the policy triangle is the way in which power is mediated (77). Actors may 
be facilitated or hindered by their power, which is characterised by “wealth, 
personality, access to knowledge or authority” as well as an individual’s organizational 
affiliations and status. In essence, who you are, what you know and who you can 
influence impacts how malaria vector control policies are made. Exworthy (84) states 
that “power draws attention to the interplay of interests in negotiation and 
compromise”.  
 
Walt and Gilson (105) integrate the process of policymaking into their framework, 
categorised in line with the prevailing theories on the stages within the policy of 
process. They further identify pertinent questions with regards to the policy process, 
such as ‘Why do issues reach the agenda? Who formulates policy? How is policy 
implemented? What makes policies change?’ For the purposes of this study, the 
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relevant questions are: Who formulates policy at the national and global levels in 
relation to vector control and what factors facilitate policy change. 
  
The strength of the policy triangle lies in its approach to policy analysis, recognizing that 
it is both a product and a process in an arena within which actors with varying degrees 
of power and influence interact to bring about a policy change.  Thus, the framework 
accommodates the iterative nature of the process while using a systematic approach to 
its examination. This makes it an incredibly powerful framework for analysing malaria 
vector control policymaking, which is often comprised of both a tool and a process to 
adopt it. The ‘3-i’ framework approaches the understanding of the policy process in a 
similar fashion by incorporating i) interests, i.e., the policy actors’ desire to achieve a 
policy outcome; ii) ideas, encompassing knowledge, values and research; and iii) 
institutions, which are the formal and informal structures, networks and organizations 
involved in policymaking (107). Nevertheless, the 3-i framework does not offer 
significant advantages over the policy triangle with regards to addressing the research 
questions posed herein. However, various other frameworks do exclusively and more 
robustly address the issue of evidence and the policy process compared to the Walt and 
Gilson policy triangle, as discussed below. 
 
2.4 Evidence and the Policy Process 
The proponents of evidence-based policies echo theories that conceptualise 
policymaking as a rational process and argue that the relationship between evidence 
and policy should be “direct, sequential and relatively rapid” (81). However, Young (108) 
highlights the increasingly prevailing view that the link between research and policy is a 
complex two-way process shaped by “multiple relations and reservoirs of knowledge”. 
Despite the opinions held by scholars criticizing the naivety of rational theories on 
policymaking, the Mexico Statement on Health Research prescribes that “health policy, 
public health, and service delivery should be based on reliable evidence derived from 
high quality research” (109). 
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Key to understanding the use of evidence in policymaking is Weiss’s (110) classification 
of research utilization into seven models, which range from the ‘problem solving’ model 
of the use of research in policymaking (which is rational and sequential) to the ‘political’ 
model, where research is ammunition to support predefined positions. In malaria 
control, the rational model of policymaking is persuasive because, arguably, more lives 
will be saved if interventions are adopted and implemented based on the best available 
evidence. 
 
The Overseas Development Institute Bridging Research and Policy project collected and 
analysed 50 case studies on the links between research and policy (111). The aim of the 
analysis was to understand why some research ideas were seen to have an impact on 
policy while others were ignored. This resulted in the Research and Policy in 
Development (RAPID) framework (108), which looks at three interlinked areas within 
which the links between research and policy are facilitated or hindered. The RAPID 
framework demonstrates that evidence-based policies are a product of the interaction 
of a myriad of factors, including conducive political contexts, the availability of sufficient 
and credible evidence, and strong links between researchers and policymakers.  
 
The strength of the RAPID framework within the context of this thesis is that it overtly 
examines the use of research in policymaking, an area which is implied but not 
exhaustively explored in the Walt and Gilson policy framework. Furthermore, the RAPID 
framework summarises key barriers to the use of evidence in policymaking and, along 
with other studies, identifies the strategies for improvement (Table 1).  
 
Table 1. Barriers and facilitators to the use of research in policymaking 
 Barriers to the use of evidence in 
policymaking 
Strategies to overcoming barriers to linking research to 
policy  
1 Absence of personal contact between 
researchers and policymakers 
 
Embedding research institutions in policymaking bodies 
(112) 
Providing policymakers with access to ongoing research, 
site visits, etc. (112) 
Involvement of policymakers in research planning and 
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design 
2 Lack of timeliness or relevance of 
research 
Limited time to implement policy 
change 
Inclusion of short-term objectives to satisfy 
policymakers (113) 
Collaboration in identifying research questions, aims 
and objectives (114) 
3 Poorly communicated research 
findings, including lack of definitive 
message 
Clear summaries with policy recommendations (114) 
Audience-specific communication (115) 
Use of knowledge brokers (114) 
Use of credible sources and experts to communicate 
research (113) 
4 Mutual distrust, including perceived 
political naivety of scientists and 
scientific naivety of policymakers 
Building of trust through sustained personal contact and 
relationships (113) 
 
5 Poor quality research Good quality research – applying The Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) assessments to the research process 
and results (116) 
6 Policymaking staff lack of capacity to 
access research 
Capacity building for policymakers in accessing and 
utilizing research findings (114) 
 
2.5 Access to New Health Interventions 
Given that access to new vector control tools is the policy being examined in this thesis, 
it is necessary to understand the concept of access and to incorporate issues specific to 
promoting access within the policy analysis framework used.  
 
Health interventions are useful to the extent that they are available to appropriate 
population groups (117). Nevertheless, widespread failures to implement cost-effective 
health interventions persist in both developed and developing countries (118). Haines 
et al. (118) propose the improvement of uptake of high quality research in the policy 
process to address this. This thesis will explore the use of evidence in policy with the 
aim of understanding the complexities surrounding this process and identify possible 
solutions.  
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2.5.1  Defining Access 
The United Nations Development Group (UNDG) defines access to medicines as having 
them “continuously available and affordable at public or private health facilities or 
medicine outlets that are within one hour’s walk of the population” (119). Frost and 
Reich (120) consider the concept of access in relation to medical interventions by 
looking at vaccines, medicines and diagnostics across a number of diseases, and define 
access as “people’s ability to obtain and use good-quality health technologies when they 
are needed”. Thus, both UNDG and Frost and Reich conceptualise access as a series of 
iterative processes, from product development to appropriate use by the end-user. 
 
The concept of wide scale access to new tools is different from the translation of a 
new/novel tool, wherein translation is said to be achieved once a product demonstrates 
efficacy in the research environment as well as effectiveness in implementation settings 
(121). Components of the translation pathway include producing basic science, 
developing a target product profile, and product development and implementation 
(121). For example, Vontas et al. (64) developed a framework for validation of new 
vector control tools, which outlines the pathway of a new product from a basic idea to 
its approval and uptake. The framework includes the policy adoption of new tools but 
does not comprehensively assess and provide recommendations for achieving policy 
adoption. While the concept of translation is clearly embedded in the concept of 
access, the focus of translation is on the viability of the product/tools and their 
performance in research and implementation settings. Unlike access, translation does 
not sufficiently consider wider factors such as the architecture and affordability of a 
product, components that Frost and Reich (120) demonstrate are key determinants of 
achieving wide-scale access. This thesis goes beyond the AvecNet project and Vontas et 
al. [63] conceptualisation of translation and examines the more encompassing concept 
of access. 
 
Frost and Reich (120) applied their framework to analysing access to a number of health 
interventions, ranging from female condoms to malaria rapid diagnostic tests, and 
44 
 
demonstrated that ensuring wide-scale access to a new intervention requires detailed 
analysis of the facilitating and limiting factors, which are organised into four streams: 
architecture, availability, affordability and adoption (Figure 3). They further argue that 
this analysis should result in the implementation of strategies around the four streams 
that promote access to a new tool. 
 
 
Figure 3. Frost and Reich access framework [70] 
 
2.5.2  Components of the Access Framework 
Within the access framework, architecture refers to the network of organisations and 
the coordinating structure for the introduction of a new health intervention. Availability 
is comprised of five processes that contribute to the reliable and regular supply of the 
new health intervention. Affordability refers to government, non-governmental 
organisation (NGO) and end-user willingness to purchase the health intervention. 
Adoption at the global, national, provider and end-user levels constitute the final 
element of the framework. Embedded in adoption is the issue of demand for the 
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intervention by four main groups of stakeholders: global policymakers, national 
policymakers, health providers and end-users (120).  
 
At least two other frameworks examining access incorporate similar concepts of 
availability, accessibility, affordability, adequacy and acceptability in considering access 
to healthcare and health interventions (122, 123). However, their utility for analysis in 
the context of the aims of this thesis are limited, since the Obrist et al. (122, 123) 
framework focuses on consumer level considerations in relation to the health 
intervention, while Mahoney et al. (122, 123) address adoption issues solely at the 
global level. In contrast, Frost and Reich (120) provide a more comprehensive 
framework by incorporating global, national and consumer level considerations into the 
concept of access from product development to the consumer adoption stage.  
 
The three access frameworks are consistent in the view that access is dependent on 
national and global policy adoption of new health interventions. As stated, the focus of 
this thesis is on global and national level drivers of policy adoption. Sub-national issues, 
while important, are not considered herein.  
 
The following section reviews the current evidence on the adoption of new health 
interventions, particularly in the area of malaria and vector control. 
 
2.6 Evidence from the Literature: Policy Adoption Process for Malaria 
Control Tools and Other Health Interventions 
 
In 2008, the first systematic review on the health policy processes of low- and middle-
income countries was published (124); only six of the 391 studies reviewed were on 
malaria and all six focused on treatment policies. Since 2008, a number of studies have 
been published on malaria policymaking, including vector control policymaking (125-
135). These studies show that financial considerations (including the cost of the new 
intervention) are the most important factors for determining national malaria control 
policies. They also highlight the importance of scientific evidence, donor preferences, 
the ability to reduce malaria prevalence, opinions of current leaders, and popular 
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pressure in influencing the decision to adopt a malaria control policy. At least two of 
these studies highlight that donor influence is disproportionately dominant in the policy 
process (30, 127). Another study highlights the added importance of local conditions, 
logistic feasibility of implementing the policy option, past experience in relation to the 
current or proposed policy, and community acceptability (125). In a more recent review 
of barriers to malaria control policymaking in East Africa (136), the authors cite 
implementability, the lack of capacity, resources and sustained political will power, as 
well as flaws in the policy process, e.g., the determination and adoption of the 
appropriate policy option compounded by institutional fragmentation, as some of the 
most significant barriers to malaria control policy adoption.  
 
In relation to methods utilised in developing this body of literature, all but one (125) fail 
to explicitly describe the framework with that is used to organise its inquiry and none 
talk about theoretical underpinning.  A number of these studies investigate the policy 
process, actors and the timelines within which the policy change occur (129-131, 133, 
137, 138). However, these studies fail to systematically organise their enquiries into a 
multi-dimensional framework such as the Walt and Gilson. This limits the scope of the 
studies analysis and results in only a few of the key concepts (policy content, context, 
actors, power and process) being analysed with none explicitly considering power. All of 
the studies utilise the case study methodology which helps provide strong insight and 
clear descriptions of the process of policy change (130, 139) however, without the 
multi-dimensional perspective that a policy analysis framework like Walt and Gilson 
offers, they provide little insight into casual relationships between factors e.g actors 
and the process or context and the policy process. Three studies (128, 129, 136) use 
quantitative methods to elicit stakeholder views on the factors or barriers that 
influence the policy change. While this is a useful way to gather a wide range of 
perspectives on general factors that influence policy change, they fail to elicit 
information on the specific factors in relation to a specific policy change. This leaves the 
malaria policy analysis arena with a paucity of studies that use robust policy analysis 
methodologies. This is in line Walt et al’s (75) findings in 2008 that highlighted the fact 
that few policy analysis in low and middle income countries explicitly discuss 
methodology. The paucity of malaria control policy analysis underscores Walt et al’s 
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(75) call for studies that explicitly outline research methods including a robust 
justification for choice of frameworks, critically apply existing policy analysis 
frameworks and sound theoretical knowledge, including theories from political and 
social science. 
 
In contrast to the malaria policymaking arena, significantly more attention has been 
paid to the adoption of vaccines into health policy. The adoption of vaccines provides 
the richest available source of insight into the factors that influence policy adoption. A 
recent systematic review of vaccine adoption identified 26 vaccine decision-making 
frameworks and 39 examples of vaccine adoption (140).  
 
The combination of the literature on vaccine adoption and what is available on malaria 
control have been used to draw inferences on the factors that facilitate the adoption of 
new malaria control interventions. These include:  
 
i. Finance and economic issues, including the price of the intervention, its cost-
effectiveness, and the availability of financing (128, 141-143) 
ii. The influence of national and global actors such as donors and technical agencies 
(126, 140) 
iii. Global consensus on the appropriateness of the intervention (142) 
iv. The appropriateness for use and technical feasibility of the intervention in the 
intended context (141, 143-146) 
v. Scientific evidence to support the intervention (through a demonstration of efficacy 
and effectiveness in various geographic/epidemiological settings) (64) 
vi. Clearly defined evidence requirements for international/national policy 
recommendations (147-149) 
vii. Research communicated in way that supports policy decisions (150, 151) 
viii. Product championing/coordination amongst stakeholders for policy adoption (128, 
151, 152) 
ix. Innovative procurement mechanisms, including robust forecasting plans (142, 149) 
x. The existence of a clearly defined policymaking process (66) 
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The ten factors outlined above demonstrate that policy adoption of new health 
interventions can be influenced by factors associated with finance, politics and scientific 
evidence. While the studies above present evidence of the barriers and facilitators of 
policy adoption, very few address malaria vector control policy and none address the 
interrelation of global and national policy adoption of new tools as done in this thesis. 
Furthermore, as Burchett et al. (140) indicate, within the existing reviews the policy 
adoption, process itself is poorly examined, resulting in a paucity of robust policy 
analysis on the adoption of new malaria vector control tools.  
 
2.7 Research Aims and Objectives 
 
This thesis aims to gather evidence and provide new insights into the available 
strategies to accelerate access to new malaria vector control tools. 
 
This thesis is based on the following premises: 
 
i. Accelerated access to new vector control tools is required to achieve the ambitious 
global malaria control and elimination targets that have been set;  
ii. Increasing insecticide resistance requires rapid, clear and evidence-based global and 
national adoption of new and innovative malaria vector control tools; 
iii. The development of a safe and effective tools is necessary but not sufficient for its 
wide-scale access (120);  
iv. A better understanding of the vector control policymaking process can provide 
insights that could accelerate access and  
v. Some of the delays in accessing new vector control tools can be avoided by 
optimizing their adoption into policy at the national and global level. 
 
The objectives of this study are: 
 
1. To carry out two national policy analyses to identify what factors influence the 
adoption of new malaria vector control tools at the national levels. 
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2. To carry out one global policy analysis to identify what factors influence the 
adoption of new malaria vector control tools at the global level. 
3. To identify what opportunities, exist at the national and global levels to 
accelerate the adoption of new malaria vector control tools. 
 
The underlying assumptions inherent in these lines of enquiry are that: 
  
 Policy processes at the national and global levels are discernible, rational and 
influenced by factors, such as evidence and finances, that can be optimised to 
accelerate access to new vector control tools;  
 Developing evidence of the effectiveness and cost-effectiveness of the new tool is 
central to accelerating access to new vector control tools; and  
 Unlocking international donor funding is at the core of facilitating access to new 
vector control tools. 
2.8 Conclusions 
 
This chapter has presented a brief introduction to health policy, including the definition 
of policy which for the purposes of this research encompasses the adoption of new 
vector control tools. An overview of the Walt and Gilson policy analysis triangle, the 
RAPID framework and the Frost and Reich access framework was presented herein. 
These form the basis for the thesis analytical framework to be presented in Chapter 3. A 
review of the evidence as it pertains to the adoption of new health interventions, 
particularly in relation to malaria and vector control tools, highlighting the gaps in 
knowledge that this thesis aims to address. The Chapter concluded by setting out this 
research’s aims and objectives.  
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3  Methods 
 
3.1 Introduction 
This chapter provides an overview of the methods used to address the overall research 
questions outlined in Chapter 2. It describes the modified analytical framework through 
which the case studies were designed and the data collected and analysed, based on 
the Walt and Gilson policy analysis triangle (77) and Frost and Reich Access Framework 
(120) introduced in Chapter 2. The final sections of the chapter outline the case study 
selection, study participant recruitment, and data collection and analysis, concluding by 
outlining the steps taken to ensure methodological rigour and ethical considerations. 
Throughout the chapter, the rationale and comparative analyses performed are 
described to justify the methodological choices made in each case study. 
 
3.2 Methodology 
As previously described, access to new health interventions is dependent on an 
understanding of the factors that influence policy adoption at both the global and 
national levels. Therefore, the research in this thesis is presented as case studies 
addressing access considerations at both levels.  
 
Case studies are a method of carrying out in-depth investigations of events their real-
life context (153) using a range of data collection methods such as  interviews, 
observation and document reviews.  Case studies are particularly useful in investigating 
phenomenons that are heavily influenced by their context (153). Yin argues that case 
studies are useful for understanding complex real life events (153). This makes them 
ideal for carrying out policy analysis given that context is an important component of 
policy adoption. Walt et al state that a well-chosen case can provide a valuable basis for 
comparison, while an unusual case can provide unique insight into factors that facilitate 
policy change (75). However, a potential shortcoming of the case study methodology 
are instances where the results are so specific to the event being investigated that 
there is little room for the findings to be applied or offer broader insight to other 
events, i.e. the findings from the case study are not generalizable. A strategy to increase 
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the generalizability of the case study finding is to conduct multiple comparative case 
studies (75). This is a factor that informed the decision conduct multiple case studies 
using a common framework. The case study methodology has been used to explore 
policy change in malaria control (80, 126, 129, 131, 154) primarily in East and Southern 
African contexts. 
 
The three case studies presented here were carried out in the West African context and 
the Global level. The case studies were carried out sequentially with the Nigeria case 
study being carried first, the Burkina Faso second and the Global last. Conducting the 
studies in this manner allowed for instruments, frameworks and approaches to be 
modified and refined as lessons were learnt and incorporated into the research process. 
However, the dichotomy into national and global levels is somewhat artificial as the 
access issues discussed traverse these levels, with an inherent inter-relationship 
between them. The organisation of research into case studies discussing national and 
global level issues provides a useful structure to the study; however, overall analyses 
and findings (Chapter 7) will consider the general issues and draw collective 
conclusions.  
 
A number of underlining views can influence the choice of methods used to answer the 
research questions. These paradigms are characterized by their position on what is 
reality? (ontology); How can we know reality?  (epistemology) and What techniques 
should you use to uncover/discover reality (methodology). An interpretive view to what 
knowledge is and how it is developed underscored the development of the research 
question and the methods used to collect data. The ontology of an interpretive 
paradigm states that reality is socially constructed i.e. there is no single reality or truth 
rather there are peoples’ subjective perspectives of reality (155, 156). The epistemology 
of an interpretive paradigm seeks to discover and interpret the underlining meaning of 
events using a variety of methods, which are primarily qualitative and can include case 
studies (155, 156). In this research effort was made to elicit, documents and understand 
the key stakeholders’ perspectives on policy processes in the three study settings.  This 
is in contrast to a positivist paradigm which states that there is only one reality, and 
discovers this single reality through measurements made by an objective observer (156, 
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157). On the other hand, the Subjective paradigm asserts that reality is based purely on 
perspectives of individuals and all knowledge is what we perceive to be real.  
 
The interpretive stance utilised in this research also differs from the Pragmatic 
paradigm, which views reality as being constantly negotiated, debated and 
renegotiated (155). The Pragmatic paradigm seeks to discover knowledge primarily with 
a view to solving problems/ effect change. While the interpretive paradigm was the 
primary influence in this research the influence of the Pragmatic paradigm are evident 
in its results (particularly the synthesis section in chapter 7) given that the aim is to 
develop strategies to accelerate access to new vector control tools.  Finally, the Critical 
paradigm states that realities are socially constructed and both reality and knowledge 
are influenced by power relations within the society (156, 158). Elements of the Critical 
paradigm can be gleaned from the research methods given the deliberate effort to gain 
insight into power and sources of influence in the policy process. 
 
 
 
3.3 Analytical Framework 
An adapted version of the Walt and Gilson framework (159) was used to inform the 
analysis of the contentious decision to scale-up larviciding in Nigeria (Chapter 4) and the 
role that evidence played in the process using the lens of the RAPID framework (111). 
The policy triangle is limited when addressing availability and affordability of a new 
vector control tool as a precursor to its access. Therefore, a modified analytical 
framework combining the Walt and Gilson policy analysis framework (159) with the 
Frost and Reich access framework (120) was developed for the Burkina Faso and global 
level case studies. Two of the four elements (availability and affordability) of the Frost 
and Reich access framework are synonymous with the four elements of the Walt and 
Gilson policy triangle. Table 2 shows the modified (Thesis) analytical framework 
indicating where overlap exists between the two frameworks.  
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Table 2. Analytical framework of the Thesis 
 
Walt and 
Gilson 
concept 
Walt and Gilson definition (77) (Policy Framework) Corresponding 
Frost and 
Reich streams 
Frost and Reich (120) definition (Access Framework) Modified 
(Thesis) 
Framework 
Actors Individuals, institutions and movements that seek to 
influence policy 
 
 
 
 
 
 
 
Architecture 
The organisational structure and relationships that interact and 
coordinate availability, affordability and adoption activities, i.e., 
the network of stakeholders involved in ensuring access to new 
vector control tools 
Note although power is implicit in the relationships and 
interactions of organisations, it is not explicitly considered in this 
framework 
Actors 
Power  Power is defined as the ability to influence, and in 
particular to control, resources 
Note Not explicitly considered in the Frost and Reich Framework 
 
Power 
Context Context refers to systemic factors such as political 
system, type of economy, employment base, national 
and international actions/cooperation that may affect 
health policy 
Incorporated in architecture Context 
Process  Process refers to the way in which policies are 
initiated, developed and/or formulated, negotiated, 
communicated, implemented and evaluated. It 
incorporates the use of evidence in the policy process 
using the lens of the RAPID framework (111) 
Adoption Involves gaining acceptance and creating demand for new vector 
control tools at all levels, i.e., global national and community 
level 
Note In this study, the scope of adoption is restricted to policy 
endorsement and demand for tools by actors at the national and 
global level 
Policy 
adoption 
process 
Content The content of the policy, which reflects the interplay 
between actors, processes and context 
 Note Not explicitly considered in the Frost and Reich Framework   
  Availability  Involves the logistics of making, ordering, shipping, storing, 
distributing and delivering new/novel vector control tools 
Note In this study, national level availability is restricted to 
ordering (i.e., choosing and procuring a new vector control tool) 
while, at the global level, it is focused on the development of the 
tool 
Availability 
  Affordability  Involves the willingness to invest in a new vector control tool by 
global organisations and national governments 
Affordability 
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3.4 Case Study Selection 
Three policy analyses case studies were performed to answer two overall research questions:  
i) What factors, at both the national and global levels, influence access to new malaria vector 
control tools? ii) What are the existing opportunities, at both the national and global levels, to 
accelerate access to new malaria vector control tools? 
 
A combination of factors influenced the selection of the three policy analyses to be performed. 
The criteria for case study selection were: 
 
 Recent vector control policy adoption/recent decision to scale-up a vector control 
intervention; 
 The relevance of the recent decision to the scale-up new vector control tools aimed at 
tackling insecticide resistance; 
 Feasibility of the study, i.e., relevance to the AvecNet project, country knowledge and local 
partners for collaboration; 
 The need to understand policy drivers in the relevant influential policy context, i.e., both at 
the global and national levels. 
 
One global level and two national case studies were performed; on the basis that two case 
studies were sufficient to provide comparisons and reduce the likelihood of eliciting findings 
that were unique to only one national setting while being a feasible number to conduct in the 
study timeframe.  
 
The first case study was done in Nigeria. Nigeria was chosen due to its recent decision to scale-
up larviciding2, which provided an opportunity for a recent national decision around vector 
control to be analysed and to assess the extent to which policy decisions conformed to the 
rational theory of policymaking. Further, Nigeria fulfilled the feasibility criterion. The student is 
                                                 
2 Professor Ranson personal communication 
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a Nigerian and who spent a number of years working with the National Malaria Control 
Programme, thereby providing insider knowledge of and access to stakeholders involved in 
national malaria policymaking.  
 
The second case study was performed in Burkina Faso since it fulfilled all four criteria for case 
study selection. In 2010, a decision was made to distribute a next generation LLIN treated with 
an insecticide and a synergist (PBO LLIN) PermaNet® 3.0 in Burkina Faso as part of the national 
distribution of LLINs in the country3 (satisfying criteria i and ii). The feasibility criterion was also 
satisfied as the AvecNet project (under which this PhD thesis resides) was running a randomised 
controlled trial in partnership with the Ministry of Health in Burkina Faso and the Centre 
National de Recherche et de Formation sur le Paludisme, Burkina Faso (CNRFP), to evaluate the 
effectiveness of Olyset® Duo (65). The combination of the distribution of a PBO LLIN and the 
network of partners through AvecNet made Burkina Faso an ideal context to explore the 
challenges and opportunities for the national adoption of PBO LLINs. 
 
The final case study was a policy analysis at the global level. The WHO mandate for health 
policymaking at the global level is well established (80). As in Burkina Faso, PBO LLINs were used 
as the object of study to understand the policy drivers for access to PBO LLINs at the global 
level. Carrying out concurrent national and global malaria vector control policy analysis was an 
opportunity to provide novel analysis, which as highlighted literature review is currently limited. 
 
3.5 Data Collection Methods 
The data collection for all three case studies involved a combination of document review and 
semi-structured interviews. The fact that this research seeks to understand and explain the 
factors that influence access to new malaria vector control tools from multiple perspectives 
within the policymaking context made the qualitative method for data collection and analysis 
ideal (160, 161). This is in contrast to quantitative methods, which assume that a singular truth 
                                                 
3 Dr N’Fale Personal Communication 
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may be deduced through the research process (162), making it unsuitable for this study. 
However, quantitative data such as numbers of LLINs distributed and their cost was extracted to 
provide additional insight where relevant. 
 
3.5.1 Document Review 
An initial document review was performed at the beginning of the research period to gain an 
understanding of policy analysis, malaria and vector control, and access to new health 
interventions. These results were used to refine the research question and develop data 
collection tools. The document review was repeated in order to refine information to specific 
case studies and gain an understanding of the relevant policy context. The results were also 
used to identify key informants (KIs) and to refine data collection tools. For example, framework 
themes were defined and institutions relevant to the framework themes were identified 
through the document review. Finally, during analysis of the research results, another 
document review was performed to identify updates to the policy context and triangulate data 
collected from KIs. Annex 5 provides a summary of the search strategy used to source published 
papers, including dates, databases and search terms used across the case studies and in 
general.  
 
Grey literature was reviewed, including national and global malaria policies, strategies and 
guidelines; national and global malaria vector control policies, strategies and guidelines; 
organograms and structures of national ministries of health; terms of reference and minutes of 
meetings of national and global policymaking bodies; policies, strategies and action plans of 
research, implementing and financing organisations involved in malaria vector control in 
Nigeria, Burkina Faso and globally. These documents were retrieved during the literature review 
and through requests to relevant organisations and individuals. Review of published and grey 
literature provided insight into the policy actors, content, context and processes of global and 
national vector control as discussed in each of the relevant chapters. Specifically, reviews 
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provided an outline of the global and national vector control architecture and context, and of 
the process for global national adoption of new tools. 
 
Document review was also used to identify the key actors (KIs) involved in ensuring new tool 
availability, affordability and adoption, and to develop the semi-structured interview guide. 
 
3.5.2 Key informant (KI) Interviews 
Sample selection: KI sample selection was a two-step process involving the identification of 
relevant institutions followed by the identification of KIs from each selected institution for 
participation in the study. Annex 6 provides a sample of the framework used to identify 
institutions and KIs. The selection of institutions and KIs throughout the study was purposeful, 
i.e., guided by the institutions and individuals that would provide information and insight to the 
themes in the research framework while representing a range of perspectives (163). KI lists 
were also verified during the interview process. 
 
Selection of institutions: Initial document reviews generated data on the national and global 
architecture, identifying all institutions involved in ensuring the availability, affordability and 
adoption of new vector control tools at each level. Institutions were categorised as follows: i) 
Policymaking organisations. At the global level, this refers to the WHO Global Malaria 
Programme and members of the committees, structures and regulatory mechanisms 
established to support and provide advice to WHO policymaking functions such as Malaria 
Policy Advisory Committee (MPAC) and, for the purposes of the study, WHOPES. At the national 
level, policymaking institutions were considered to be the national ministries of health, 
including the national malaria control programmes. ii) Research organisations, including 
academic or research institutions engaged in vector control and/or insecticide resistance 
research expertise. iii) Private sector, including those institutions in the commercial for-profit 
sector as well as public–private partnership organisations involved in the development, 
manufacture and/or sale of vector control tools; iv) NGOs include KIs from national NGOs 
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implementing malaria control projects. v) Donor organisations, referring to international donor 
organisations that fund vector control activities such as the Global Fund to fight AIDS, 
Tuberculosis and Malaria (GFATM) and United Kingdom Department of International 
Development (DfID) and vi) Multilaterals, including United Nations technical agencies as well as 
multilateral funding institutions supporting malaria control. 
 
Selection of individuals: KIs within each institution were considered the most senior person 
and/or the individual within the organisation tasked with the overall responsibility for vector 
control. All KIs were contacted either by telephone or by email to request participation in the 
study. They were sent an information sheet on the purpose of the research, key research 
background documents, including the glossary of research terms Annex 7, and the interview 
guides Annexes 8-10. It was not feasible to interview KIs from every organisation identified, as 
more than one institution was identified in each category. A number of principles guided the 
selection of KIs. Firstly, the KIs were selected to ensure that the sample captured all of the 
perspectives (principle of maximum variation) and efforts were made to include KIs who could 
speak with expertise (critical cases) on each of the analytical framework themes. Where a KI 
declined to participate, they were asked to recommend an alternative individual within or outside 
their organisation that could offer a similar perspective, who was then approached to take part in 
the study. While the sampling method as described above was purposeful incorporating principles 
of maximum variation and critical cases, validity was ensured through triangulation of information 
across all interviewee perspectives, and by the end of the interviews no new information was 
being elicited from KIs.  
 
3.5.2.1 Interview Guide 
Semi-structured interviews with KIs were conducted using an interview guide. The choice of 
semi-structured interviews allowed KIs to discuss their opinions, views and experiences in detail 
without the inhibition that closed-ended questions entail (164). In total, 40 interviews were 
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conducted across all the three case studies (Table 3), representing 88.8% of the number of 
interviewees targeted to answer the research questions. 
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Table 3 A breakdown of key informant profiles 
 
Policy
maker 
Researcher 
Private sector 
for 
profit/Product 
manufacturers 
NGOs Donor Multilateral 
Identified but 
unable to 
participate 
Total 
targeted 
Total 
interviewe
d 
Nigeria 3 1 1 5 1 3 
1 private sector 
(Refusal) 
1 multilateral 
(Unavailable) 
16 14 (87.5%) 
Burkina 
Faso 
4 2 0 3 2 2 
1 donor  
(Refusal) 
1 policymaker 
(Unavailable) 
15 13 (86.6%) 
Global 4 3 2 0 4 * 
1 policymaker   
(Refusal) 
14 13 (92.8%) 
Total 11 6 3 8 7 5  
 
45 
 
40 (88.8%) 
*Key informants played multiple roles, i.e., an organisation may fit into more than one category, e.g., researcher as well as a policymaker 
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The guide was developed prior to the interviews based on 5 of the 7 (Content and Context 
were gleaned from desk reviews) a priori themes from the study’s analytical framework. 
The initial semi-structured interview guides (Annexes 8–10) consisted of approximately 15 
open-ended questions. However, during fieldwork, the guides were further developed 
allowing for the incorporation of emerging themes and exploration of developing lines of 
investigation (164). There was some variation in the guides and data collection methods 
used between case studies. Across all three studies, all but one interview was audio 
recorded. Details of steps taken in these instances are given in the relevant chapters (5 and 
6). 
 
3.5.2.1.1 Interview Guide Nigeria 
The semi-structured interviews (March 2013) for Nigeria aligned more to the Walt and 
Gilson policy framework (77) and explored the national policymaking process (including use 
of evidence in the process), context, actors, power and the content of the national policy. 
The guide was administered in English and face-to-face, allowing observations to be made 
regarding any non-verbal communication and to seek any clarification if necessary.  
 
3.5.2.1.2 Interview Guide Burkina Faso 
The guide for Burkina Faso focused on five of the seven areas of the analytical framework 
as the policy context and content were gleaned from document reviews. A Burkinabe 
research colleague from the CNRFP (Mr Traore) conducted 12 of the 13 interviews in 
French (April 2014). To ensure quality, the researcher provided Mr Traore with an 
orientation on the research topic and interview guide prior to the commencement of the 
study, providing knowledge and insight into the aims and objectives of the research. Mr 
Traore and the researcher conducted four out of the 13 interviews together. After each 
interview, the audio recording was reviewed, translated and discussed for quality 
assurance, after which Mr Traore conducted the remaining nine interviews. 
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3.5.2.1.3 Interview Guide Global 
The global study interviews, covering five of the seven areas of the analytical framework, 
were all conducted by the researcher, in English in June-July 2014. However, since the KIs 
were located in more than one country, about 50% of the interviews were conducted by 
telephone. All but one of the United Kingdom-based interviews were performed in person. 
 
3.6 Qualitative Data Analysis 
 
3.6.1  Framework Approach 
All three studies followed the framework approach (160) to data analysis; the details of 
steps in individual studies are outlined in the relevant chapters. The coding framework for 
the three studies was based on the modified analytical framework. A portion of the chart 
used for analysis is provided in Annex 11. 
 
The framework approach to data analysis is described by Richie et al. (160) as a “matrix 
based analytic method which facilitates rigorous and transparent data management such 
that all stages involved can be systematically conducted”. This method of analysis was 
deemed the most appropriate for this study in order to provide explanations within the 
policy process as it allows for the utilisation of deductive as well as inductive qualitative 
analysis, i.e., the use of pre-established as well as emerging themes (165). Thus, given that 
data collection was performed across three contexts, the framework approach to data 
analysis provided structure whilst allowing for the exploration of any emerging context-
specific issues. This permitted a comparable set of data to be collected whilst considering 
context-specific issues arising during the course of data collection, which is in contrast to 
other qualitative methods such as ethnography, which simply describe or narrate events 
(160). 
 
The framework approach consists of five main steps: 
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Familiarisation: Immersion in the data through transcribing, reading and rereading the data 
(160). 
 
Identifying a thematic framework: An iterative process that continues throughout the study 
using a priori and emerging themes in the indexing stage (160). 
 
Indexing: NVivo10 was used to carry out indexing and support the next process – charting. 
 
Charting: This involved the development of matrices where each respondent is allocated a 
row and the themes are presented across columns, allowing for all KI responses in relation 
to a given theme to be analysed (i.e., responses across rows) as well as for each theme to 
be summarised and analysed across all KIs’ answers (i.e., responses across columns) (160). 
 
Mapping and interpretation: The development of a matrix allowed for the data to be 
explored and for areas of congruence and divergence to be identified, as well as for 
summary positions according to themes and respondent type to be developed and initial 
conclusions (subsequently interpreted in light of the wider literature) to be drawn (160). 
 
3.6.2  Document Analysis 
Key national and global policy documents collected for the preliminary fact-finding review 
were also analysed for content and context (166). Handwritten notes were used to support 
the review of each document and capture pertinent points. For content, the documents 
were reviewed by capturing key messages of the document, gaps in the evidence outlined, 
and the type of evidence used to support positions/assertions made in the document. For 
context, documents were reviewed in relation to the wider literature noting authors and 
affiliation, target audience, timeframe of the document and relevant 
political/socioeconomic factors that may have influenced its production or content. The 
analysis of organisational documents in this manner supported their use in triangulating KI 
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interviews and interpreting findings in case studies in light of the current literature, i.e., 
whether the findings of this research contradicted or confirmed the literature reviewed. 
 
3.6.3  Synthesis of Findings from the Three Case Studies 
The synthesis of the findings from the three case studies was carried out in four 
overlapping stages. The aim of the synthesis was to systematically compare the three case 
studies and using the framework approach to produce further insight into the findings from 
the individual case studies.  The first step in the synthesis of the results was the in-depth 
review of the results of each case study. Secondly, the coding of the findings of the three 
case studies according to the thesis framework; thirdly the development analytical themes 
and finally the use of the analytical themes as the basis for developing strategies to 
accelerate access to new vector control tools. 
 
The first step was a process of re-familiarisation with the data through an in-depth review 
of the findings. This involved rereading the findings of the three case studies all of which 
had been conducted at least year before the synthesis was carried out.  
 
The second stage of the synthesis involved the coding of the key findings from each case 
study according to the thesis framework (the adapted Walt and Gilson and Frost and 
Reich). This involved collating the findings from each case study in relation to the relevant 
framework theme. For example, the findings in Nigeria, Burkina Faso and at the Global level 
in relation to the framework theme – adoption were collated and summarized into a 
matrix.  
 
The third stage of the synthesis involved the generation of analytical themes. Up to this 
stage the synthesis exercise had involved collating the findings from the three case studies 
according to the thesis frameworks.  However, this third stage sought to go beyond the 
findings of the individual case studies by generating higher level analytical themes (167). 
Therefore, factors that influence policy were elicited from matrix developed in step two. 
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This involved seeking common factors that either positively or negatively influenced policy 
adoption in the three case studies. This resulted in eight factors that were found to 
influence policy (policy influencers in Table 10). 
 
In the final stage, the aim of the synthesis was to use the findings of the three case studies 
to develop strategies to accelerate access to new vector control tools. Therefore, the 
implications of each policy influencer were considered with a view to leveraging positive 
influencers and mitigating negative ones.  This resulted in the identification of five areas 
that required intervention in order to accelerate access to new vector control tools. For 
example, four of eight the policy influencers are evidence related. Thus, the first of the five 
areas identified for intervention addresses the evidence related findings from the three 
case studies. 
 
In order to ensure rigour, the synthesis methods, policy influencers and five areas for 
intervention were presented to and interrogated by the thesis supervisors.  The coding of 
findings, the development of analytical themes and associated strategies for accelerating 
access to new vector control tools was an iterative process informed by the results of the 
three case studies and documents reviewed. 
 
3.7 Ensuring Rigour 
In order to ensure the validity of the research and the robustness of its findings, the steps 
described below were taken to ensure rigour. 
 
3.7.1 Triangulation 
The data collected was triangulated, i.e., considered from at least two different points 
(157). As described above, two data collection techniques were used to ensure the validity 
of the data and to provide a comprehensive picture of the study (163). Responses from the 
KIs, where possible, were triangulated using the documents reviewed by looking into the 
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wider literature on policymaking in order establish similar or contrary explanations for the 
research findings. 
 
3.7.2  Transparency of Methods and Analysis 
Transparency of the research and analyses conducted was achieved by providing a full 
description of the research process. In addition, KI interview results and interpretation of 
the data quotes are provided to demonstrate findings. 
 
3.8 Ethical Considerations 
This thesis was carried out with a view to ensuring no harm was done to the participants of 
the research, that their privacy and anonymity was ensured, that their confidentiality was 
respected, that informed consent was obtained, and that the data collected was not 
misrepresented when interpreted or disseminated (157, 160). This was achieved by 
obtaining the following: 
 
3.8.1  Ethical Approval  
Prior to commencement of data collection, ethical approval was obtained from the 
Liverpool School of Tropical Medicine Ethics Committee in relation the studies in Nigeria, 
Burkina Faso and at the global level. In addition, in Nigeria, ethical approval was obtained 
from the Nigerian National Research Ethics Committee (Annex 12); in Burkina Faso, 
approval was obtained from the National Research Ethics Committee - ‘Comite D’ethidue 
pour La Recherche En Sante’ (Annex 13) as well as the CNRFP Research Ethics Committee 
(Annex 14). Approval from the CNRFP ethics committee was required in order for their 
member of staff to take part in data collection (i.e., KI interviews) in Burkina Faso. The 
ethics approval from Liverpool School of Tropical Medicine (Annex 15) covered the global 
study and no additional ethics approval was deemed necessary. 
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3.8.2  Informed Consent 
Prior to interviews, each KI was provided with a copy of the research information sheet 
(Annex 16), a copy of the consent form (Annex 17) and, where requested, a copy of the 
interview guide. At the start of each interview, the interviewer went through a printed copy 
of the consent form with the KI and reiterated what their involvement in the research 
would be, what would be done with the information provided and that they could 
withdraw from participating at any time. The consent form asked for preferences to be 
indicated in terms of use of quotes and permission to be audio recorded. All KIs were asked 
to sign the consent form before participating in the study. Across the three studies, only 
one KI agreed to take part in the study but not be audio recorded; in that instance, detailed 
notes were taken and typed up within 24 hours of the interview. In three instances, once in 
the Nigerian study and twice in the global study, the KI asked for the recorder to be 
stopped at certain points during the interviews and then restarted when the sensitive 
information had been shared. Such information was not quoted or used as part of the 
formal analysis but added to the context and lens through which the data was analysed. 
 
3.8.3  Confidentiality and Anonymity 
Procedures were taken from the research design stage through to the data collection, 
analysis and dissemination stages to ensure that confidentiality and the anonymity of the KIs 
was maintained, particularly given that the KIs in this research are relatively high profile 
individuals, as follows:  
i. Interview data was separated from any means of identifying the KIs 
(codes linking interview data to individuals were stored separately and securely);  
ii. All data collected was stored securely in a password-protected computer. Only those 
directly involved in the research (researchers and supervisors) have had access to the 
primary data files;  
iii. Data from individual interviews has not been discussed or disseminated in 
ways that might make an individual identifiable;  
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iv. In order to avoid the possibility of individual identification quotes have been made 
anonymous. Furthermore, where requested, each KI was given the opportunity to 
read their section/quotations of the analysis before it being included in the report 
and were given the option of not being quoted at all, anonymously or otherwise;  
v. Where direct quotations are used to illustrate a point, they have been made non-
attributable to the individual and only the perspective of the individual providing the 
quote has been indicated, e.g., researcher; vii) Given the relatively small and 
connected pool of actors in this field, there is a risk that KIs can be identified by their 
perspective and responses. KIs were fully informed of how the study would utilise 
their data and opinions so they could moderate their responses accordingly;  
vi. In instances where data has been collected from one individual within a given 
category – anonymity has still been maintained as interviewees have been sampled 
from a wider pool of possible respondents (e.g researchers in Nigeria) or the 
classification of respondent has been broadened. For example in the global study 
where the policymaker category was broaden to policy advisors in order to  include 
WHO (technically the only policymaker at the global level)  as well as its policy 
advisors structures.  
vii. When writing up the study results, care has been taken to present the arguments in 
a constructive action-oriented way.  
 
3.8.4  Protection from Harm for Key Informants and the Researcher 
The research, and consequently the interviews, focused on decision-making procedures 
within the malaria vector control field, and did not cause undue physical distress. A 
potential source of sensitivity was in discussing the intimate decision-making processes 
within national and global organisations, resource allocation decisions and/or power play 
with/between institutions. In order to minimise this risk, KIs were reassured of their ability 
to withdraw from the study at any point; secondly, KIs were encouraged to only share what 
they felt comfortable sharing and could choose not to respond to some questions if they so 
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wished. As stated above, on three occasions, KIs opted to go off record and, on a number of 
occasions, KIs opted not to respond to a question.  
 
Care was taken to choose an appropriate interview time and venue and to keep the 
duration of the interview to a maximum of 90 minutes so as to avoid any problems with 
using up valuable working time of KIs.  
 
A potential source of discomfort to the researcher was in the review and dissemination of 
information provided by influential actors within national and global vector control 
policymaking processes. Where the findings of the research were deemed to be sensitive, the 
researcher was guided by her thesis supervisors in the presentation of the results in a 
manner that maintained the integrity of the research while ensuring diplomacy on sensitive 
issues.  
 
3.8.5  Reciprocity and Dissemination 
KIs will also be provided with an opportunity to access the full study report upon request. 
Results of Chapter 4 have been published in a peer-reviewed journal (Annex 20). Results of 
Chapter 5 have been accepted for publication in a peer-reviewed journal, whereas the results 
of Chapters 6 and 7 will be submitted for publication in due course. 
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4 Results:  National Malaria Vector Control Policy: An 
Analysis of the Decision to Scale-up Larviciding in Nigeria 
ABSTRACT 
Background: New vector control tools are needed to combat insecticide resistance and 
reduce malaria transmission. WHO endorses larviciding as a supplementary vector control 
intervention using larvicides recommended by WHOPES. The decision to scale-up 
larviciding in Nigeria provided an opportunity to investigate the factors influencing policy 
adoption and assess the role that actors and evidence play in the policymaking process, in 
order to draw lessons that help accelerate the uptake of new methods for vector control. 
 
Methods: A retrospective policy analysis was carried out using in-depth interviews with 
national level policy stakeholders to establish normative national vector control policy or 
strategy decision-making processes and compare these with the process that led to the 
decision to scale-up larviciding. The interviews were transcribed, then coded and analyzed 
using NVivo10. Data were coded according to pre-defined themes from an analytical policy 
framework developed a priori. 
 
Results: Stakeholders reported that the larviciding decision-making process deviated from 
the normative vector control decision-making process. National malaria policy is normally 
strongly influenced by WHO recommendations, but the potential of larviciding to 
contribute to national economic development objectives through larvicide production in 
Nigeria was cited as a key factor shaping the decision. The larviciding decision involved a 
restricted range of policy actors, and notably excluded actors that usually play advisory, 
consultative and evidence generation roles. Powerful actors limited the access of some 
actors to the policy processes and content. This may have limited the influence of scientific 
evidence in this policy decision. 
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Conclusions: This study demonstrates that national vector control policy change can be 
facilitated by linking malaria control objectives to wider socioeconomic considerations and 
through engaging powerful policy champions to drive policy change and thereby accelerate 
access to new vector control tools. 
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4.1 Introduction 
The scale-up of vector control has been critical to the reduction in malaria transmission 
seen over the past decade (5). Key tools for vector control include LLINs and IRS (168). 
In sub-Saharan Africa, the percentage of households owning at least one insecticide-
treated net increased from 3% to 54% between 2000 and 2013 (168), with the number 
of nets delivered to malaria endemic countries by manufactures increasing from 6 to 
136 million between 2004 and 2013 (168). However, new vector control tools are 
urgently needed to combat the increasing resistance that is threatening the 
effectiveness of existing insecticide-based interventions (5, 37) and to control malaria 
vectors not targeted by current interventions (e.g., those that bite outdoors). 
 
LSM is the management of water bodies that are potential breeding sites for malaria 
vectors. It includes habitat modification or the addition of chemicals to water bodies to 
prevent the development of adult mosquitoes (larviciding). Larviciding has been 
recognised as a valuable addition to malaria vector control in specific settings. WHO 
recommends that, in sub-Saharan Africa, LSM should only be implemented as a 
supplement to LLINs and IRS in clearly defined habitats, particularly in urban areas 
where malaria vector breeding sites are few, fixed and findable (7, 67). In 2012, national 
malaria control programmes in six African countries reported using larviciding (67). 
 
In recent years, Economic Union of West African States (ECOWAS) has generated a 
renewed interest in scaling-up larviciding in West Africa. A tripartite agreement 
between ECOWAS, Venezuela and Cuba was signed in 2009 to provide financial and 
technical support to scale-up larviciding in the region with a view to eliminating malaria. 
Technology transfer for the establishment of microbial larvicide factories in Ghana, 
Nigeria and Cote d’Ivoire forms part of the agreement, in a bid to create jobs and make 
larvicides readily available in the region (169). Microbial larvicides have been shown to 
be protective against malaria, but only one strain (Bacillus thuringiensis subsp. 
israelensis, strain AM65-52, WG) has been approved for larviciding by WHOPES (170). 
The ECOWAS larviciding plans involve the use of two larvicides produced by the Cuban 
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company, Labiofam. These larvicides, Bactivec® (Bacillus thuringiensis SH-14) and 
Griselesf® (Bacillus sphaericus stump 2362), do not currently have WHOPES approval. 
 
Malaria is endemic in Nigeria and remains a serious public health problem with 97% of 
the total population at risk of infection (171). LLINs are the main prevention strategy in 
the country, with the current National Malaria Strategic Plan (NMSP) aiming for 80% 
LLIN ownership and use by 2013 (172). However, only 41% of households have at least 
one LLIN (171). IRS is considered a complementary strategy to LLINs in Nigeria and has 
been piloted in some states (coverage 1% within the targeted states), with the objective 
of being scaled-up to cover 20% of the targeted states’ population, primarily in urban 
areas, by 2013 (171). LSM (including larviciding) is included in the current NMSP (172, 
173), but its use to date has been extremely limited. Thus, plans to scale-up larviciding 
nationwide, using non-WHOPES-approved products, represents a deviation from the 
current malaria control strategy in Nigeria. 
 
Given the alarming rise in insecticide resistance in Africa, it is likely that many countries 
are going to have to consider changing their vector control policy and deploying 
additional vector control interventions. The decision to scale-up larviciding in Nigeria 
provided an opportunity to investigate the factors influencing policy adoption and 
assess the role that actors and evidence play in the policymaking process in order to 
draw lessons that help accelerate the uptake of new methods for vector control. 
 
4.2 Methods 
4.2.1 Analytical Framework 
A review of the literature on policy analysis was carried out to identify suitable 
analytical frameworks for policy analysis. An analytical framework which combines the 
policymaking context, actors, process, content, power (77), and the role of evidence in 
policymaking (151) was developed (Figure 4 and 
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Table 4).  
 
 
 
 
Figure 4. Analytical framework 
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Table 4. Definitions of terms used in the Analytical Framework (Adapted from Walt 
and Gilson [103]) 
Framework Category Definition 
Context Systemic factors, including political, 
economic and social, at national and 
international levels, that influence vector 
control policy 
 
Actors Stakeholders (individuals or organisations) 
that make/influence vector control policy 
 
Process The way polices are developed 
 
Content The technical content of the specific policy 
under analysis 
 
Evidence in policymaking “Any form of knowledge, including, but 
not confined to research, of sufficient 
quality to be used to inform decisions” 
(81) 
  
Power  The ability to influence, and in particular, 
the ability to control resources; power is 
characterized by authority, finances, and 
access to knowledge 
 
The framework was used to guide all aspects of the study from the identification of 
documents for the desk review, identification of KIs, development of study instruments, 
and data analysis. The concept of power, which can be expressed in various ways, is a 
crucial element of the Walt and Gilson framework (77). In this article, we investigate a 
number of dimensions of power expressed in the policy process including ‘decision-
making’ (174), ‘agenda setting’, (175), ‘thought control’ (176), and the ability to 
undermine influence (177). Recognising that power is methodologically difficult and 
sensitive to investigate (79, 178), we sought to gather information by asking questions 
on which actors carried the most influence in the policy process and why. 
 
4.2.2  Document Review 
A review of published and unpublished national documents was undertaken to 
understand the national vector control policy context, identify the content of the 
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national vector control policies, identify the key actors involved in national vector 
control, and inform the development of the semi-structured interview guide. 
Documents reviewed included national malaria policies, strategies and guidelines; 
national malaria vector control policies, strategies and guidelines; organograms and 
structures of the Federal Ministry of Health (FMOH); and terms of reference and 
minutes of meetings of national policymaking bodies; policies, strategies, action plans, 
press releases and web pages of policymaking bodies as well as research, implementing 
and financing institutions involved in malaria vector control in Nigeria. 
 
Documents were sourced through online searches (Google Scholar and PubMed) and 
requests to relevant individuals and organisations. The review was supplemented with 
documents identified by stakeholders during interviews. To guide the document review, 
different categories of policy (health, meso and macro) and strategy, as used by Mays 
(179) and Buse (81), were defined (
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Table 5). 
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Table 5. Definitions of levels of policies 
Term Definition 
Health Policy Decisions, plans, and actions that are undertaken to achieve 
specific healthcare goals within a society; it defines a vision for 
the future which in turn helps to establish targets and points of 
reference for the short and medium term; courses of action (and 
inaction) that affect the set of institutions, organisations, 
services and funding of the health system  
Macro-level 
policies 
National high level policies that are generally broad in nature 
and require several inputs to achieve their aspiration, e.g., 
reduce child mortality 
Meso-level policies National programme level translation of a macro policy into a 
working structure for an implementable programme, e.g., 
universal coverage of LLINs, targeted use of IRS 
Strategy Strategy is the direction in which the human and physical 
resources will be deployed and applied to achieve the objectives 
of the policies, e.g., universal coverage of LLIN (the policy) 
through the free mass distribution to households (the strategy) 
 
4.2.3  Identification of Key Informants (KIs) 
The document review identified a broad range of stakeholders involved in the vector 
control policymaking process in Nigeria. These were categorised as policymakers, 
researchers, private sector representatives, multilateral agency representatives, and 
NGO representatives. For the purposes of this study, policymakers include staff of the 
FMOH working in the National Malaria Control Programme (NMCP); NGOs include 
respondents from national NGOs implementing malaria control projects; multilaterals 
include United Nations technical agencies as well as multilateral funding institutions 
supporting malaria control; researchers include those working in academia as well as 
those in national institutes of research; and private sector refers to those in the 
commercial for-profit sector involved in the sale of vector control tools and insecticides. 
KIs were purposefully sampled to cover a comprehensive subset of the national 
stakeholders and represent each stakeholder category. 
A list of KIs was drawn up and contacted to request interviews. A greater number of 
participants were interviewed from the NGO category as they made up the largest 
number and diversity of organisations and individuals contributing to the policymaking 
process. The initial list of KIs was expanded to include additional KIs identified during 
interviews. 
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All KIs were anonymised by assigning interviewee numbers so that their names and 
affiliations/institutions were not identifiable. However, quotes are assigned to their 
stakeholder category, e.g., policymaker or NGO, in order to highlight their perspective. 
 
4.2.4  Data Collection 
The interviews followed a semi-structured, open-ended format and were structured to 
explore the context, actors, process, content, power, and the use of evidence in both i) 
national vector control policy decisions and ii) in the planned scale-up of larviciding. See 
Annex 9 the interview guide. In March 2013, the researcher conducted the interviews in 
English in Abuja, Nigeria. The interviews were transcribed by a transcription service and 
the researcher checked all for accuracy. 
 
4.2.5  Data Analysis 
The researcher entered interviews into NVivo10 for data management and analysis, and 
coded data according to the pre-defined themes in the policy framework using content 
analysis. Key themes were then summarised into areas of consensus and divergent 
views across stakeholder perspectives, and quotes used to illustrate key themes. All 
authors were involved in the analysis and interpretation of data. 
 
4.3 Results 
A total of 14 national level stakeholders were interviewed: three policymakers, one 
researcher, one private sector representative, four multilateral agencies, and five 
NGOs. The interviewees were a comprehensive subset of the potential respondents. All 
key in-country Roll Back Malaria (RBM) and 14 of the 20 members of the Integrated 
Vector Management Subcommittee (IVM-SC) (the main technical body coordinating 
government and stakeholder input into vector control policy) were interviewed, 
encompassing all identified stakeholder categories. Table 6 presents the matrix of all a 
priori themes and sub-themes that emerged from analysis. 
 
Table 6. A priori themes and emergent sub-themes Nigeria Policy Analysis 
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 A Priori Themes from thesis 
analytical framework 
Emergent Sub-themes 
1 Context - 
  Larviciding Context 
2 Actors Policy/strategy decision making actors 
  Advisory/technical Actors 
  Consultative Actors 
  Evidence generation Actors 
  Larviciding Actors 
3 Process Larviciding policy process 
4 Content Larviciding Policy content 
5 Evidence in policymaking Larviciding Evidence in policymaking  
6 Power I.  
 
The narrative for the results is based on the document review and KI perceptions. The 
normative process is as described by the Framework for the coordination of malaria 
control programme in Nigeria (180) and the WHO Malaria Programme Review 2013 
(181) supplemented by the respondents’ perceptions of the ‘normal’ policy process. 
The larviciding decision-making process is then compared and contrasted with this 
‘norm’. 
 
4.3.1 Normative Vector Control Policy Analysis 
4.3.1.1 Context 
Nigeria is a Federation of 36 states, with three tiers of government (federal, state and 
local), each of which has a constitutional mandate to formulate and implement health 
policies and programmes (181). The primary effect of the federal nature on the vector 
control policymaking context was the recognition by all respondents that, while the 
federal government has oversight of health policy, states can choose which vector 
control strategies to resource and implement based on their local context. 
 
“You see the nature of Nigeria is such that even when policies are made in the national 
level it is now left to the State to adopt it” (Researcher) 
 
Vector control policymaking is heavily influenced by WHO policies and 
recommendations of universal coverage of LLINs and the scale-up of IRS. 
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“... We align A LOT with the Global Malaria Programme, WHO” (Policymaker) 
 
The health policy context is also influenced by the NMCP’s role in contributing to the 
wider national health, social and economic development objectives as articulated in the 
2010 Nigerian National Strategic Health Development Plan (182) and the Nigerian 
Vision 2020 strategy (183). National policy documents revealed that national malaria 
vector control policymaking largely involves meso-level policies and decisions around 
appropriate vector control strategies, i.e., the working structure of implementation. 
Thus, when KIs were asked about policymaking, they invariably spoke about strategy 
decision-making. 
4.3.1.2 Actors 
Actors involved in vector control strategy decision-making generally participated in one 
or more of four main capacities: i) policy/strategy decision-making; ii) 
advisory/technical; iii) consultative; and iv) evidence generation. Figure 5 presents a 
synthesis of respondents’ views on the actors and their roles in the strategy decision-
making process. 
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Figure 5. Functions of actors in vector control policymaking 
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All KI’s recognised that the FMOH has ultimate responsibility for health policymaking in 
Nigeria. The NMCP, as a department of the FMOH, executes policy and fulfils a 
coordination role. States have concurrent jurisdiction to make policy and strategy 
decisions. 
 
“National malaria control program is statutorily responsible for policymaking, as a 
division in the federal ministry of health because, you know, in Nigeria health is 
decentralised, national, state and then the local government levels” (Policymaker) 
 
Respondents cited the ministries of education, information, women’s affairs, 
environment, agriculture and finance as stakeholders in the vector control strategy 
decision-making process. Regulatory bodies such as the National Agency for Food and 
Drug Administration and Control, who oversee the use of products such as insecticides, 
were also cited as being critical to vector control strategy decision-making and 
implementation. 
 
Advisory/technical: All partners involved in malaria control in Nigeria are members of 
the RBM, led by the FMOH (181). They provide advice to the NMCP, helping steer the 
overall direction of malaria control activities. As a group, they engage with the strategy 
decision-making process through the Ministerial Coordination Committee on AIDS, TB 
and Malaria (181), which is composed of three technical working groups (one for each 
disease). The Malaria technical working group has six sub-committees (mirroring the six 
NMCP departments) including the IVM-SC. The main technical input into vector control 
strategy decisions by stakeholders is through the Integrated Vector Management Sub-
Committee (IVM-SC) (180). 
 
Consultative: KIs recognised that stakeholder consultation and consensus building is an 
integral part of the vector control strategy decision-making process. While there were 
no clearly defined junctions where consultations take place, it was recognised, across all 
respondent categories, that consensus should be built across a wide range of actors to 
facilitate strategy adoption and successful implementation. 
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“It is recognised that malaria control is a collective responsibility and that in coming up 
with a strategy the platform for debate needs to be expanded to segments of the public, 
private, civil society” (NGO) 
 
Evidence generation: All KIs recognised that WHO recommendations provide the first 
line of evidence used to support or oppose a vector control strategy. However, it was 
also recognised that WHO recommendations are broad, leaving room for tailored 
interpretations at country level depending on local context. 
 
“... but we cannot just grab it [evidence] and change our policy ... everything that comes 
into the country must be piloted, so the evidence we generate from that pilot will inform 
our decision as to whether we can include it in our policy” (Policymaker) 
 
The NMCP coordinates with researchers from academic and research institutions to test 
new products in local trials for vector susceptibility and community acceptability. KIs 
from the public and private sector reported that the norm is for manufacturers to 
finance these trials with the NMCP and researchers overseeing the testing. This locally 
generated evidence is a prerequisite for the adoption of a vector control strategy, 
particularly in determining which insecticides to use. 
 
“Everything that comes into the country that has a potential of adding value into vector 
control must be piloted, so the evidence we generate from that pilot will inform our 
decision as to whether we can include it in our policy” (Policymaker) 
 
Research institutions, such as the National Institute of Medical Research and individuals 
from a number of universities at national and, in some cases, state level, also 
participate in the IVM-SC. However, without a clearly formalised link or tradition of 
commissioning research by the NMCP this interaction is more opportunistic and based 
on personal relationships. 
 
“... The country as a whole does not have a health research plan and so when people do 
research they do research to publish, to get promotion ... ... there is no formal channel, if 
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I find something that is interesting the only thing I can do is talk to my director who can 
then call a press briefing” (Researcher) 
 
4.3.1.3 Policymaking Process 
Interviewees from all categories reported that the normal policy process is initiated by 
a recognised failure in this strategy, the potential for new funding or the availability of 
new evidence. The IVM-SC is the forum for debating the need for, and evidence in 
relation to, a strategy adoption or change (180). Interviewees all agreed that strategy is 
normally developed primarily by the NMCP in collaboration with the members of the 
IVM-SC, and channelled to the national coordinator and then the Minister of Health for 
endorsement with consultation of wider stakeholders at key points in the process. 
 
“These sub-committees are made up of partners who are experts ... so when a policy is 
about to be made, these partners come together and brainstorm and take a decision on 
if that policy will benefit the country and if they think it would, then they work on it and 
then send it to the Honourable Minister of Health for him to ratify” (NGO) 
 
In some instances, the decision is referred to the National Council on Health (NCH) and 
the Federal Executive Council (FEC). While there was uncertainty around what factors 
trigger the involvement of NCH and FEC, the use of government funding was cited as 
one potential factor. 
“A lot of time if that policy involves Nigeria’s money it will have to go to the FEC” (NGO) 
 
4.3.1.4 Content 
The policy targets and progress against them for malaria vector control in Nigeria are 
summarised in Table 7. 
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Table 7. Targets and progress: malaria vector control in Nigeria  
 
 
Intervention 
Progress to 2010  
(184) 
2013 Target (172) 
Indoor Residual Spraying 
(IRS) 
 
1% of target population 
received IRS  
At least 80% of targeted 
population protected 
Distribution of Long 
Lasting Insecticide-
treated Nets (LLINs) 
 
42% ITN household 
ownership and 29% use 
achieved  
At least 80% of households 
with two or more LLINs/ITNs 
and 80% use by 2013 
Larviciding Piloted in four states 
 
As appropriate in some 
selected areas 
 
4.3.1.5 Evidence 
When asked about evidence, KIs cited a wide range of sources as trusted forms of 
evidence. These included WHO recommendations, results from household surveys, 
systematic reviews, meta-analyses, published literature, implementation research, 
feedback, and results of locally generated evidence. 
 
“First and most important will be WHO recommendations, second will be published 
literature and documents from RBM working group, and then the last will be lessons 
learnt documentation and reports” (NGO) 
 
KIs viewed scientific evidence as being useful for lobbying, creating awareness, 
documenting objective positions, defending decisions, and catalysing change. However, 
it was recognised that the necessary evidence was not always available. Furthermore, 
different stakeholders value and prioritise evidence differently. For example, 
respondents involved in funding malaria, typically external donors, appeared to place 
more value on the use of cost-effectiveness in decision-making. 
“...most of it is donor money, so donors are more aware of trying to get the best bang 
for their buck” (NGO) 
 
“Cost-effectiveness has been a concept of donors, UN agencies, partners and not 
government, sensu stricto” (Multilateral) 
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Whereas policymakers prioritise locally generated evidence. 
 
“What I am trying to say is that, local evidence is very critical, but you must compare it 
with the standard” (Policymaker) 
 
Finally, it is recognised that, in the process of decision-making, evidence can be ignored. 
As the debate proceeds from the technical to the political levels, wider political and 
socioeconomic factors can come more strongly into play. 
 
“But the disconnect is when it gets to minister of health a lot of political influence comes 
into play” (NGO) 
 
4.3.1.5.1 Power 
Interviewees identified two main groups of actors as having the most influence in the 
policy process. First, all stakeholder categories recognised the national and state 
government’s mandate to endorse policy decisions, thus conferring significant influence 
over the process. 
 
“For national policymaking, policy change decision-making, definitely as I told you 
before is the government” (Multilateral) 
 
Second, donor influence was viewed as a key driver in the policy process. Respondents 
generally viewed the biggest catalyst for policy change as donor funding with one 
respondent citing the Global Fund to Fight AIDS, Tuberculosis and Malaria as an actor 
that has been able to utilise its financial power to drive through a number of policy 
changes. 
 
“The potential for new funding could drive a policy process, for instance if a donor has 
an interest in helping in the country changes its policy ... And this is very common with 
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Global Fund, for instance it has been able to drive a number of policy changes that go 
faster than ordinarily because the motivation to change the policy is there” (NGO) 
 
4.3.2  Larviciding Policy Analysis 
4.3.2.1.1 Context 
One of the key factors that facilitated the decision to scale-up larviciding was its 
potential to contribute to national economic development objectives through the 
technology transfer and the establishment of a microbial larvicide factory in Nigeria. 
 
“In a country like Nigeria definitely there is interest to see more job creation, more 
wealth creation” (NGO) 
 
“At the point at which an intervention is targeted at economic development but is said 
to have benefits for malaria control be it remotely or otherwise, and the audience for 
that has a bigger agenda and malaria control is just the smallest part of it, the tendency 
is that the malaria message gets drowned out” (NGO) 
 
These views recognise that contributions to the wider socioeconomic context can be 
highly influential in malaria vector control strategy decisions. 
 
4.3.2.1.2 Actors 
When asked about the actors involved in the decision to scale-up larviciding in Nigeria, 
interviewees cited ECOWAS, the office of the Presidency of Nigeria, and the Minister of 
Health. None of the interviewees mentioned that the decision had been technically 
debated at the IVM-SC level. A number of actors who normally participate in vector 
control policy decisions felt excluded from the larviciding decision, particularly those 
that play advisory, consultative and evidence generation roles. 
 
“It’s a closed [discussion] ... in fact it’s not something we should talk about. That’s why 
the donor agencies or development partners in Nigeria are against that project, because 
it is shielded from them” (Private sector) 
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“The discussion on larviciding did not include donors” (NGO) 
 
4.3.2.1.3 Process 
Interviewees reported that the decision-making process for larviciding deviated from 
the normal vector control decision-making process. The process flowed from the top 
(ECOWAS and presidential levels) to the bottom (NMCP level). The prevailing 
perception by all interviewees was that decisions were taken at high levels. 
 
“There is nothing people like us can do where the minister meets and ECOWAS takes a 
decision that this is what we want to do” (Researcher) 
 
The normal vector control policy process is contrasted with the larviciding process in 
Figure 6. The larviciding decision process, as described by the respondents, was shorter, 
appears to have been started by a decision at the highest levels of government, and 
circumvented a number of policy processes and actors that are reflected in the normal 
processes of vector control policymaking. 
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Figure 6. Vector control actors and processes: normative versus larviciding example 
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4.3.2.1.4 Content 
The Nigerian NMSP 2009–2013 currently recognises the “limited application of 
larviciding and environmental management” for vector control (172). A new NMSP for 
2014 and beyond is being developed and it is expected that it will feature larviciding 
more prominently to reflect the country’s commitment to nationwide scale-up. Beyond 
that, KIs were unable to give details of what the larviciding strategy would entail. 
 
4.3.2.1.5 Evidence 
Most respondents cited the use of some evidence to support the larviciding decision. 
KIs reported that ‘small’ evidence, i.e., evidence from the local pilot projects supported 
by the larvicide manufacturer, was used as the basis for the decision to implement 
larviciding at scale. This is in line with the reported norm for evidence in policymaking, 
with locally produced evidence being used to validate international evidence in the 
local context. However, in this instance, results from local trials were used to support 
the use of the Bactivec® strain, which is not recommended by WHOPES, and some 
actors, primarily those outside of government, perceived that the evidence produced 
was not open to scrutiny and debate. 
 
“It may not be big evidence, because I know people are looking for the big evidence, … 
we don’t have that type of evidence we are still generating” (Policymaker) 
 
“These studies were just to find out the efficacy of some of the larvicides, it is not an 
extensive one but just to determine the efficacy and once that has been determined, we 
said ok if we deploy this thing, following the appropriate standard and the best practices 
that will be able to achieve much hence we decided to do that” (Policymaker) 
 
Members of the broader stakeholder group were either unaware of the role of 
evidence or questioned the quality of the evidence used in the decision-making 
process. 
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“I’m sure it [evidence] would have played some role, but then like I said, the decisions 
were taken at a higher level ...” (NGO) 
 
“I don’t want to use the word ‘questionable’. But also there are doubts, there are 
concerns as to the concrete, you know like the strength of their evidence” (NGO) 
 
“There is no evidence there. In fact, from what I know the matter has gone up high 
before the evidence were being gathered” (Private sector) 
 
“There was this larviciding project that was embarked upon by Rivers State government 
by Labiofam where they used some insecticide and the report indicated that malaria 
prevalence in Rivers State actually had come down” (Policymaker) 
 
The prevailing view amongst the wider stakeholders is that there exists little evidence 
and no policy framework to support nationwide larviciding in Nigeria with Bactivec®. All 
stakeholders, except for the policymakers, held this view. 
 
“No scientific evidence to support the decision to carry out nationwide larviciding” 
(NGO) 
 
“In Nigeria they got it wrong; the larviciding they want to do is not based on any policy” 
(Private sector) 
 
The stakeholders’ objection to the larviciding strategy in Nigeria is summed up by three 
arguments. First, that Nigeria does not represent an appropriate context for the 
larviciding: 
 
“I think we do not represent the kind of place that larviciding would be effective on a 
large scale” (NGO) 
 
However, the policymakers assert that the implementation of larviciding will be aligned 
to the WHO position on larviciding. 
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“It is going to be in the context of that “few, fixed and findable,” unfortunately many 
people who are inside the box think that we are taking larviciding everywhere in Nigeria 
is not like that … no reasonable technical person will, it doesn’t make sense” 
(Policymaker) 
 
Second, there were concerns that the selection of larvicide strain used was not 
WHOPES recommended, which contradicts the usual reliance on WHO 
recommendations and that the local evidence generated and used to support this 
decision was not sufficiently robust or independent. 
 
Finally, and perhaps where the strength of the wider stakeholder’s argument lies, is in 
the fact that larviciding represents a distraction from the primary malaria control 
interventions. 
 
“When you look at malaria control, spending all this money on larviciding when you 
don’t have sufficient funding to fill all your gaps for other commodities, you know, from 
a cost effective perspective, it would be more cost effective to take that money and put 
it into nets, if you’re doing vector control or RDTs [Rapid Diagnostics Test] or ACTs 
[Artemisinin-Combination Therapy] right, from a whole perspective of Malaria control” 
(NGO) 
 
4.3.2.1.6 Power 
The tripartite agreement between ECOWAS, Venezuela and Cuba features financial and 
technical support to scale-up larviciding and technology transfer. Hence, financial 
power played a major role in the larviciding decision, but those exercising power were 
different to those perceived to wield this power in the normative situation. 
 
Rivers State, the site of some of the pilot studies used as evidence for scaling-up 
larviciding, is the proposed site of the bio-larvicide factory (169). The Rivers State 
governor is a highly influential politician, hence the technological and direct 
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socioeconomic benefits of larviciding to Rivers State potentially created a formidable 
champion for scaling-up larviciding. 
 
The commitment to scaling-up larviciding at the highest levels of government in Nigeria 
made the decision virtually unstoppable, with the hierarchical structure of the FMOH 
making the decision difficult to challenge. 
 
“At the point at which decisions are taken at the highest level of government the natural 
tendency from the government standpoint is you support the decisions that are made by 
our superiors” (NGO) 
 
In addition, there was an apparent restriction of information flow whereby all 
respondents, including those in NMCP, could not outline the details of the strategy for 
implementing larviciding beyond the fact that it will be scaled-up nationwide. This 
control of information limits the policy actor’s ability to debate and build consensus 
around the intervention in the usual way. 
 
4.4 Discussion 
This study is the first time that the decision to scale-up larviciding has been compared 
with normal policymaking processes in Nigeria. A review of the health policy analysis 
literature up to 2007 (124) included only six articles on malaria, all of which focused on 
treatment policies in Africa. Since then, there have been a number of policy analyses in 
sub-Saharan Africa looking at malaria treatment policy (128, 129, 185, 186), malaria in 
pregnancy interventions (187), and diagnosis (132). 
 
Changing malaria policy is generally seen to be a complex process (138, 188). For 
example, the adoption of LLINs as global and subsequently national policy across sub-
Saharan Africa was a lengthy process involving multiple studies to demonstrate efficacy, 
effectiveness, cost-effectiveness, and acceptability to end-users (22). In the southern 
and east African contexts, policy analyses have been carried on integrated vector 
management (127, 189), malaria control including vector control (126, 133), malaria 
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vector control (125) and IRS (190). These studies have highlighted the value of local 
champions, international networks and the involvement of researchers in policy 
development in translating research into policy (133). They also identified the critical 
importance of empirical data in informing decision-making and a need for a 
coordinated multipronged approach to vector control (189). These studies demonstrate 
how factors, such as outside influence and past experience of an intervention, can slow 
the process of policy change (125). 
 
Policy analysis literature from South East Asia identifies similar critical factors in shaping 
policy despite being primarily focused on HIV/AIDS and universal health coverage (75, 
191-193). Only one study in this context addresses malaria policy change, but focuses 
on the region’s unique epidemiological challenges. The focus on regional cooperation to 
deal with cross border malaria transmission and elimination is not currently directly 
comparable to the sub-Saharan African context (194). 
 
The larviciding decision in Nigeria demonstrates a number of examples of power in 
policymaking. The decision was characterised by a top-down policy process with the 
FMOH overtly exercising its power to involve new actors and restrict the involvement of 
some traditional actors. All participants recognised that the Nigerian government had 
the ultimate decision-making power in policymaking. However, a tradition of involving 
the RBM partners, private sector, NGOs and the research community has created the 
expectation of wider participation and power sharing. This consultative process usually 
creates opportunities for debates to occur and promotes the production and exchange 
of evidence (108). Hence, the decision to restrict the actors involved and knowledge 
shared in the policy process allowed for selective use of evidence, akin to what Weiss 
describes as the political use of research (110), causing concern over the quality of 
research evidence used in policymaking as observed in other contexts (127). The 
actions of the FMOH undermined the norm of closely adhering to WHO policies, which 
traditionally set the context (agenda) for policymaking in malaria control. 
 
Studies have cited a belief that donor preferences and agendas were exerting too much 
influence on malaria policies in the countries and that national level government actors 
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are not adequately engaged in malaria control policymaking (126). In this instance, 
national leadership/ownership of a policy decision and engagement of different actors 
was highly controversial and heavily criticised. In 2012, WHO published an interim 
position statement on the role of larviciding in malaria control (7) in a bid to provide 
clear recommendations as a number of countries explored the use of larviciding. 
Alongside WHO’s technical mandate, it is arguable that this statement had the power to 
influence global opinion, i.e., an exercise of power as thought control. It is difficult to 
ascertain if the reaction of traditional actors was based only on the cited technical 
reasons, or if it was also due in part to displeasure at their power to influence being 
undermined. Either way, this analysis highlights a potential conflict between greater 
national ownership of malaria policy decisions and adherence to internationally 
recognised standards and policy guidance which some view as an externally imposed 
donor construct. 
 
This study demonstrates the persuasive power, especially to national policymakers, of 
considering the wider socioeconomic context of vector control. The proposed local 
manufacture of the product, and the labour intensive nature of the intervention 
delivery, has potential to create large numbers of jobs and benefit the local and 
national economy. National level political actors may have selected the intervention 
based inter alia on the potential domestic economic benefits. The societal and 
economic benefits of controlling malaria are commonly used to justify intervention in 
malaria control. However, when it comes to selecting between alternative interventions 
to control malaria, the process and actors tend to focus on evidence of health benefits 
(effectiveness) and cost-effectiveness. Cost-effectiveness analysis ignores the wider 
economic benefits of malaria control to domestic economies. Economic evaluations of 
alternative vector control interventions at country level would do well to consider the 
domestic economic impact of each approach and, where these differ between 
interventions, it should form the basis of discussion/debate with stakeholders beyond 
the malaria/health sector. If interventions are effective and can be shown to have a 
positive economic benefit (either directly or indirectly through their impact on malaria) 
this could help generate additional domestic financing for malaria control. This would 
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help achieve the Abuja declaration target of 15% government contribution to health 
expenditure (195). 
 
Political analysts recognise that the policymaking process is highly variable, ranging 
from a set of clearly defined stages followed by the rational weighing of competing 
options with the selection of the most optimal choice (91), to a process of muddling 
through a complex and messy reality (92). In this study, interviewees reported a clearly 
defined decision-making process where evidence is weighed and the most appropriate 
option implemented. The decision to switch from targeted to universal distribution of 
LLINs was cited as a particularly successful example. The larviciding decision is a 
deviation from the reported norm, arguably falling on the messy end of the 
policymaking spectrum. Stakeholders seeking to engage in the process need to be 
aware of the risk that, even in countries with rational policymaking systems, deviations 
from the established norm may occur and each decision can be different. 
 
4.5 Conclusions 
This Chapter reaffirms that engaging powerful policy champions at the global and 
national levels can drive policy processes forward and thereby accelerate access to new 
vector control tools. It also suggests that a greater focus on the domestic economic 
benefits of malaria control could help generate greater domestic policy support and 
potentially finance for its control. However, care needs to be taken to ensure that 
inclusion of economic or other national goals does not result in health policies that are 
not based on evidence of intervention effectiveness and internationally recognised 
standards of best practice. 
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5 Results:  Challenges and Opportunities Associated 
with the Introduction of Next Generation Long Lasting 
Insecticidal Nets for Malaria Control: A Case Study 
from Burkina Faso 
ABSTRACT 
Background: Reductions in malaria incidence in Africa can largely be attributed to 
increases in malaria vector control activities; predominately the use of LLINs. With 
insecticide resistance affecting an increasing number of malaria endemic countries and 
threatening the effectiveness of conventional LLINs, there is an increasing urgency to 
implement alternative insecticides. The aim of this study was to identify potential 
challenges and opportunities for accelerating access to next generation LLINs in Burkina 
Faso, a country with areas of high levels of insecticide resistance. 
 
Methods: An analytical framework was used to guide the selection of key informants, 
data collection and analysis. Semi structured interviews were carried out with key 
informants in April 2014 in Burkina Faso. Interviews were conducted in French and 
English, audio recorded, transcribed and entered into NVivo10 for data management 
and analysis. Data were coded according to the framework themes and then analysed 
to provide a description of the key points and explain patterns in the data.  
 
Results: Interviewees reported that the policy architecture in Burkina Faso is 
characterised by a strong framework of actors that contribute to policymaking and 
strong national research capacity which indirectly contributes to national policy change 
via collaboration with internationally led research. Financing significantly impacts the 
potential adoption, availability and affordability of next generation LLINs. This confers 
significant power on international donors that fund vector control. National decisions 
around which LLINs to procure were restricted to quantity and delivery dates; the 
potential to tackle insecticide resistance was not part of the decision-making process. 
Furthermore, at the time of the study there was no WHO guidance on where and when 
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next generation LLINs might have a more positive impact on malaria transmission, 
severely limiting their adoption, availability and affordability. 
 
Conclusions: This study shows that access to next generation LLINs was severely 
compromised by the lack of global guidance. In a country like Burkina Faso where WHO 
recommendations are relatively quickly adopted, a clear WHO recommendation and 
adequate financing will be key to accelerating access to next generation LLINs. 
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5.1 Introduction 
Reductions in malaria incidence in Africa are largely attributable to improved vector 
control, predominately the use of LLINs, IRS and, to a lesser extent, LSM (5, 34). LLINs 
are one of the most cost-effective measures against malaria (24, 196), with WHO 
recommending universal coverage with LLINs (defined as universal access and use) for 
all people at risk of malaria (197). Currently, pyrethroids are the only class of insecticide 
approved for use on LLINs, and therefore the rapid increase in mosquito resistance to 
pyrethroids represents a serious concern (5, 37). The loss of LLIN effectiveness would 
be catastrophic, jeopardising the ability to achieve malaria control and elimination goals 
(198). 
 
Insecticide resistance management strategies and alternatives to conventional LLINs 
need to be implemented. One option is to provide access to ‘next generation LLINs’ 
treated with two or more insecticides (combination LLINs), or with an insecticide and 
the synergist PBO (PBO LLINs), designed to be more effective against pyrethroid-
resistant vectors. Access to new LLINs requires the ability to acquire and use them. In 
this study we adopt the Frost and Reich view that access is a series of logistical, 
economic and political processes that affect acquisition and use (120).  
 
Two PBO LLINs (PermaNet® 3.0 and Olyset® Plus) are currently available on the market 
after receiving WHOPES interim approval as standard LLINs in 2008 and 2012, 
respectively (60, 61). In 2014, the WHO VCAG, whose remit is to advise WHO on new 
forms of vector control, recognised PermaNet® 3.0 as having “increased bio-efficacy” 
compared to pyrethroid-only LLINs in areas of insecticide resistance (62). 
Recommendations for evaluating next generation nets have recently been published 
(62), but at the time the study was conducted, there were no normative guidelines on 
when and where these should be deployed. Burkina Faso is one the few countries 
where a PBO LLIN was deployed as part of a national campaign in 2010 and 2013 (199). 
 
Chapter 5 presents an analysis of the context, content, processes, actors, power, and 
role of evidence in malaria vector control policymaking in Burkina Faso and of the 
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decision to deploy PBO LLINs in a national campaign in Burkina Faso. The study aims to 
identify potential challenges and opportunities for accelerating access to new vector 
control tools in Burkina Faso.  
 
5.2 Methods 
 
5.2.1  Study Site  
Insecticide resistance is widespread in Burkina Faso (200) and, in the southwestern 
region of the country, the high level of resistance is reducing the susceptibility of insects 
to insecticides on conventional LLINs (45). Furthermore, despite two LLIN distribution 
rounds in 2010 and 2013, and over 70% of children under the age of 5 years reportedly 
sleeping under LLINs (201, 202), the national prevalence of P. falciparum was 61% in 
children aged 6 months to 5 years in 2014 (202). Detailed follow-up studies in different 
regions of the country have found no reduction in malaria rates following the 2010 
distribution programme (203, 204). It has recently been confirmed that a third of the 
nets procured by Le Programme d'Appui au Développement Sanitaire (PADS, the 
procurement department of the Ministry of Health) for the 2010 distribution were 
counterfeit, non-WHOPES-approved LLINs, packaged as genuine WHOPES-approved 
LLINs (205). The GFATM Office of the Inspector General has highlighted significant 
weaknesses in the procurement process for the 2010 campaign. These weaknesses 
were exploited by two suppliers who provided almost 2.7 million nets that were not 
properly treated with insecticide and reportedly caused side effects to recipients (205). 
At the time the interviews for this study were conducted, knowledge of this fraud was 
not in the public domain and the study team were not aware of it. Approximately 1.6 
million (20%) of the LLINs distributed in 2010 were a PBO LLIN, PermaNet® 3.0 (H Pates 
Jamet, Vestergaard Frandsen, personal communication), but there was no 
accompanying monitoring and evaluation plan to compare the efficacy of the PBO LLINs 
with conventional LLINs.  
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5.2.2  Analytical Framework 
The modified analytical framework comprised of seven themes derived from all five 
concepts (actors, power, context, content, and process) in the Walt and Gilson policy 
analysis framework (77), with two additional themes, availability and affordability, from 
the four themes in the Frost and Reich framework (120) (Table 8) Given that the policy 
under review relates to the introduction of a malaria vector control tool, the themes of 
availability and affordability (not contained in the Walt and Gilson framework) are 
important. The themes of architecture and adoption from the Frost and Reich 
framework are the equivalent of the actors and process themes in the Walt and Gilson 
framework.  
 
Table 8. Framework used for sampling, interview guide and data analysis  
 
  Definition (Adapted from Walt and Gilson unless otherwise indicated) 
 
1 Context The systemic factors, such as political system, type of economy, employment 
base, national and international actions/cooperation, which may have an 
effect on health policy 
2 Content The content of the policy, which reflects the output of the interplay between 
actors, processes and context 
3 Actors The network of institutions and individuals that influence the adoption of a 
new policy 
4 Power  The ability to influence, and in particular to control, resources; 
it can be seen in a number of dimensions including decision-making (174), 
agenda setting (100), thought control (176), control of financial resources 
and access to/level of knowledge (81) 
5 Policy Adoption 
Process  
The way in which policies are made, i.e., initiated, 
developed/negotiated/formulated/endorsed; in this study, this includes the 
use of evidence in the policymaking process 
6 Availability In this study we restrict consideration of availability to ordering (i.e., 
choosing and procuring a next generation LLIN (Frost and Reich) 
7 Affordability Involves the willingness to pay for (finance) a next generation LLIN by global 
organizations as they are the primary donors of vector control (Frost and 
Reich) 
 
The modified framework was used to guide the selection of relevant policy stakeholder 
groups for interview, develop themes for the semi-structured interview guide, and for 
data analysis. For the purposes of this study, the definition of policy extends beyond a 
broad statement of goals (81) to include individual aspects of a policy such as the use of 
a specific tool (83).  
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5.2.3  Desk Review 
In March 2014 and March 2015, PubMed-Medline, Web of Science, Global Health, Jstor, 
and Taylor & Francis were searched for peer reviewed literature using the following 
search terms: “Burkina Faso”, “malaria”, “malaria control”, “malaria prevention”, 
“vector control”, “policymaking”, “policy analysis”, “decision-making” and “evidence-
based policy”.  
 
In addition, using the same terms, Google, Google Scholar, the Programme National de 
Lutte Contre le Paludisme (PNLP) website, as well as partners’ websites, were searched 
for relevant reports, strategies, policies and meeting minutes. The purpose of the desk 
review was to identify the key actors (institutions and individuals) involved in national 
vector control for interview, to refine the research question and semi-structured 
interview guide, and to supplement findings from these.  
 
5.2.4  Study Participants 
The identification of the study participants was a two-step process. Using the literature 
and the local knowledge of two Burkinabe collaborators (Mr Traore and Dr N’Fale), 
institutions that participated in national malaria vector control policymaking were 
identified. An initial list of 15 institutions was drawn up and one KI from each was 
contacted to request participation. KIs were considered to be the most senior person 
tasked with LLIN policy, implementation, procurement, and research or funding. One 
additional KI was identified during the interviewing process 
 
KIs were categorised into six groups: policymakers – staff of the Ministry of Health 
(MoH) working as part of the PNLP; implementers – working for NGOs to implement 
malaria control projects; multilaterals – employees of United Nations technical agencies 
supporting malaria control; donors – including employees of organisations that finance 
and procure malaria control tools; researchers – those working in academia/national 
institutes of research; and private sector – those in the commercial for-profit sector 
involved in the sale of vector control tools and insecticide products. While the sample 
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size was guided by feasibility, KIs were selected to encompass viewpoints from all six 
categories. 
 
5.2.5  Key Informant (KI) Interviews  
Interviews were carried out in April 2014 in Ouagadougou, Burkina Faso. All interviews 
were conducted by the lead researcher and Mr Traore; 12 of the 13 interviews were 
conducted in French by Mr Traore and one in English by the lead researcher. The 
interviewers jointly reviewed the first four interviews conducted to establish 
consistency in data collection. The interviews followed a semi-structured, open-ended 
format, which was developed in English and subsequently translated into French (Annex 
8). 
 
The semi-structured interview guide included questions on who was involved in the 
policymaking process; who carried the most influence and why; how vector control 
policies were made (including the role of evidence); and factors that influenced the 
availability and affordability of PBO LLINs.  
 
All KIs gave signed consent for participating in the audio-recorded interviews and for 
the use of anonymous quotes. In reporting quotes KIs roles (e.g., policymaker) are 
disclosed to highlight their perspective. Ethical clearance was obtained from ethics 
committees at Liverpool School of Tropical Medicine and Burkina Faso (Annex 13-15) 
5.2.6  Data Analysis  
Translated and accuracy-checked transcripts were entered into NVivo10 for data 
management and analysis through the following four steps: i) familiarisation (reading of 
transcripts); ii) coding data according to themes in analytical framework; iii) 
summarising data by KI and themes; and iv) synthesis of the key points in each theme 
and exploration of patterns in the data.  
 
5.3 Results 
A total of 13 KIs were interviewed: two researchers, four policymakers, three 
implementers, two donors, and two multilateral agencies. Three KIs (one donor and 
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two policymakers) did not participate; one declined and two were not available. The KIs 
represented five categories as no national private sector actor was identified or 
interviewed. However, this perspective was later captured informally through 
discussions with a representative of Vestergaard Frandsen. We present findings 
according to the analytical framework themes, including one sub-theme that emerged 
during interviewing, i.e., the classification of forms of power.  Table 9 presents the 
matrix of all a priori themes and sub-themes that emerged from analysis. 
 
Table 9. A Priori Themes and Emergent Sub themes Burkina Faso Policy Analysis 
 
 A Priori Themes from thesis 
analytical framework 
Emergent Sub-themes 
1 Context - 
2 Content - 
3 Actors Policymakers (Decision makers) 
  Policymakers (Technicians) 
  Researchers 
  Technical ad Financial Partners 
4 Power Power as decision making 
  II. Power to influence opinion 
  III. Financial Power 
5 Adoption IV. - 
6 Availability I. - 
7 Affordability I. - 
 
Within each theme, we highlight barriers and opportunities for accelerated access to 
next generation LLINs in Burkina Faso. Additional quotes to support the themes are 
presented in Annex 19. 
 
5.3.1  Policymaking Context 
In Burkina Faso, the entire population is at risk of malaria. In 2013, there were 
approximately 3.7 million reported confirmed malaria cases and over 6,000 deaths (43). 
Malaria accounts for 50% of all outpatient consultations, 57% of hospitalisations, and 
46% of deaths (206). 
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At the national level, the MoH (Ministère de la Santé), through the PNLP, is responsible 
for all health policy and strategy development, partner coordination and resource 
mobilisation (207, 208). The regional and peripheral levels focus primarily on 
implementation activities.  
 
As one of the world’s poorest countries (209), Burkina Faso is reliant on external 
organisations to finance most aspects of its malaria control interventions. In 2011, over 
US$ 70.6 million was spent controlling malaria (210), 68% of which was provided by 
GFATM, 15% by the United States Agency for International Development (USAID), and 
about 12% by the government (210). Figure 7 shows the breakdown of 2011 
expenditure on malaria control by funding source.  
 
 
Figure 7. Sources of malaria control funding in Burkina Faso, 2011 
 
In 2010, almost 8 million LLINs were distributed nationwide, 88.9% were financed by 
GFATM through two funding rounds 7 and 8. Other sources of LLINs include those 
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procured using donor basket funds by PADS (6.9%) and by USAID (1.7%), International 
Federation of Red Cross and Red Crescent societies (1.7%), and United Nations 
Children’s Fund (UNICEF) (1.3%)4. Figure 8 shows the sources of support for LLINs in the 
2010 LLIN nationwide distribution campaigns. In 2013, GFATM financed over 90% of the 
LLINs distributed.  
 
Figure 8. Funding source for LLINs distributed in 2010 
 
5.3.2  National Vector Control Policy Content 
The overall goal of the Burkina Faso National Malaria Strategic Plan 2011–2015 is to 
reduce malaria morbidity by 75%, compared to 2010 levels, and malaria mortality to a 
level close to zero by the end of 2015 (210). Table 10 summarises the vector control 
objectives in the Strategic Plan (210), the coverage of interventions of populations at 
risk as at 2012 (211), and the revised national objectives as of March 2014. In line with 
                                                 
4 Unpublished data Programme National de Lutte Contre le Paludisme (PNLP) 
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WHO recommendations, one objective is to achieve and maintain 100% of the 
population sleeping under a LLIN by the end of 2015. 
 
Table 10. Original and revised vector control policy objectives in Burkina Faso’s 
National Malaria Control Strategic Plan 
 
 
 
 
5.3.3  Policymaking Actors  
The KIs identified actors involved in policymaking as the MoH and its technical 
departments such as PNLP; other ministries such as those for finance, communications 
and environment; research centres, including the CNRFP and Centre Muraz; technical 
and financial partners, including WHO, GFATM, UNICEF, USAID, International 
Federation of Red Cross and Red Crescent societies, and PLAN Burkina. 
 
All KIs recognised the central role of the Comité National de Pilotage de la Lutte Contre 
le Paludisme (Comité de Pilotage), the national steering committee for malaria, in 
 Vector control 
objectives in the 2011-
2015 strategic plan 
(210) 
Progress towards 
target in Burkina 
Faso as of 2012 
(211) 
Revised vector 
control 
objectives 2014 
(210) 
2014 Malaria Indicator Survey 
Results (202) 
1 100% of the population 
sleeping under long-
lasting insecticidal-
treated nets (LLINs) 
Approximately 50% 
of total population 
at risk 
Achieve and 
Maintain 100% 
coverage  
71% of the households have 
access to at least one LLIN 
 
In households with at least 
one LLIN, 74 % of the 
population of these 
households slept under 
mosquito nets at night 
 
2 100% of the 
populations of the four 
health regions targeted 
(South-West, Cascades, 
Hauts-basins and 
Mouhoun) benefit from 
indoor residual spraying 
(IRS) 
Approximately 1% of 
population covered 
Suspension of 
IRS  
 
3 100% of the targeted 
breeding sites in the 
Central and Hauts-
Bassins regions are 
covered by larviciding. 
No data Extension of 
larviciding to 
Bobo-Dioulasso 
region 
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supporting PNLP in delivering its mandate. The Comité de Pilotage is composed of five 
commissions, including one focused on vector control. The main responsibilities of the 
vector control commission are to make recommendations to PNLP in defining vector 
control strategies, support the development and revision of guidance documents, 
monitor the implementation of vector control activities, and monitor insecticide 
resistance (212). 
 
The KIs and the terms of reference of the Comité de Pilotage (212) outlined four main 
groups of actors and the roles that they played in the policymaking process (Figure 9).  
 
 
 
Figure 9. Actors and their roles in national policymaking 
 
Researchers: Four national research centres conduct malaria research across the 
country. Data generated feeds in to the national policymaking process through the MoH 
and Comité de Pilotage (207, 213). However, KIs, particularly researchers, multilaterals 
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and donors, outlined that, while local research/researchers are valuable, there is a need 
to collaborate with international research institutions to strengthen the credibility of 
research outputs. 
 
“Even if a research is made in Burkina Faso, if the signature is international it means 
that you have done it in collaboration with an international institute, this is very 
important. That is because in the eyes of donors, the international character is of great 
value” (Policymaker) 
 
Technical and financial partners: Multilaterals, donor and NGOs are collectively known 
as technical and financial partners. They provide technical advice and financial input to 
the policy development and implementation.  
 
“The TFP [Technical and Financial Partners] …., they have money and they have the 
ideas, knowledge. Ok? Money and knowledge” (Researcher) 
 
Policymakers: KIs considered policymakers to be the technicians that drafted the 
policies and the decision-makers who ratified these. 
 
Technicians: All KIs recognised PNLP as the technician who drafts the policy document 
coordinating inputs from researchers, the technical advisers and other stakeholders. 
 
“Technical departments are really conducting daily follow-up-evaluation of the 
Programmes, which lead to new information which requires that a policy be changed. 
They also give a technical draft to the Office of the Ministry of Health where they decide 
on what needs to be done” (Researcher) 
 
Decision-makers: All KIs recognised the role of the national government through the 
MoH and the cabinet to make final decisions on ratifying policies that had been drafted 
by the technicians. 
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“…but now when the policy goes for decision making, the decision is taken at another 
level that I called politicians; when I say politicians. I mean the ministries, the Parliament 
who approve policies” (NGO) 
 
5.3.4  Perceptions of Power  
Power was observed when KIs identified the actors they thought carried the most 
influence and when KIs described the roles various actors played in the policymaking 
process.  
KIs identified different forms of power: 
 
i. Power as decision-making: This dimension of power was expressed as the 
national government’s ability to endorse or reject a policy. 
 
“As a technician you can write policies, write strategies that are relevant enough 
according to you; and they will go to the highest level for decision making, that's 
something else. Those at the highest level will decide on whether they are going for this 
policy or not” (NGO) 
 
ii. Power to influence opinion: WHO was viewed as an important actor as its 
recommendations influenced national policy content and directed what donors 
support, thereby mediating actor’s (e.g., PNLP’s) options when drafting policy 
documents. National researchers also saw themselves as having a role (and to 
some extent influence) in contributing to the global evidence base, which in turn 
influences WHO recommendations. 
 
“If the WHO recommends something, tomorrow you will see that people put it in 
application very quickly” (Policymaker) 
 
iii. Financial power: All KIs cited financial resources as being the most powerful 
reason for policy adoption. Consequently, GFATM who funds most of malaria 
control in Burkina Faso was perceived as the most influential actor (210). 
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“The Global Fund plays the most important role because the Global Fund is financing the 
malaria control programme by 80%. So for many policies concerning malaria control, 
the Global Fund influences much even if it is not making [the] decision all alone” (Donor) 
 
Although donors were viewed to possess a great degree of power, their power was not 
absolute. All KIs recognised WHO recommendations’ influence over policy content and 
donor funding and two KIs viewed decision-makers to be the most powerful actors.  
 
5.3.5  Policy Adoption Process  
KIs recognised that the first step in the policy adoption of a new vector control tool 
would be international endorsement/recommendation of the tool. 
“First step in [the] adoption process is the international adoption of the product. .… If 
Burkina Faso wants to adopt a new policy, first of all that policy must be proved 
internationally” (NGO) 
The PNLP draft the policy document with input from the partners in the Comité de 
Pilotage, acting in an advisory capacity. The policy is then submitted to the MoH and 
the national assembly for endorsement.  
 
“The country adopts; when I say the country adopts I mean the coordinator of the 
national programme of malaria control must prepare the case file and submit to the 
hierarchy. That is to say, the directorate of disease control, the General Directorate of 
Health, the General Secretariat, and the Ministry. Now, if it is accepted, it becomes part 
of the policy” (Policymaker) 
 
A donor’s willingness to finance was perceived to be one of the most powerful 
incentives for policy adoption. 
 
“Locally here what I’m saying is just come with your resources saying that you have 
money to support such strategy, it will be accepted” (Researcher) 
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All KIs expressed a certain level of pointlessness in going through the adoption process 
without global adoption and funding already being in place.  
 
“The Government has very few resources to put in, so resources are coming usually from 
the donors. They [donors] want to have it approved by the WHO first before putting 
their money. So meaning that you can have a very nice and promising result, but you 
need to put in place a lobby group just to push it and get it approved internationally 
before coming back” (Researcher) 
 
Figure 10 outlines the policy adoption process as described by KIs showing that the 
genesis of the national policy process is at the global level. 
 
Figure 10. National policy adoption process for a new vector control tool 
 
5.3.6  The Role of Evidence in Vector Control Policymaking  
There are strong formalised relationships between research centres, the MoH and 
Comité de Pilotage, with clear channels for communicating research results to key 
policymakers within the MoH and the wider stakeholders (213). 
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“At national level, you have the research institutions who will, based on the new 
findings, just report by [MoH] hierarchy which also transfer these findings to the 
Comité de Pilotage” (Researcher) 
 
While this should foster increased use of research in policymaking, as described above, 
nationally generated research was perceived to have limited impact on policy. 
 
“Nationally here you have a very nice result, but after you finish, you close your reports, 
you publish, you go and report, nobody is talking about it. You have to wait to get it 
approved internationally and now it comes back” (Researcher) 
In this context, it is worth noting that PermaNet® 3.0 was evaluated in Burkina Faso 
using WHOPES protocols and included in a publication describing the results of a similar 
trial from multiple settings (214). 
 
5.3.7  Availability 
Five brands of LLINs were distributed in 2010: Interceptor®, Dawa plus®, PermaNet® 
(including PermaNet® 2.0 and 3.0), Netprotect® and Olyset® net (45). When KIs were 
asked about factors influencing availability (choosing and procuring LLINs), a number of 
issues came to light. 
Firstly, the primary factor determining LLIN availability is WHOPES recommendation. 
 
“A decision maker before accepting a brand of nets must make sure that it is a net that 
is recognised by the WHO; and accepted in line with WHOPES standards” (NGO) 
 
Secondly, in line with the perceptions on the importance of financial power, all KIs 
noted that, for current and future vector control tools, such as next generation LLINs, 
price would be a key factor in determining availability. 
 
“Alright, money is the issue because even the Global Fund is considering the price. When 
you want to buy mosquito nets through the Global Fund you cannot budget for any 
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mosquito net which costs 5 or 6 dollars each because the Global Fund could buy at 2 or 
3 dollars each if they need a huge quantity of it. So the Global Fund will not accept those 
prices” (Multilateral) 
 
The factors influencing the decision to distribute a PBO LLIN (PermaNet® 3.0) were 
explored. A few KIs were aware that PermaNet® 3.0 had been distributed but none 
were aware of what influenced the decision to purchase and distribute them.  
 
“They provided us with that product [PermaNet® 3.0], there’s no criteria on which we 
can ourselves choose PermaNet 3.0 just because we think resistance is lower with it 
than other products” (Policymaker) 
 
The decision to distribute PermaNet® 3.0 appeared to be based on price and actions of 
international/external actors, i.e., net manufacturers. 
 
“[I was] not aware of the decision, [it] looks like it was taken outside. The materials 
[PermaNet® 3.0] were ordered by an external body and sent to the country” 
(Researcher) 
 
Currently, once approved by WHOPES, all brands and types of LLINs (including PBO 
LLINs) are considered the same. Therefore, country decisions focus on articulating 
specifications (physical characteristics, insecticide, binding process, dimensions, etc.) to 
the relevant procurement department. This choice can be influenced by a desire to stick 
to tried and tested products or a protection of individual interests. Taken in the context 
of the counterfeit nets distributed in 2010, comments made by some KIs have added 
significance. They seem to confirm that some actors were aware of the fraud and of the 
potential for high value contracts to be mismanaged for personal financial gain.  
 
“So people are afraid of the unknown, they fear anything which is new, they think the 
other tools are already effective, and then they limit themselves to the old tools, but 
most often it is because some people have their own interests [claps] because if they 
import nets, they know what it's worth. People have their own deal in the contract. It is 
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the same people who awarded the mosquito net contracts in 2010 to their friends that 
we all we know.” (NGO) 
 
It is worth noting that nets distributed in 2013 were procured through the GFATM 
voluntary pooled procurement system. Recognising weaknesses in their own practices, 
GFATM have also initiated a number of improvements including pre-shipment testing of 
nets, greater oversight of bidders’ relevant experience and the appropriateness of 
tender specifications, and are seeking to recover funds from those implicated in the 
counterfeiting (205).  
 
5.3.8  Affordability 
In Burkina Faso, the affordability of LLINs effectively means the willingness of 
international donors to finance it, which in turn is influenced by global 
recommendations.  
 
“If the WHO approves the new tool, I believe that international initiatives will agree to 
finance the tool and I’m sure it will become more accessible” (Policymaker) 
 
Cost was viewed as a major influence on donors’ willingness to finance, with one KI 
citing the case of IRS being halted due to its relatively high cost. 
 
“There is not only the issue of effectiveness but also the problem of cost. Why is it that 
the indoor spraying which is very effective is unfortunately stopped? Because it is very 
expensive! It is so expensive that we cannot afford it” (Multilateral) 
 
A barrier to affordability, raised by all KIs, is the need to meet set targets, which is 
jeopardised if the new tool is more expensive and the funding envelope remains fixed.  
 
“You have set amount of money but still need to achieve universal coverage. While your 
target remains universal coverage because you have signed up the Abuja declaration if 
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you want to buy more expensive nets you will have to find additional funds.” 
(Multilateral) 
 
Just one KI raised the issue of differences in performance between net types. 
 
“Now they need to show us the methods that allow us to have more impact, The Global 
Fund is naturally interested in the impact, the efficiency and the effectiveness, and we 
will not get away too much from the prescribed actions at the international level in 
relation to a resistance that occurred, this for sure.” (Donor) 
 
KI’s highlighted that an opportunity for improving availability and affordability would be 
more independence from international funding in the form of allocation of national 
funds to malaria control. 
 
“So the first issue would be just trying to work with the policymakers to allocate 
resources for their own policy instead of just waiting for resources coming somewhere” 
(Researcher) 
 
5.4 Discussion  
Case studies have proven to be an effective method in exploring real life policy events 
(75, 153), including examining gaps in access to drugs (215), the development of family 
planning programmes (216) and the coordination of donor aid policies in developing 
countries (217). In Burkina Faso, much of the national policy analysis in the malaria field 
has focused on the adoption of artemisinin-based combination therapy and home-
based management of malaria (213, 218-220). However, Burkina Faso appears 
amenable to the timely translation of global guidance on malaria control into national 
policy; being one of the first countries to adopt intermittent preventive treatment for 
infants and seasonal malaria chemoprevention (211).  
This is the first time the Frost and Reich framework has been used to analyse national 
malaria vector control policymaking in Burkina Faso. The framework and its elements, 
when combined with those of the Walt and Gilson framework (77), are suitable for 
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national level policymaking analysis (recognising that sub-national factors, while 
important, were beyond the scope of the present study) and all responses fitted into 
the themes contained within the framework. However, the different dimensions of 
power and the different categories of policy actors are nuances within existing themes 
that emerged during the interviews. 
 
A strong framework of actors linked to research centres has been identified as one of 
the key strengths of malaria control in Burkina Faso (210). Burkina Faso has a strong 
track record of malaria vector control research with two internationally recognised 
research groups; they are at the forefront of insecticide resistance research with in 
excess of 14 publications with Burkinabe first authors on this topic in the past 10 years. 
More recently, a Burkina-based study was one of the first to demonstrate that standard 
LLIN effectiveness is compromised by insecticide resistance (45). Despite this, the 
researchers interviewed felt that the ability for their outputs to influence national 
policy was dependent on collaboration with international researchers. 
 
While not mentioned by any KIs, the desk review showed that WHO’s Evidence 
Informed Policy Network (EVIPNet) in Burkina Faso (consisting of Burkinabe 
policymakers and researchers) has successfully supported evidence-based policymaking 
on wide-scale access to artemisinin-based combination therapies and has been pivotal 
in getting this funded by the GFATM (219, 221).  
 
This study identified three dimensions of power. While only the government had power 
over which policies were endorsed, this was limited by its relatively low financial power. 
Conversely, those with financial power, such as the GFATM, are limited by the 
commitment to only support tools endorsed by WHO. While no actors were seen to 
have absolute power, financial resources conferred significant power on those that 
fund vector control. This is captured by the KIs’ perception that it is futile to adopt a 
policy without financial backing. This finding is consistent with studies that have 
observed the potential for new funding to change the policymaking landscape (220) and 
push through policy adoption (222). In a country like Burkina Faso, where financial 
power is concentrated in the hands of one institution (GFATM), the potential for 
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scaling-up access to a new tool is tied to their willingness to finance it. This is in contrast 
to studies that show instances of policies being driven by actors involved in its 
implementation (bottom up approach) (178, 223). This contrast is not surprising given 
that the LLINs are predominately delivered and financed from the top down (197). 
 
This study highlights the need for increased domestic funding for malaria control 
commodities (208) to reduce donor dependence (126) and increase the power of 
policymakers in Burkina Faso to choose appropriate interventions for their setting. 
Other studies have demonstrated the potential for high-level global subsidies to 
improve the availability of affordable high quality malaria control interventions (224). 
This may be something that needs to be considered if the new vector control tools 
replacing those whose efficacy is being eroded by resistance have a higher unit cost. 
 
The GFATM new funding model is a potential opportunity to improve access to new 
malaria control tools like next generation LLINs. The new funding model directs up-front 
allocations, aligned to national strategic priorities (225). Thus, a country like Burkina 
Faso would be able to make a case for the purchase of next generation LLINs using 
GFATM resources, even where these are more expensive, if it were able to document 
reductions in the effectiveness of standard LLINs and greater effectiveness of new tools.  
 
Vector control policymaking in Burkina Faso is largely based on policy transfer, i.e., 
policy ideas from one space and time influencing another (83). The national policy 
process is well defined, but is dependent on global malaria policymaking and available 
resources. Despite the recognition by VCAG of potential additional benefit of PBO LLINs 
against insecticide resistant mosquitoes (62), at the time the study was conducted 
there was no WHO guidance on where and when next generation LLINs might positively 
impact on malaria transmission, severely limiting their ability to be adopted at the 
national level and financed by the main donors. In December 2015, the WHO Global 
Malaria Programme (GMP) released recommendations on conditions for use of LLINs 
treated with PBO (63). It recognised that PBO LLINs have increased bio efficacy in 
certain settings, but argued that the evidence was too limited to justify a complete 
switch to PBO nets in all settings. It is evident that a switch from conventional LLINs to 
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PBO LLINs would not be appropriate in all settings as, in areas where mosquito 
populations remain susceptible to pyrethroids, there is no rationale to implement a 
product that is likely to have a higher unit cost. However, rather than provide guidelines 
on when and where a switch to PBO LLINs may be justified, WHO recommends pilot 
exploratory implementation with robust monitoring and evaluation (63). Nevertheless, 
it also states that PBO LLINs should “only be used where universal coverage […] will not 
be reduced”, which means that pilot studies are only likely to be possible where PBO 
nets are provided free of charge or at the same price as standard LLINs.  
 
Donor policies only permit WHOPES-recommended LLINs (226, 227) with countries 
having little control over the net selection. As WHOPES do not currently distinguish 
between PBO and conventional LLINs, the potential to tackle resistance is not part of 
the decision-making process in LLIN procurement in Burkina Faso. In Burkina Faso, KIs 
confirmed that the donor’s procurement department or agent oversaw the competitive 
bidding process where the cheapest LLIN was bought. Vestergaard Frandsen, the 
manufacturers of PermaNet® 3.0, have since confirmed that it was offered at a 
competitive price in Burkina Faso to ensure they were used in the right context (H Pates 
Jamet, Vestergaard Frandsen, personal communication). 
 
The price of a next generation LLIN was viewed by KIs as the single most important 
factor in determining its affordability (i.e., willingness to purchase). This was linked to 
donors desire to get the highest LLIN coverage for a given level of expenditure which, in 
turn, stems from global and national targets for universal coverage with LLINs. While 
not suggesting that these targets should be abandoned, it is important to review them 
in light of the potential for insecticide resistance to reduce LLIN performance. In the 
absence of a clear recommendation of when and where to target next generation LLINs, 
countries may be left deploying LLINs that are less effective in areas with insecticide 
resistance to meet coverage targets at the expense of potentially more effective 
solutions.  
 
The benefits of PBO LLINs, which can be up to US$ 2.30 more expensive than standard 
LLINs (199), might be clearer if donors and national programmes incorporated impact 
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measures (overall reduction in transmission) into procurement decisions and focussed 
on the cost-effectiveness of alternative tools (as opposed to unit cost). In order for this 
to make a difference, evidence-based global recommendations on when and where 
next generation LLINs are likely to provide the greatest protection, and the likely 
magnitude of this effect, are urgently required. The current absence of global guidance 
on the role and cost-effectiveness of next generation LLINs in vector control in 
countries with insecticide resistance is a critical barrier to donor funding and national 
adoption of next generation LLINs.  
 
5.5 Conclusions 
This study shows that access to next generation LLINs was severely compromised by the 
lack of global guidance on where and when they should be deployed. In a country like 
Burkina Faso, where WHO recommendations are relatively quickly adopted, a clear 
WHO recommendation is the key to unlocking financial resources for and accelerating 
access to next generation LLINs. It remains to be seen whether the December 2015 
WHO recommendation will impact on access to these products.  
 
Furthermore, evidence collected by national research institutions on insecticide 
resistance should be extended to monitor (changes in) effectiveness of standard LLINs. 
As well as supporting evidence-based national policymaking, these data should be given 
greater credence in funding applications to key donors and in global policymaking. 
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6 Results: Global Adoption of Next Generation Long-
Lasting Insecticide-Treated Nets: Challenges and 
Opportunities for Accelerated Access 
 
ABSTRACT 
 
Introduction: Vector control has been attributed to averting 3.3 million deaths from 
malaria between 2001 and 2012, however insecticide resistance has the potential to 
derail these achievements. Access to innovative vector control tools is required to 
sustain achievements and attain malaria elimination goals. This study aimed to identify 
the opportunities and barriers at the global level to accelerating access to the next 
generation of LLINs, using synergist nets treated with both pyrethroids and piperonyl 
butoxide (PBO LLINs) as an example. 
 
Methods: Semi structured interviews were carried out with key informants between 
June and July 2014. Interviews were conducted in English, audio recorded, transcribed 
and entered into NVivo10 for data management and analysis. Data were coded 
according to themes in a modified analytical framework and emergent themes using 
content analysis.  
 
Results: Key informants (KIs) were interviewed including policymakers (4), researchers 
(3), donors (4) and representatives of the private sector (2). KIs reported that the 
adoption of PBO LLINs can be facilitated by independent and clearly communicated 
evidence which demonstrates the failure of current tools and the effectiveness of PBO 
LLINs as well as secondly a policy process that is clear and timely policy adoption 
process. The KIs reported that the availability PBO LLINs is predicated on factors 
including: the ability to forecast the PBO LLIN market size; willingness of donors to pay 
for PBO LLINs (affordability); fostering of innovation and clarity on the process and 
evidence required to convince policymakers. Affordability of PBO LLINs is influenced by 
WHO recommendation and the price of PBO LLINs being comparable to conventional 
LLINs. 
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Conclusions: Four fundamental factors that need to be addressed in order to facilitate 
increased access to PBO LLINs were: i) robust quality evidence on the effectiveness 
(including cost effectiveness) of PBO LLINs compared to conventional LLINs; ii) clear 
recommendations on where and when PBO LLINs should be used; iii) innovative 
procurement mechanisms that support forecasting of demand and facilitate price 
reductions; and iv) more effective coordination amongst the vector control 
stakeholders to increase awareness and concerted action around tackling the threat of 
insecticide resistance with short and long-term solutions.  
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6.1 Introduction 
Vector control is recognised as the only approach that has led to malaria elimination in 
parts of Europe, Middle East, South Asia, North and South America, and North Africa 
(20, 228). Significant progress in malaria control has been recorded in the last decade, 
with 3.3 million deaths being averted between 2001 and 2012, and a decrease in the 
incidence of confirmed malaria, contributing to the progress towards achieving 
Millennium Development Goals 4 (a two-thirds reduction in the mortality rate from all 
causes among children aged under 5 years), 5 (improving maternal health) and 6 
(combat HIV/AIDS, malaria and other diseases) (211, 229). The scale-up of access to 
(coverage and use) LLINs is recognised as a major contributor to these successes (34, 
211). However, there is global consensus that insecticide resistance has the potential to 
derail the malaria control achievements to date (230). Concerted action is required to 
ensure the continued success of malaria control efforts with current strategies and the 
development and timely introduction of innovative vector control tools (5) such as next 
generation LLINs.  
 
Two next generation LLINs (PermaNet® 3.0 and Olyset® Plus) treated with pyrethroid 
and piperonyl butoxide (PBO LLINs) are currently available on the market. Two 
additional next generation LLINs treated with a combination of two insecticides 
(combination LLINs) are currently being tested in Phase III trials or being considered by 
WHOPES, with potential first use anticipated between 2016 and 2018. In addition, 
various other new vector control tools are currently being evaluated by WHOPES, 
including insecticide treatment kits for bednets and insecticide formulations for IRS and 
larviciding, some of which are being repurposed from agricultural insecticides in order 
to address insecticide resistance (231).  
 
Potential obstacles to access of a health intervention include its cost, weak health 
systems, low political commitment, and barriers to its manufacture and delivery (120). 
This study aimed to identify the opportunities and barriers at the global level to 
accelerate access to next generation LLINs using PBO LLINs as an example. 
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6.2 Methods 
The study involved an initial desk review followed by a series of semi-structured in-
depth interviews with identified key stakeholders involved in vector control tool 
development, research, policymaking and funding at the global level.  
 
6.2.1  Analytical Framework 
A modified analytical framework comprising all five themes (actors, power, context, 
content and process) in the Walt and Gilson policy analysis framework (77) and two 
themes (availability and affordability) from the Frost and Reich framework (120) was 
used in this study (see Chapter 3). The framework was used to guide the development 
of search terms for the desk review, the selection of relevant policy stakeholder groups 
for interview, the development of themes for the semi-structured interview guide, and 
for data analysis. Given it has been demonstrated that policy can be defined as a tool 
(83), for the purposes of this global level analysis, policy adoption refers to WHO policy 
recommendation of a PBO LLIN. 
 
6.2.2  Desk Review 
In March 2014, an initial search was conducted in PubMed-Medline, Global Health and 
Google Scholar using the following search terms: “malaria vector control”, “malaria 
health policy”, “malaria vector control policymaking”, “health policy analysis”, 
“evidence-based health policy”, “evidence-based policy-making”, “access to: health 
interventions, medicines, vaccines”. Data on the global policymaking context and global 
policymaking actors (used to inform KI identification) was extracted and was used to 
refine the research question and develop semi structure interview guides for data 
collection.  
 
In May 2015, after key informant interviews and during the data analysis and write up 
stage, a further search was conducted in the same databases using the same terms to 
update the information retrieved in the initial document search. Articles were restricted 
to those published in English between 1990 and 2015. See Annex 5 for the full search 
strategy. 
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Additional documents were identified through recommendations from colleagues, 
reference lists of included articles and the websites of identified institutions, and 
included book chapters; presentations from conferences and unpublished consultancy 
reports; old and current global malaria policies, strategies and guidelines on vector 
control and insecticide resistance; terms of reference and minutes of meetings of 
bodies such as RBM, MPAC, VCAG, Vector Control Technical Expert Group (VCTEG), and 
WHOPES; and policies, strategies and action plans of global research, implementing and 
financing organisations involved in malaria vector control including USAID, DfID, 
GFATM, and the Innovative Vector Control Consortium (IVCC).  
 
Data on the global policymaking context and global policymaking actors (used to inform 
key informant (KI) identification). The document review was supplemented by 
reviewing further studies and reports provided by KIs during interviews.  
 
6.2.3  KIs  
KI sample selection was a two-step process, i.e., the identification of relevant 
institutions and then the identification of KIs from within each institution for 
participation in the study.  
 
The initial document review identified relevant institutions by examining the 
institutions/committees that contributed to the development/manufacture, 
testing/evaluation, and assessment of PBO LLINs for policy adoption and those that 
would potentially be involved in the funding of PBO LLINs by using institutions who 
have funded LLINs in the past a proxy. Institutions identified were categorised as 
follows: i) private sector representatives, referring to those in the commercial for-profit 
sector and public–private partnership organisations involved in the development, 
manufacture and/or sale of PBO LLINs; ii) researchers, including those working in 
academia or research institutions with vector control and insecticide resistance 
research expertise; iii) donors, referring to international donor organisations that fund 
vector control; and iv) WHO and members of its technical advisory committees, 
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structures and regulatory mechanisms established to support WHO policymaking 
functions such as MPAC, VCAG, VCTEG and WHOPES, henceforth referred to as ‘policy 
advisors’.  
 
KIs were considered the most senior person and/or the individual within the identified 
institution tasked with the largest responsibility concerning the relevant framework 
theme and/or LLIN intervention. Through this process, 14 stakeholders were identified 
and contacted for participation in the semi-structured interviews.  
 
6.2.4 KI Interviews 
In June and July 2014, Ms Tesfazghi conducted all interviews in English. As the location 
of KIs included the United Kingdom, United States of America, and Switzerland, half of 
the interviews were conducted by telephone or Skype and the other half face-to-face. 
The interviews followed a semi-structured, open-ended format using a guide (Annex 10) 
that was pretested by Ms Tesfazghi on a colleague. The semi-structured interviews 
focused on the 5 of the 7 themes in the modified analytical framework; data on policy 
context and content were gleaned from document reviews. 
 
6.2.5  Data Analysis  
Ms Tesfazghi transcribed recorded interviews. Transcripts were entered into NVivo10 
for data management and analysis and were re-read to gain familiarity. Data were 
coded according to the themes in the analytical framework. An analysis matrix was 
developed summarizing coded data by KI and themes (Annex 11 shows an excerpt of 
the matrix). Summaries of the themes were further analysed and refined to provide a 
description of the key points in each theme and explain patterns in the data. Two KIs 
were contacted for follow-up information in light of recommendations made by WHO in 
December 2015 on the conditions for use of PBO LLINs, after initial interviews had been 
conducted. Additional documents sourced after the recommendation was also used to 
provide insight into the initial document reviews and KI responses. These have been 
reflected in the results and discussion sections. 
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6.2.6  Ethics 
Ethical approval for the study was obtained from the ethical committee of the Liverpool 
School of Tropical Medicine. All KIs gave informed signed consent for participating in 
the interviews. All but one KI gave consent for their interviews to be audio-recorded. 
Anonymity was maintained by assigning all KIs with numbers so that their names and 
affiliations/institutions were not identifiable to anyone other than the primary 
researcher during data collection, analysis and write up. However, their roles (e.g., 
researcher), are disclosed alongside quotes to highlight differences and similarities in 
perspectives. 
 
6.3 Results 
A total of 13 interviews were performed (four policy advisors, four donors, two private 
sector representatives, and three researchers). One identified policy advisor was not 
available for participation. These categorisations do not reflect the fact that half of the 
KIs played multiple roles and therefore carried multiple perspectives, e.g., one 
individual was primarily a researcher but also served on policymaking advisory 
committees. The illustrative quotes shown represent the KIs identified based on the 
study categorisation in Section 2.3. Additional quotes to support the themes are 
presented in Annex 18.  
 
The desk review and interview results are organised according to the seven analytical 
framework themes. Table 11 presents all a priori themes and sub-themes that emerged 
from analysis. Within each theme, barriers and opportunities for accelerated global 
access to PBO LLINs are highlighted.  
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Table 11. A Priori Themes and Emergent Sub themes Global Policy Analysis 
 
 A Priori Themes from thesis 
analytical framework 
Emergent Sub-themes 
1 Context Lessons from artemisinin resistance5  
2 Content - 
3 Actors - 
4 Power Shifting balance of power 
5 Adoption V. Evidence 
VI. Data on failure of current tools 
VII. Evidence of Effectiveness 
VIII. Independent and clearly communicated 
evidence 
IX. Lengthy and unclear global policy adoption 
process 
X. Developing an effective tool  
XI. Availability of a product champion 
6 Availability II. Forecasting the PBO LLIN size of the market 
III. Affordability of PBO LLINs 
IV. Fostering innovation 
V. Ability to meet global demand 
VI. Clarity on the process and the evidence base 
required to convince policymakers 
7 Affordability II. Scientific and economic evidence; 
(presented under Evidence) 
III. WHO recommendation (presented under 
Adoption) 
IV. Price 
 
 
6.3.1  Policymaking Context 
In sub-Saharan Africa, the proportion of the population with access to an ITN in their 
household increased dramatically from 3% in 2004 to 49% in 2013 (43). Ninety 
countries (42 of which are in the Africa region) have adopted IRS for vector control, 
although its implementation and coverage to date have been relatively low (43, 211). 
As of 2013, 4% of the global population at risk of malaria were protected by IRS (43). 
 
                                                 
5 Emerged from KI interviews even though they were not specifically asked about context 
131 
 
The number of African countries reporting resistance to the pyrethroid insecticides 
used to treat LLINs has increased as a result of large scale distribution campaigns across 
countries (5). While there is limited evidence on the epidemiological impact of 
insecticide resistance on the effectiveness of vector control interventions, at least five 
countries (Mozambique, South Africa, Senegal, Benin and Burkina Faso) have linked 
insecticide resistance to reduced effectiveness of vector control tools, leading to an 
increase in recorded malaria cases (37, 45, 46). However, the lack of adequate 
insecticide resistance monitoring at country level likely disguises the full extent of the 
problem (232). 
 
6.3.1.1  Lessons from Artemisinin Resistance 
All KIs drew parallels between insecticide and drug resistance, specifically artemisinin. 
There was a consensus that the vector control community could learn lessons from the 
manner in which the threat of artemisinin resistance was handled as a global issue. This 
resulted in Worlds Health assembly declaration that this malaria drug should never be 
used as a monotherapy (233). The proponents of artemisinin resistance containment 
are seen to be particularly skilled at communicating the drug resistance issue and 
advocating for solutions. 
 
“I think that the pharmacologists and the medics and the doctors in the malaria world 
have done a much better job of making the case for drug resistance. … if you listen to 
the people who have been making the case for managing artemisinin resistance, their 
presentation of the information, their ability to influence the key stakeholders, their 
ability to get investment in those things has far exceeded the ability of the vector control 
community in that sense. And they have done a much, much better job of advocacy for 
those issues, which is entirely proper, they’re not cheating, it’s just that they’ve seen a 
problem that relates to their area of expertise and they’ve done a very good job of 
advocating that set of issues…. we need the key individuals in the vector control 
community to coalesce and to drive this as a community” (Private sector) 
 
132 
 
6.3.2  Global Vector Control Policy Content 
From a global perspective, LLINs and IRS are considered the two core vector control 
methods (232). WHO recommends “full coverage of all people at risk of malaria in areas 
targeted for malaria prevention with LLINs” (31). It is recommended that LLINs should 
be considered a public good for people living in endemic areas and should be provided 
free of charge or highly subsidised to achieve and sustain full coverage in all 
transmission settings (31). In 2014, the WHO VCAG, whose remit is to advise WHO on 
new forms of vector control, recognised that PermaNet® 3.0 has “increased bio-
efficacy” compared to pyrethroid-only LLINs in areas of insecticide resistance (62). In 
December 2015 WHO issued a recommendation recognising that PBO LLINs may 
provide increased efficacy in some settings, but that they should be used only where 
universal coverage with LLINs and/or IRS will not be compromised. The 2015 
recommendation also calls for accelerated deployment of PBO LLINs for evaluation 
purposes (63).  
 
6.3.3  Policymaking Actors  
Four groups of actors were identified through the desk review and KIs as being involved 
in accelerating access to PBO LLINs. 
 
i. Product developers/manufacturers: These are actors involved in the research, 
development and manufacture of PBO LLINs. All KIs recognised that, without the 
actions of these actors, there would be no development or production of PBO 
LLINs. 
ii. Policymakers/policy advisors: WHO, through its GMP, is responsible for the 
setting, communicating and promoting the adoption of evidence-based norms, 
standards, policies and guidelines to malaria endemic countries with support 
from technical expert committees which include the MPAC, Evidence Review 
Groups (ERGs), VCTEG and WHOPES (232). VCAG is an advisory group jointly 
established by the GMP and the Department of Control of Neglected Tropical 
Diseases to review and assess the public health value, ‘proof of principle’ 
(epidemiological impact) of new tools, approaches and technologies (232). 
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VCTEG is charged with making recommendations to MPAC on the “effectiveness 
and appropriate mix of vector control interventions, including the adoption of 
new forms of vector control following the ‘proof of principle’ from the Vector 
Control Advisory Group” (234). WHOPES plays a role in the adoption of new 
tools as it is responsible for evaluating the safety, efficacy and operational 
acceptability of pesticides for public health use (235). It also sets standards, 
promotes and coordinates the testing and evaluation of pesticides, including 
those used to treat LLINs (235). ERGs are time limited bodies set up to review a 
clearly defined area of work, and to provide evidence-based recommendations 
to the MPAC (234). 
iii. Researchers: Studies and the results of the KI interviews show that researchers 
have a critical role in gathering evidence to capture the extent of the insecticide 
resistance problem (37), demonstrate the failure of current tools (45) and test 
the effectiveness (or lack thereof) of new tools, e.g., PBO LLINs (65). This type of 
evidence provided by researchers was viewed by all KIs as a key facilitator of 
policy adoption. 
iv. Donors: All KIs listed donors like GFATM, USAID/President’s Malaria Initiative 
(PMI), DfID as vital to ensuring access to PBO LLINs, particularly as their 
willingness to invest in new tools (affordability) is a key determinant of access. 
Issues of affordability are considered in greater detail below. In addition to 
traditional donors, one KI from the private sector highlighted the importance of 
donors such as UNITAID who provide catalytic funding or high-level subsidies for 
new malaria diagnosis, treatment and vector control interventions as being 
important in facilitating access. 
 
 
6.3.4  Perceptions of Power 
When asked about which actor wielded the most influence in ensuring access to new 
malaria vector control tools, all KIs described what can be viewed as a shifting balance 
of relative influence, i.e., different actors were seen to be ‘most influential’ at different 
points. Figure 11 is a simple illustration of the shifting balance of influence at various 
134 
 
stages of the process. The figure aims to show the most influential actor at a particular 
point in time, recognising that all actors wield a level of influence at all stages. 
Manufacturers were viewed as being particularly influential at the product 
development stage of access to PBO LLINs as they were responsible for decisions 
around investing in innovation and implementing product development initiatives.  
 
“So let’s start with the product development process and the first step is clearly they 
have the product developed, so the first set of first key players is the industry who are 
developing the products” (Private sector) 
 
At the product evaluation stage, the evidence generated by independent researchers is 
crucial, conferring significant influence on the actions of researchers at this stage in 
developing, synthesizing and communicating evidence.  
 
“There is then a slightly softer group who influence it [policy] very strongly, by softer I 
mean they don’t have a direct decision making role, but they have a very strongly 
influencing role which is the people who create the evidence about the impact of those 
products” (Private sector) 
 
At the policy adoption stage and beyond, WHO and donors were seen to wield the most 
influence, respectively; see Section 3.7 on the financial influence wielded by donors. 
 
“Then when you do have a new product, which will hopefully happen in the near future, 
I think there is a massive role that organisations such as ours have to play in making 
sure that these new products are funded so that we create a market for them” (Donor) 
 
“And you need, WHO, WHOPES, they have to be heavily involved because we would look 
to them for guidance, so it would be a quite powerful thing if they say all countries 
should be investing in these particular nets; that’s quite influential” (Donor) 
 
“I guess it is WHO because they are the ones that in the end say, yes, they should be 
used and there should be a recommendation on it, or not so in that first decision-making 
135 
 
point it will be them. I mean later on the balance of the influence would possibly 
change” (Policy Advisor) 
 
 
Figure 11 Actors involved in access to new malaria vector control tools and the stages 
at which they are most influential 
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6.3.5  Global Policy Adoption Process 
The results of the document review show that global malaria policy adoption is a non 
linear iterative process between the primary policy setting organisation (WHO) and 
advisory groups with defined roles and a, Figure 12 (234).  
 
 
Figure 12. A schematic of the key WHO policymaking process [224] 
ERG, Evidence review groups; VCTEG, Vector control Technical Expert Group; MPAC, Malaria Policy Advisory 
Committee; VCTAG, Vector Control Advisory Group; WHOPES, WHO Pesticide Evaluation Scheme 
 
In 2011, WHO established the MPAC to provide independent advice on key malaria 
topics to the WHO Director General, who has the mandate to make WHO malaria policy 
recommendations and guidelines. MPAC develops this advice based on data from 
malaria endemic countries (232) and input from VCAG, VCTEG, WHOPES and ERGs 
(Figure 12). In relation to new vector control tools, VCAG assesses whether the tool’s 
concept works, WHOPES sets the standards, which the tool must meet, and VCTEG 
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determines the tool’s role in vector control in relation to other tools. MPAC advises 
WHO, which makes policy recommendations. The establishment of MPAC was intended 
to improve the timeliness, transparency, independence and relevance of WHO’s 
recommendations (236). Some KIs, particularly those from the donor and researcher 
categories were unable to comment on the effect of the reorganisation on the global 
vector control policymaking process. 
 
 “I think everybody is a bit confused about what the role of VCAG is to be honest and 
VCTEG you know everybody out there is going like, so how does this link to WHOPES etc. 
and I don’t have the answer to that either, I’m probably as confused as everybody else 
and I think it’s an area that requires a lot more clarity about how these different bits are 
joined together” (Donor) 
 
Furthermore, there is no clarity around instances when recommendations from 
different groups within the process seemingly contradict one another, as is suggested 
by some actors (particularly those in the private sector) in response to the PBO LLIN 
recommendation issued in December 2015 (237). In contrast to the confusion 
expressed by donors and researchers at least one KI (a policy advisor) was able to 
vividly describe how the VCAG, WHOPES and VCTEG executed their relative roles in 
relation to vector control policymaking.  
 
“What does it [the new tool] do? How does it work? Does it really work? For that you 
need [those] who are going to …test it to distraction, for me that’s VCAG’s task. Having 
established that, there are two further tasks; one is for WHOPES and one is for vector 
control TEG [VCTEG]. So one is ‘okay, we’re going to put out our tender for our 
companies to produce contraptions like these. What should our tender say? What are 
the standards that we should be looking for in such a thing when they produce them? … 
we need some set of minimum standards, that is WHOPES job. And then for VCTEG, its, 
what’s their role? In which battles do we want them? Where should we put them? 
Should we bring them into the beginning of the battle or the end of the battle, or 
what?” (Policy Advisor) 
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The synthesis of KI responses on the factors that facilitated the adoption of new vector 
control tools into policy resulted in broad consensus under four sub-themes.  
 
6.3.5.1  Evidence  
All KIs agreed that evidence was a key-determining factor for the adoption of PBO 
LLINs. However, in describing the evidence base required, there were nuances to the 
issue, which are categorised into three sub-themes as follows.  
 
6.3.5.1.1 Data on Failure of Current Tools  
KIs from all categories identified the need for robust data to show the operational 
impact of insecticide resistance and that current insecticide-based vector control 
interventions are failing. However, this was said to be hindered both by the fact that it 
is technically difficult to link insecticide resistance to intervention failure and that 
national insecticide resistance surveillance systems generally lack the 
resources/capacity to carry out the monitoring.  
 
“Well I mean if there was compelling epidemiological evidence that what we are 
currently doing, not just nets but all insecticidal interventions were beginning to fail, 
then I think that will help” (Private sector) 
 
6.3.5.1.2 Evidence of Effectiveness 
All KIs recognised that robust evidence on the effectiveness of PBO LLINs was important 
for policy adoption.  
 
“The consensus that having a good strong evidence base to show that it’s effective … I 
would say the most important thing is the evidence and then everything else would flow 
from that” (Donor) 
 
Two KIs cited the need for evidence to show that PBO LLINs are more effective than 
LLINs from both an entomological standpoint, i.e., more effective at interrupting blood 
feeding and/or killing malaria transmitting mosquitoes, and an epidemiological 
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standpoint, i.e., a reduction in malaria morbidity and mortality. Further, all KIs 
highlighted the lack of data in terms of quality and quantity as an existing barrier to the 
adoption of PBO LLIN. 
 
“I think the other thing that is an enormous barrier is the quality of experimental 
evidence that comes forward…. One of the sets of combination nets is being delayed in 
this process because there are a number of poor quality trials associated with it that 
confused the data set” (Private sector) 
 
Poor data quality is exacerbated by a lack of clarity on the data requirements needed to 
effect a policy change. 
 
“It does need both a clear definition of what the data requirements are for creating a 
policy decision and what the nature of the trials, quality standards of trials that we need 
to execute in order to deliver that data” (Private sector) 
 
Data on cost-effectiveness was viewed as an essential component of the evidence 
package required to influence adoption. 
 
“I think the thing that would drive adoption in the first instance is the primary cost 
effectiveness question” (Private sector) 
 
6.3.5.1.3 Independent and Clearly Communicated Evidence 
Whilst all KIs agreed a package of evidence was required to positively influence policy, 
there was also a recognition that such a package regarding PBO LLINs was currently 
lacking. One KI cited two possible reasons for this: the trustworthiness of the evidence 
(given that manufacturers fund the studies) and a lack of consensus, resulting in 
evidence that is equivocal and not clearly communicated.  
 
“And independence, I suppose is another thing because that’s what is really lacking from 
the debate at the moment ….On one hand you expect the company to pay because 
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they’re going to make all the profits if it goes well, but on the other hand there’ll be a 
trust issue if they do pay” (Researcher) 
 
“Well, that’s the point we need consensus on it. There’s no use one doing it and the 
other not agreeing and yes it’s a difficult job because anything that WHO suggests, Dr X 
will disagree with. Anything that Dr X suggests…. Dr Y will disagree and that’s the end. 
Well, but somehow, we have to gradually move towards consensus” (Researcher) 
 
6.3.5.2  Lengthy and Unclear Global Policy Adoption Process 
KIs from the researcher, donor and private sector categories stated that the process is 
lengthy and that the relative roles of the numerous policymakers/advisors were 
unclear. 
 
“The main barrier I would argue is that it’s [the adoption process] not well defined and 
so nobody knows exactly what place they have to go, how long it’s going to take, who’s 
going to make critical decisions, etc. And that’s really where things are seriously not 
good at the moment in the world of vector control” (Researcher) 
 
The recent recommendation by the WHO on conditions of use of PBO LLINS was an 
important attempt to resolve this bottleneck. However, KIs contacted after the 
recommendations where published stated that the recommendations do not indicate 
where and under what conditions countries might consider deployment. Furthermore, 
the KIs stated that the recommendations emphasise that universal coverage of LLINs 
and/or IRS should not be compromised and call for robust evaluation – the nature and 
parameters of which are not clearly defined. 
 
The December 2015 PBO LLIN recommendation has been openly criticised by members 
of the private sector as demonstrating a poorly defined scope and lack of transparency 
around the approval processes for new tools with in WHO (237). This is in stark contrast 
to the picture some KIs (particularly policy advisors) and the WHO documents present 
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on the relative roles of the policymaking process being clearly defined and relatively 
straightforward.  
 
 
6.3.5.3 Developing an Effective Tool  
KIs identified in the donor and private sector categories recognised that developing a 
truly novel tool was very difficult. Currently, the PBO LLINs undergoing evaluation still 
incorporate pyrethroids, with one KI describing them as an interim/stopgap measure 
until LLINs treated with two or more non-pyrethroid-based insecticides become 
available on the market. Donor and private sector KIs viewed the absence of a truly 
novel product as a barrier to global adoption of tools like the PBO LLINs.  
 
“I think it will be easier to do when there are completely novel insecticide coming into 
this moment when we talk about combination nets it’s a pyrethroid plus something else 
but may or may not work very well or we are talking about nets with a synergist in but I 
wouldn’t necessarily call nets with synergist combination nets” (Private sector) 
 
6.3.5.4 Availability of a Product Champion 
All KIs recognised the role that prominent figures have played in promoting access to 
LLINs and artemisin-combination therapies (ACTs), corroborating studies that cite the 
need for a high profile product champion (120). However, two KIs cited the lack of an 
advocate for the adoption of PBO LLINs.  
 
“You need product champions that are not the manufacturers of the nets. I know there 
were a group of people there that synthesised the evidence [on LLINs] and said look at 
all these trials they are showing the same thing and really pushed it. I think the same is 
happening a bit with repellents at the moment now. So I think it needs somebody, a 
group of people preferably multi-disciplinary, to really start pushing it forward and I 
can’t really see that happening at the moment” (Researcher) 
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While the ability to champion vector control solutions was considered by KIs to be 
somewhat hindered by the lack of robust evidence, a clear process, an innovative tool, 
and/or a product/group of product champion(s), KIs cited a number of opportunities to 
facilitate the global policy adoption of PBO LLINs. 
 
Firstly, the existence of the relatively newly created WHO advisory bodies, such as 
VCAG, is viewed by KIs as a positive step in facilitating global adoption of PBO LLIN. 
while the uncertainty about relative roles with other policy influencing bodies exist 
amongst some categories of KIs, the very existence of a body tasked with making 
recommendations on the ‘proof of principle’ of new vector control tools was viewed by 
all KIs, particularly policy advisors, as a positive step. 
 
“Well, I think that the primary barrier in the last five years has been has been non-
existence of the vector control advisory group. And now that that exists and is in a 
position, before VCAG there was nothing and when one said who do I go to, to have a 
policy about this, there’s nothing. So, now that VCAG exists, now there is the right place 
to go to, and as I was saying before, it’s not perfect realistic yet but they are still 
learning. But they are at least empowered to make those decisions and make those 
recommendations; so I think that primary thing has been overcome. I think there is still 
some uncertainty about the relationship between VCAG and WHOPES and how those 
two things interacts and how products move from one to the other and what’s their 
relative part of the process is and I think that would get sorted out by people actually 
bringing things forward and trying and presenting them to the process” (Private sector) 
 
“I think that actually the existence of the VCAG, Vector Control TEG [VCTEG] have 
already assisted, accelerated the process of policy development” (Policy Advisor) 
 
In June 2014, when interviews were conducted, KIs expressed a need for a clear WHO 
recommendation, on the utility of next generation LLIN, as well as when and where 
they would be appropriate, would have a direct and significant impact on their 
availability and affordability.  
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“I mean if I was a manufacturer, which obviously I’m not, I wouldn’t scale-up 
significantly of course until I’ve got my WHOPES approval and the WHO policy position 
in place” (Policy advisor) 
 
“It’s not just that you have a net out there but this net’s going to give more bang for the 
buck. Having it in a separate category is important because when we procure nets 
basically, right now all nets are the same…. Because there’s no global standard that says 
any of them are different from the other, they all go into one batch and then the price 
basically drives which net you procure. So obviously, these need to have been endorsed 
in some way that they are in a separate category because otherwise you are just going 
to have price driving the procurement” (Donor) 
 
Based on the private sector response and follow up communication from Donors, it 
would appear that the December 2015 WHO recommendation does not provide the 
clarity needed. 
 
At the time of the interviews (June-July 2014) one KI was optimistic about the future of 
the adoption process and expressed that solutions to this barrier were eminent.  
 
“There’s a sense that that whole area of the strange special things that happen around 
vector control regulatory process is on the verge of getting resolved and it’s not 
something that we worry about terribly much at the moment because there seems to be 
some good solution proposals outside there, and the [Gates] Foundation is putting a lot 
of effort into addressing those” (Private sector) 
It appears that though not expressly stated some of the solutions this KI alluded to was 
the launch of the I2I partnership. 
 
6.3.6 Availability 
The availability of PBO LLINs was predicated on five factors cited by KIs, which convinced 
manufacturers to engage in their development and manufacture.  
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6.3.6.1 Forecasting the PBO LLIN Market Size 
All KIs viewed the ability to forecast the PBO LLIN market size as the biggest motivator 
for manufacturers to develop and produce them. 
 
“The positive thing would be if the manufactures were confident that there was a 
market, I think that’s quite important and that they won’t produce unless they think they 
can sell it” (Policy advisor) 
 
KIs reported that forecasting the size of the market is hindered by limited data on where 
current LLINs are failing and no recommendations on the context in which PBO LLINs 
should be used. These limitations make it virtually impossible to estimate the market 
share that PBO LLINs will have when rolled out. 
 
“So, there isn’t a clear market today, you can’t point to a clear market today and say 
30% of the bed net market is combinations nets and it’s going to grow to 50% in five 
years, there’s just no data that would support anything like that. And it would be very 
interesting to understand of the two PBO nets, … just how much market share they were 
taking” (Private sector) 
 
The inability to predict the market share of PBO LLINs was viewed by all categories of KIs 
to be aggravated by fluctuations in demand for any type of LLINs as a result of funding 
uncertainties and the tendency to distribute LLINs through mass campaigns every 3 
years, resulting in high demand during a year followed by relatively low demand in 
subsequent years (238).  
 
“The predictability of financing, we’re in a bit of an unpredictable period at the moment, 
that would be one of the things would potentially be putting me off as a manufacturer” 
(Policy advisor) 
 
In addition to the direct resolution of the issues around improved data on LLIN failure 
and clarity around normative guidelines on where and when PBO LLINs would be 
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appropriate, most KIs recognised that improving the global tendering and procurement 
processes around LLINs is vital to facilitating the availability of PBO LLINs.  
 
“We should look at the procurement process and somehow try and get away from the 
problems associated with tenders. I would promote a multiple year tender, the tender 
wouldn’t just be for 500,000 nets, 20 tons of it or IRS spray, it would be for the resistance 
management program. …It’s all part of the long-term tendency. I think it will ease out 
the uncertainty, commercial companies would have more confidence therefore they will 
be more willing to invest” (Private sector) 
 
It was also recognised that changing the tendering/procurement process and providing 
predictability would require concerted effort on the part of all actors and particularly 
donors. 
 
“In effect pooled procurement by the three agencies [GFATM, PMI and DfID] I think 
would also be very helpful in that context so that the manufacturers know when the 
product will be needed, how much of it will be needed, and they can manufacture 
according to that and by doing that they can cut down on cost” (Donor) 
 
6.3.6.2 Affordability of PBO LLINs 
All KIs viewed the affordability of a PBO LLIN as a critical factor in determining it 
availability.  
 
“For the manufacturers it’s the money. If they see a product in their class being bought, 
it’s pump money into our product and if there’s a reason why they bought some other 
product in this class instead of ours, fix it” (Policy advisor) 
 
The factors that were reported to influence the affordability of PBO LLINs are 
considered in the detail in the section on affordability.  
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6.3.6.3 Fostering Innovation 
KIs from the researcher, donor and, most strongly, from the private sector categories 
cited the limited protection of innovation, as a direct result of the nature of the 
WHOPES registration process, as a barrier to availability. In particular, the ‘equivalence 
process’, where new LLIN brands are able to receive WHOPES recommendation if they 
are chemically equivalent to an original product that has received WHOPES 
recommendation, is viewed as a disincentive to innovate.  
 
“They also have to have some sort of protection for their innovation; which seems to be 
a major issue that’s coming up now that if they develop these nets, especially for 
something quite innovative, spend millions developing and then marketing them, and 
then the generic comes along and has the same idea and then they’ve lost all their 
market” (Researcher) 
 
The protection of innovation is vitally important, particularly in light of the fact that KIs 
recognised the technical difficulty inherent in developing a truly innovative product.  
 
 
6.3.6.4 Ability to Meet Global Demand 
Two manufactures (Sumitomo and Vestergaard Frandsen) currently have PBO LLINs on 
the market, giving rise to concerns from two KIs from the researcher and policy advisor 
categories, regarding the ability of manufactures to meet global demand. 
 
“There are some issues like if it were to be only one manufacturer whereas now there is 
some diversity, still not a lot but there are a number of WHOPES approved long lasting 
nets. So what is going to happen to those companies that were making the ones that 
aren’t the combination ones? Are we gonna lose those players cos if you say that you 
shouldn’t be using a mono-therapy net then what’s going to happen to them” (Policy 
advisor) 
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6.3.6.5 Clarity on the Process and the Evidence Base Required to 
Convince Policymakers 
Researchers, private sector and donors all cited a need for clarity on the policy adoption 
process as well as the package of evidence required to convince policymakers as a 
current barrier to the availability of PBO LLINs. 
 
“I think there needs to be a clear process for evaluating the products. A clear 
understanding of how you measure if one of these products is better than a current 
standard LLIN and then be able to communicate with people who are procuring this net 
that this is better than a normal net by some standardised level and therefore it is worth 
paying an extra however much the net is going to be” (Donor) 
 
 
6.3.7  Affordability 
Over the past decade, 80%–90% of vector control has been funded by international 
donors (32). Thus, when considering the issue of affordability, all but one KI outlined 
factors that were likely to influence an international donors’ willingness to invest in the 
purchase and distribution of a PBO LLIN. 
 
“Vector control for malaria is at least 80% if not 90% financed by international funds, so 
obviously affordability is driven to 80% or 90% by what convinces donors to invest in 
that. They would be convinced by experts, by academics, by VCAG, by all of the bodies 
who would review the data, make a judgment on whether that’s good or not, and, if it’s 
a more expensive product (which is very likely to be the case), whether that increase in 
whatever it brings is worth the money you have to fork out for it” (Researcher) 
 
One KI highlighted that the lack of local production of LLINs, and the probability that 
PBO LLINs will also be an external solution, discouraged national funding allocation for 
vector control. 
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“To a degree, there is a fatigue amongst African leaders and ministers of health against 
nets because they’re seen as a product that comes from outside of the continent that’s 
been pushed by donors. I think if there is an economic development, even if the nets are 
slightly more expensive, I think it’d be a much more sustainable market if they were 
actually manufactured within the continent” (Policy advisor) 
 
Three factors were perceived to be critical in influencing the international donor’s 
willingness to invest in a PBO LLIN: i) scientific and economic evidence, ii) WHO 
recommendation (see Section 6.3.5), and iii) price. 
 
6.3.7.1 Price 
All KIs agreed on the assumption that more effective next generation LLINs (PBO or 
combination LLINs) are likely to be more expensive. KIs, particularly those from the 
Donor category, reported that the absence of guidance on when it would be rational to 
pay more (supported by robust cost effectiveness analysis) and limited resources 
hinders the affordability of PBO LLINs.  
 
“It’s going to be a difficult prioritisation decision by a country that hasn’t got enough 
money to sustain universal coverage to buy more expensive nets. And with the new 
funding model, it’s much more the decision of the country than of the global fund itself 
but it’s about how you prioritise that resource package” (Policy advisor) 
 
“I think the other big chunk is getting the funders happy with the idea that they’re going 
to have to pay more for the nets. It’s unrealistic to expect these products to arrive at the 
same price that the pyrethroid bed nets are today and the intervention funders need to 
get their minds around that” (Private sector) 
 
However, IRS programmes have been abandoned in the past due to the increased costs 
of switching to more effective alternatives.  
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“Well, I mean without knowing the price for it, I think the biggest barrier for it being 
rolled out would be cost. You know, anything that costs more than what the current 
pyrethroid LLINs cost will be a problem. And you can see this very nicely at the moment 
already where with the spraying, I mean the switch to a different carbamate that should 
be occurring, is not occurring at the rate it should be because actually if you do start 
rotation....a switch to a carbamate in areas of pyrethroid resistance, you can basically 
forget about your spray program because the size of it would be so small with the 
existing funding that uptake of that is going to be very limited and you can see that in 
the world malaria report where coverage of IRS from 2011 to 2012 it’s come down quite 
a bit because of this need to switch and, well, if you can’t switch then you may as well 
not do it at all, that’s sort of the long and short of that. So I think the adoption of the 
combination nets would be faced by similar challenge unless the cost is somewhat 
comparable” (Donor) 
 
A number of KIs cited the potential for increased costs to impact the ability to sustain 
required LLIN coverage levels.  
 
“The change that needs to go on with the investors is about a shift from coverage to 
impact as their metric. But at the moment, because in effect all the products are the 
same, it makes sense to have a coverage-focused metric. If you move into a world in 
which the products aren’t all the same, then coverage is no longer a viable metric and 
one needs to move to impact as a metric, that’s much more difficult to measure” 
(Private sector) 
 
While KIs did not consider it  likely that donors would abandon LLIN programmes 
altogether, the ultimate affordability question, as one KI stated, is:  
 
“Can manufacturers produce this [PBO LLINs] at a cost that the market would bear, 
especially given that there are funding constraints on all sides” (Donor) 
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Two KIs felt that discussions around LLIN durability have facilitated a shift in 
conceptualization of cost effectiveness, with some donors moving from price per LLIN 
to models that consider price per year of effective coverage. 
 
“I think you’d find that for the durability, for example, if you said we’re not doing unit 
price, these days, they’d be very happy with that. Now, that was definitely not true in 
2010, but I think things have changed. And if you said, oh, we’ve got these reasons to 
suppose that this product is better value for money in terms of dollars per year of 
coverage even though it’s not the cheapest per unit, if your data is good, they’ll go with 
that” (Researcher) 
 
KIs cited the potential for catalytic funding and/or high-level subsidies to address the 
affordability issues and facilitate access to PBO LLINs. 
 
“So I think the adoption of the combination nets would be faced by similar challenge 
unless the cost is somewhat comparable and yes, you know, somebody can put some 
catalytic funding in there initially to create the market” (Donor) 
 
6.4 Discussion 
This study considers the opportunities and barriers associated with the global vector 
control policy adoption of PBO LLINs. The study identified three fundamental factors 
that have a knock on effect on all other areas which when addressed can facilitate 
increased access to PBO LLINs, namely i) evidence to facilitate global adoption; ii) global 
adoption which is key to facilitating availability and affordability; and iii) price, which is 
central to improving affordability in the current resource-constrained context. 
 
The global policymaking context is experiencing a period of rapid changes and since this 
study was conducted a number of key changes have taken place including the 
establishment of the I2I partnership and the publication of guidelines for testing new 
LLIN products (including PBO LLINs) to determine efficacy in areas of high insecticide 
resistance (240) and recommendations on the conditions for use of PBO LLINs (63). The 
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impact of these developments on the study outcomes and future directions are 
highlighted where applicable.  
 
6.4.1  Evidence 
This study demonstrates that a package of evidence that is independently developed 
and clearly communicated comprised of evidence of the problem (failure of current 
tools), the effectiveness of the new tools, and cost effectiveness data are core 
requirements for access to new tools. In the policy adoption process for PBO LLINs, 
evidence constituted a barrier, as policymakers had not clearly articulated the package 
of evidence required to change policy, leading to recommendations that pose more 
questions. This lack of clarity impacts on the actions of the manufacturers in their 
preparation of evidence packages to convince policymakers. The current adoption 
process, as far as evidence is concerned, is one of trial and error. 
 
In future, if guidance on evidence requirements is pre-issued to manufacturers and 
evidence dossiers are developed with WHO and expert committees conducting 
inspections of manufacturing sites, concerns raised by KIs about the lack of clarity 
around the evidence base required to influence policy are likely to be addressed. These 
actions could also raise confidence in the independence of the evidence generated as 
well as promote closer engagement between the manufactures and policymakers and - 
a strategy seen to promote the appropriate use of evidence in policymaking (112). 
 
The I2I seeks to foster innovation by allowing the review of new vector control tools to 
be evaluated and recognised for claims superiority (241). This would theoretically 
encourage developers of new vector control tools to innovate and develop vector 
control tools that perform beyond minimum safety and efficacy standards on which 
they are currently assessed.  
 
The issue of evidence is also significant in convincing donors to fund PBO LLINs, given 
that donors are considered to be evidence driven. This study demonstrates that, though 
for different reasons, donors, policymakers and manufacturers all require robust 
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evidence of sufficient quality that supports a clear policy recommendation. This is an 
instance where the interests of all actors, including researchers, who rely on research 
publication for promotion (151), are aligned. Therefore, improved coordination across 
all actor categories may result in generating relevant evidence for policy change.  
 
6.4.2  WHO Recommendations 
The lack of WHO recommendations/normative guidance on where and when PBO LLINs 
should be deployed is a serious obstacle to access. It hinders national adoption, as seen 
in the Burkina Faso case study (Chapter 5), and causes uncertainties regarding market 
share and returns on investment, making manufacturers reluctant to venture into 
development and manufacture (231).  
 
Further, the main donors are unwilling to fund tools that have not been recommended 
by WHO (242, 243). In instances where PBO LLINs have WHOPES approval as a standard 
LLIN (PermaNet® 3.0 and Olyset® Plus), from a funding perspective, they are treated the 
same as standard LLINs, making it difficult for manufacturers to charge more for any 
additional benefits they provide. This cycle continues considering that, as shown herein, 
the willingness of donors to fund a tool (affordability) is directly linked to the 
manufacturers’ willingness to develop and manufacture it (availability). In contrast KIs 
recognise the need for donors to make a conceptual shift from coverage to impact as 
their metric making a case for more effective PBO LLINs.  
 
In theory the recent recommendation by WHO gives donors the justification required to 
fund PBO LLINs, but its emphasis on maintaining universal coverage makes a shift to 
PBO LLINs virtually impossible in practice given resource constraints and fixed 
budgetary envelopes. The 2015 PBO recommendation lends some credence to the 
confusion expressed by KIs around the policy process. While it is clear that in giving 
advice to the WHO – director general, MPAC receives input from several bodies (Figure 
11), it is not clear how differences in opinions and seemingly contradictory positions are 
resolved. This leads to what the researcher (quoted above) describes as a lack of clarity 
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on where to go and who has the final word on issues to do with vector control 
policymaking. 
 
An important development is the establishment of the Innovation to Impact (I2I) 
partnership in 2015 (after KI interviews were conducted) to support a clear path to 
market for tools by making the global adoption process transparent and timely (241). 
The partnership aims at achieving these objectives by: 
i. Ensuring that vector control tools are evaluated based on evidence dossiers (with 
pre-submission of guidance to developers) (241). This would potentially provide 
clarity on the specific evidence base required to influence policy. 
ii. Ensuring that evidence is generated in close coordination with WHO (including 
manufacturing site visits by WHO experts and committees) (241). This would 
contribute to addressing the concerns around the independence of the evidence 
generated by product manufactures. 
iii. Ensuring that WHO utilises of a wide range of experts independent of the 
developers to review product dossiers multiple times a year (241). This would 
improve the transparency and the timeliness of the review process. 
iv. Ensuring that guidance is provided to funders and countries to facilitate 
comparative assessments of vector control tools (241), thereby facilitating decision-
making on the choice of funding/deploying vector control tools in relation to 
existing vector control tools.  
 
In future I2I plans to provide guidance to funders and countries that allows comparative 
assessments of vector control tools. Guidance of this nature would facilitate access to 
new vector at tools by aiding decisions on where and when the new tools are the most 
appropriate compared to older tools. However, the extent to which the partnership 
improves the global adoption process remains to be seen.  
 
 
6.4.3 Price 
The potential cost of PBO LLINs, as with most insecticide resistance management 
measures, is a major barrier to access (198). International disbursements to malaria-
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endemic countries have increased markedly, from less than US$ 100 million in 2000 to 
US$ 1.97 billion in 2013 (211). While this shows a significant increase in international 
funding, the upward funding trend has slowed since 2009 and it is recognised that the 
current funding environment, including for vector control, is constrained (211). The 
recent ERG recommendations may result in donor and countries being dis-incentivised, 
as purchasing more expensive tools while maintaining universal coverage is difficult 
within a fixed funding envelope and a resource-constrained environment.  
 
A viable solution to address higher prices includes improved forecasting of demand for 
PBO LLINs over a number of years and pooled procurement. These practices can result 
in improved forecasting/predictability of PBO LLIN demand and lead to lower prices 
(198). This is being used as a strategy to reduce to cost of next generation insecticides 
for IRS under a UNITAID supported project called NGENIRS (244). This project is a 
positive precedence, however given the seriousness of the threat of insecticide 
resistance to vector control and the long-term goal of malaria elimination, an increase 
in resource commitments and an adjustment to the concept of paying higher prices for 
more effective tools may be the inevitable cost. This adjustment may be aided by a shift 
from measuring the coverage (i.e. number of tools distributed) to the measurement of 
their impact. 
 
While none of the study KIs cited plans to subsidise the cost of PBO LLINs, subsidies, 
local manufacture and sustained financing were viewed as effective strategies for 
promoting availability and mitigating cost barriers. These strategies were instrumental 
in promoting access to ACTs and antiretroviral therapies (141, 224, 245, 246). An 
important distinction between the access to ACTs and PBO LLINs is that, for ACTs, there 
was unity behind the concept and a number of different products were available (247). 
However, without clarity on what package of evidence will result in policy change, 
solutions to reduce price and advocacy for high-level subsidies of PBO LLINS will be 
premature.  
 
Studies have shown that policy champions can be powerful in facilitating access to new 
interventions (120, 151). In the malaria context, this has been pivotal in drawing 
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attention to the need for increased access to Rapid Diagnostic Tests (RDTs) and ACTs 
(120, 247, 248). The missing link for vector control tools that address insecticide 
resistance appears to be policy champions comprised of multi-disciplinary actors 
coordinated in gathering, packaging and disseminating evidence as part of advocacy to 
address insecticide resistance in general using tools such as PBO LLINs.  
 
6.5 Conclusions 
This study demonstrates that a package of independently developed and clearly 
communicated evidence that demonstrates the failure of current tools as well as the 
effectiveness and cost effectiveness the new tool are key facilitators for policy 
adoption. The case study underscores the need for greater clarity on the relative roles 
of the key policy advisory bodies. In addition, while the recent  2015 guidance on the 
use of PBO LLINs is a welcome development, clearer WHO guidance on where and 
when countries may choose to deploy PBO LLINs is still required to promote donors’ 
willingness to invest in them. In addition, the study highlights that efforts on innovative 
procurement mechanisms that can support forecasting of demand and facilitate price 
reductions are needed in order to foster availability and affordability. Finally, this study 
demonstrates that more effective coordination amongst the vector control 
stakeholders is urgently required to collect robust and appropriate data and raise the 
profile of the threat of insecticide resistance as well as advocate short- and long-term 
solutions.  
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7 Chapter 7: Synthesis of Findings and 
Recommendations for Accelerating Access to New 
Vector Control Tools 
 
7.1 Introduction 
The overall aim of this thesis was to explore the factors influencing access to new 
vector control tools so as to develop recommendations on improving strategies to 
accelerate access. A synthesis of the findings from the three case studies in Chapters 4–
6 is presented, followed by a discussion of the five key areas that must be strengthened 
in order to accelerate access to new malaria vector control tools. 
 
 
7.2 Synthesis of Results from the Global and National Case Studies 
As stated in Chapter 1, the achievements of SDGs is linked to the elimination of malaria 
which in turn is dependent on vector control strategies that utilise new and innovative 
vector control tools. However, these new vector control tools can only be useful if the 
people who need them can access them (109). People’s ability to acquire and use 
(access) new vector control tools is predicated on a number of factors at the global, 
national and sub-national levels (152). The aim of this thesis was to gain insight into the 
factors, at both the global and national levels, that influence access to new malaria 
vector control tools and to provide recommendations on strategies for accelerated 
access. This line of enquiry was framed around the two questions: 
 
 What factors influence the adoption of new malaria vector control tools at both the 
national and global levels? 
 What opportunities exist at the national and global levels to accelerate the adoption 
of new malaria vector control tools? 
 
As detailed in Chapter 3, the synthesising of the findings was an iterative process 
informed by data from the three case studies and documents reviewed. This process 
resulted in the identification of eight key policy influencers with the key findings in 
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relation to each case study summarised in Synthesis of key findings from the three case 
studies presented in Chapters 4–6 .  
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Table 12. Synthesis of key findings from the three case studies presented in Chapters 4–6  
 Policy influencer Global Case Study –  
Policy analysis of next generation 
LLINs 
Nigeria Case Study – 
Policy analysis of larviciding scale-up 
Burkina Faso Case Study – 
Policy analysis of next generation LLINs 
1 Evidence regarding 
the problem, e.g., 
insecticide resistance  
Evidence of the magnitude, intensity 
and impact of insecticide resistance is 
required 
Use of insecticide resistance data for 
decision-making is not routine 
Capturing insecticide resistance data was 
important, but local evidence does not 
directly impact policy 
2 Evidence regarding 
the tool 
The effectiveness of new the tool in 
multiple settings is required 
Evidence demonstrating the failure of 
old tools  
WHO recommendation is accepted as 
evidence of effectiveness 
WHO recommendation is accepted as 
evidence of effectiveness 
3 Evidence source and 
quality 
Independent/clearly communicated 
evidence is required for policy 
adoption 
Local evidence is necessary (even if 
funded by manufacturers)  
International sources of evidence are 
ideal  
4 Data on cost-
effectiveness 
Data on cost-effectiveness of the new 
tools is required  
Cost-effectiveness is viewed as a donor 
construct and is an ancillary factor 
Unit price rather than cost-effectiveness 
is important because in the absence of 
increased resources, actors would rather 
deploy potentially less effective/cheaper 
tools than new/more effective and 
expensive tools 
5 Transparent and 
timely policy adoption 
process 
Lengthy and poorly defined policy 
process 
Poor articulation of evidence required 
to facilitate policy adoption 
Well defined national policy process 
Policy process is disconnected from 
researchers  
Policy process can be ignored by high-
level politicians to adopt their priorities 
Well defined national policy process  
Strong links between policymakers and 
researchers  
National policy adoption is futile without 
global adoption and donor funding for 
intervention 
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6 Availability and source 
of financing  
About 80% from international donors, 
mainly GFATM 
Primarily international donor funds 
National resources can be committed 
when intervention is aligned with high-
level politician priorities, e.g., economic 
development through technology 
transfer 
Primarily international donor funds  
Absence of WHO recommendation 
impedes donor funding  
7 Price of new tools The price of the new tool can be a 
barrier, particularly if the expectation 
is to deploy without losing current 
coverage levels within a fixed funding 
envelope 
The price of larviciding was not an issue 
– government prepared to 
fund/explore alternative funding 
sources 
Unit price of the new vector control tools 
is paramount in order to achieve 
universal coverage targets within a fixed 
funding envelope 
8 Product champion Multiple messages need to be clearly 
communicated -the scale of the 
insecticide resistance problem, the 
appropriate tools and the appropriate 
context to address insecticide 
resistance 
Confusion as to the advocacy/policy 
champion mandate of the actors and 
partnerships aimed at facilitating 
access to new vector control tools 
High-level regional and national actors 
pushing the scale up of larviciding 
The emphasis in Burkina Faso was less 
about policy champions at the national 
level but more on the need for the global 
adoption and funding of new vector 
control tools 
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7.3 Accelerating Sustained Access to New Malaria Vector Control Tools 
In order to leverage on the potential for the 8 policy influencers, identified in table 10, 
to accelerate access to new vector control tools, five areas need to be addressed: 
 
i. Increased availability of high quality, robust, appropriate and independent 
evidence that demonstrates the magnitude, intensity and impact of insecticide 
resistance, the effectiveness and cost effectiveness of new tools; 
ii. A transparent and timely global adoption process that facilitates national 
adoption and international funding;  
iii. Diversified funding sources for procuring new vector control tools at the global 
and national level; 
iv. Innovative mechanisms to address the price of new vector control tools at the 
global and national level; and  
v. Strengthened coordination among global, regional and national actors to clearly 
communicate the issue of insecticide resistance and champion appropriate 
vector control policies and tools.  
 
The following sections present a discussion on these five areas using evidence from the 
three case studies and document review to support the recommended courses of 
action. 
 
7.3.1 Increased Availability of High Quality, Robust and Appropriate 
Evidence 
The three case studies corroborate previous reports that demonstrate that evidence 
often has a role in policymaking (81, 130, 151, 249, 250). However, the case studies also 
show that, in relation to new vector control tools in the context of insecticide 
resistance, the ability for evidence to influence access is nuanced and what is required 
varies by policy level. The package of evidence currently required to facilitate global 
policy adoption needs to better demonstrate the full extent of the insecticide resistance 
problem at country level as well as the relationship between the various insecticide 
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resistance mechanisms and malaria vector control tool failure, linking the 
entomological effects of insecticide resistance to epidemiological impact. More 
conclusive evidence of this nature is required, but difficult to develop (37, 251).  The 
evidence related issues are the most immediate priority to be addressed as in the 
absence of this package of evidence, policy support for adoption of new vector control 
tools to tackle insecticide resistance, particularly at the global level, will continue to be 
slow. However, to date, the development of robust and appropriate evidence in 
relation to new vector control tools has been slow, indicating that while this 
recommendation is key the feasibility of its operationalisation will be affected if not 
supported by i) a transparent and timely global adoption system (section 7.3.2) and ii) a 
strengthened coordination among global, regional and national actors (section 7.3.5). 
The impact of the absence of evidence appears to be less significant at the national 
level, where data was either not routinely collected (Nigeria) or lacked the power to 
directly influence national policy (Burkina Faso). 
 
Evidence regarding the effectiveness and cost-effectiveness of the tool was confirmed 
as a significant policy facilitator. In both national settings, WHO recommendations were 
accepted as sufficient evidence of the tool’s effectiveness. However, in Nigeria, but not 
in Burkina Faso, local data was an additional requirement for adoption, confirming 
studies that argue that the role of local evidence is dictated by the national policy 
context (222, 252). At the global level, the availability of independent, clearly 
communicated, robust evidence to demonstrate the effectiveness of the tool in 
multiple settings was required to influence policy, and cost-effectiveness data was 
regarded as an important element of the package of evidence. However, at the national 
level, it was viewed as ancillary because it was considered a donor construct (Nigeria). 
In Burkina Faso, price rather than cost-effectiveness was viewed as being more central 
to achieving universal LLIN coverage targets, which currently emphasise universal 
coverage of tools rather than impact on malaria transmission. Whilst universal coverage 
targets should not be discarded, the role of new vector control tools in reducing malaria 
transmission in areas of insecticide resistance while not necessarily achieving universal 
coverage needs to be explored. 
 
 162 
The recent WHO recommendation on the use of PBO LLINs calls for the phased roll-out 
of new tools for evaluative purposes (63). On the one hand this is a valid means of 
developing policy relevant evidence that considers the nuances inherent in the 
evidence requirements at the global and national levels. However, this strategy should 
have been implemented earlier in the PBO LLIN adoption process in order not to further 
delay their wide scale access. Furthermore, these evaluations require human and 
financial resources to be implemented. A resource option would be for national 
policymakers, particularly in countries that require local evidence for national adoption, 
to prioritise these evaluations and include them in applications to donors like the 
GFATM and the President’s Malaria Initiative (PMI), which in the past have been 
predisposed to supporting pilot-based deployment of new tools in the context of robust 
entomological data gathering (253). These actions need to be underpinned by the 
development of national capacity to carry out routine data collection and large-scale 
trials, a recommendation that is extremely difficult to implement given the recognised 
shortages in key expertise such as entomologists (254). In addition, the use of the 
evidence at national level to directly influence policymaking needs to be enhanced 
using strategies that have demonstrated to be effective (111). 
 
In future, pre-issued guidance to manufacturers should facilitate the early development 
of policy relevant evidence and avoid delays in access due to a lack clarity around the 
evidence needed to influence policy (241). In addition, in order to accelerate access, 
global policymakers may consider options like issuing interim recommendations based 
on minimum standards of safety and efficacy in order for vector control tools to act as a 
stopgap while evidence or more effective options are being developed (139). 
 
Finally, future analyses need to explore the potential for regional level evidence to be 
developed and used to influence policy across multiple national contexts, taking in 
account the unique malaria transmission settings, a viable option would be the 
implementation of multicentre trial sites. Additionally, initiatives such as Elimination 8 – 
a coalition of eight southern African countries aimed at aligning policies and 
strengthening regional surveillance and analysis – can be explored as a template for 
regional cooperation in relation to developing a robust evidence base.  
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7.3.2  A Transparent and Timely Global Adoption Process 
The global and Burkina Faso case studies show that a transparent and timely global 
adoption process can facilitate access to new vector control tools, particularly as global 
adoption significantly impacts on international funding. In the absence of this, product 
innovation and development is potentially stifled, and national adoption and 
international financing is hindered. Conversely, the national level policy process 
appeared to be well defined, though it was undermined by high-level politicians in 
Nigeria and futile in the absence of funding in Burkina Faso.  
 
Some commentators hold the opinion that the recent WHO recommendation on PBO 
LLINs has exacerbated the confusion in malaria vector control policymaking, lengthened 
the PBO LLIN access timeline and further discouraged innovation in the development of 
new vector control tools (237). Further, it remains unclear whether new vector control 
tools manufactured with completely novel insecticides will require additional regulatory 
approvals and the required timeframe for this, since, to date, all insecticides being 
employed for public health purposes were repurposed from agricultural use (255). This 
may add a further layer of regulatory approval steps that the public health community 
currently has little experience in tackling, as well as further time.  
 
Furthermore, KIs from the global study held the view that innovation for the 
development of novel vector control tools is potentially stifled, firstly, due to the public 
health market being less profitable than the agricultural insecticide market (256) and, 
secondly, due to the WHOPES equivalence process conferring an unfair advantage on 
the manufacturers of generic tools. However, the harm to industry may be overstated 
given that two innovating manufacturers (Sumitomo Chemical and Vestergaard 
Frandsen) still account for 75% of the GFATM- and PMI-financed LLINs (257). 
 
At the global level, there is optimism that the lack of transparency in the malaria policy 
process is being addressed by the creation of the WHO MPAC, the VCAG and the 
strategic use of the VCTEG (80, 236). While some of this optimism may have been 
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eroded by the view that the recent PBO LLIN recommendation was not transparent, the 
plans articulated by the I2I partnership to make the global adoption process more 
timely and transparent are positive steps. These establishment of these bodies and 
partnership suggest that addressing issues in relation to the transparency and 
timeliness of global policy adoption is both imminent and feasible. (241). This 
partnership, in conjunction with the existing WHO mechanisms, is potentially a very 
powerful instrument for imminently addressing the shortcomings of the global 
adoption process  (257, 258). Whilst recognising that the I2I partnership is relatively 
new, a potential weakness in its current approach to national adoption of new vector 
control tools is the disproportionate emphasis on the national registration of tools at 
the expense of addressing the drivers of national policy adoption. Although registration 
can prove to be a barrier, and the process involved in the registration of vector control 
tools in countries needs to be accounted for in the access timeline, registration did not 
emerge in the Nigeria or Burkina Faso case studies as a major barrier or facilitator to 
access. However, this may be due to fact that both larviciding and PBO LLINs utilize 
chemicals that have long been registered and in use at national level. 
 
It is noteworthy that, if the difficulties around the required evidence base discussed 
above are not addressed, the likelihood for the global adoption process to be 
transparent and timely will continue to be hindered, thereby hampering the success of 
any mechanisms established to accelerate access to new vector control tools. In future, 
the system needs to be more timely than has been exemplified by the case of PBO 
LLINs, i.e., the evidence required to facilitate policy adoption needs to be clearly 
defined and the process needs to be shorter and more transparent, particularly with 
regards to the relative roles and inputs of the various global policymaking/advisory 
bodies. The extent to which the plans of MPAC, VCAG and VCTEG, as well as the I2I 
partnership, will improve the global adoption process for vector control tools and 
navigate any additional regulatory approvals, and the extent to which these may result 
in additional delays, remains to be seen. 
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7.3.3  Diversified Funding Sources for Procuring Vector Control Tools  
The potential for the availability of funding to positively and powerfully impact the 
adoption of a tool was confirmed in the national case studies. Specifically, the source of 
the funding created a significant impact on adoption of new tools. Indeed, the 
underlying assumption at the inception of this thesis was that unlocking international 
donor funding was at the core of facilitating access to new vector control tools. This 
assumption was valid given that, between 2005 and 2013, approximately 80% of the 
funds spent on malaria control were from international donors (32). However, the 
Nigeria case study showed surprising results, whereby the potential for national funding 
facilitated policy change, while the Burkina Faso case study demonstrated the dangers 
inherent in the overreliance on international funding, particularly as they are highly 
influenced by a global adoption process that is still in the process of being improved.  
 
Furthermore, history has demonstrated the devastating impact that donor fatigue has 
had on countries unable to fund malaria control themselves (4). Indeed, the failure of 
the previous global eradication efforts and malaria resurgence in a number of countries 
has been attributed, at least in part, to a lack of sustained donor support. A diversified 
funding base that includes national funding streams is the only way to ensure rapid and 
sustained access to vector control tools in countries that need them until malaria 
elimination is achieved. Thus, any efforts to promote access to new vector control tools 
as a means of eliminating malaria that do not incorporate strategies to diversify the 
funding base and include national funding sources, where possible, are likely to fail (2).  
 
Considering donor fatigue and the attractiveness of ‘African solutions for African 
problems’ (222, 259), the local manufacture of new vector control tools, supported by 
technology transfer, offers the potential for national economic development and is a 
powerful strategy for facilitating national funding (138, 260). For example, the lack of 
adequate technological transfer has been a problem in promoting access to vaccines 
and this strategy is now being actively promoted as a means to accelerated access 
(261). These examples should serve as a sign that national governments can invest a 
significant amount of time and human resources in interventions that serve economic 
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and health interests. However, the feasibility of increased government funding in 
relatively poor countries like Burkina Faso remains slim. National governments, 
international donors, RBM and WHO, along with partnerships such as I2I and IVCC need 
to work together to make diversified funding for new vector control tools feasible by 
incentivising countries like Nigeria, which are potentially able to commit funds to vector 
control tools, to do so. 
 
The potential for funding to influence policymaking is arguably evident at the global 
level, where studies have demonstrated the potential of the Bill and Melinda Gates 
Foundation (BMGF) spending patterns to influence the direction of global malaria policy 
(262). In 2007, Bill and Melinda Gates called for the renewed focus on eradicating 
malaria (263). In 2008, the Director-General of WHO credited the BMGF for “taking that 
very brave step to challenge us [to aim for malaria elimination]” (264). Critics suggest 
that the BMGF places too much emphasis on biomedical interventions like vaccines, 
diverting focus from interventions that do not fit into the BMGF’s priorities such as the 
building of resilient public health systems (262). At the global level, diversification of 
the funding base will ensure that, where one actor does not support a particular tool 
due to delays in WHO guidance or as a result of institutional priorities, access is not 
jeopardised because other funding sources are inadequate or do not exist.  
 
It is not recommended that WHO’s central function of promoting the adoption of 
evidence-based policies be by-passed, because while the Nigeria case study has been 
cited in this thesis as an example of policy adoption being facilitated as a result of 
national commitment and resources, it is a situation that can be abused, leading to 
policies based on political interests rather than evidence. However, it is unsuitable for 
inefficiencies at the global level to constrain national policy adoption as was the case in 
the Burkina Faso analysis.  
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7.3.4  Innovative Mechanisms Reducing the Costs of New Vector 
Control Tools 
The high cost of an intervention is potentially a powerful obstacle to its access (152). 
The perspectives of the KIs in the global and national analysis show that this can 
particularly be true when there are cheaper alternatives to the new vector control tool 
in question, even if these alternatives are less effective. For example, the price of 
insecticides was cited as a major factor in the discontinuation of the IRS programme in 
Burkina Faso (Chapter 5). The global and Burkina Faso analyses established that global 
and national stakeholders assume that PBO LLINs and subsequent next generation 
LLINs will cost more than standard LLINs. Indeed there is some evidence of relatively 
large price differentials between standard and PBO LLINs (199) (265) (266), but at the 
same time there is evidence gathered during this research and others of much smaller 
price differentials (199). While, the determinants and extent of this additional cost 
remains unclear and are beyond scope of this thesis, it is clear that there are 
opportunities for countries to negotiate the reduction of the price of a new vector 
control tool. Future research should explore market analysis to identify strategies to 
reduce prices taking into consideration some of the suggestions by KIs in the global case 
study. One suggestion was the development of longer-term flexible vector control 
strategies that incorporate a mix of cheaper and more expensive vector control 
interventions, deployed in-country as appropriate local evidence of transmission and 
insecticide resistance setting. This provides a level of upfront predictability and 
transparency that can promote better price negotiations.  
 
The global case study found that the availability of a new vector control is influenced by 
the sustainability and predictability of the market, i.e., the manufacturer’s ability to 
forecast key elements of the market, including price, market size and demand over 
multiple years. The global study, like other analyses on expanding access to new vector 
control tools, calls for improved procurement procedures as a means of overcoming the 
forecasting issues around market size, demand and price. These coordinated 
procurement practices already exist for standard LLINs, with some extent of 
collaboration occurring between donor agencies such as GFATM, PMI and UNICEF (256, 
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265, 266). The feasibility of a recommendation for coordinated procurement in relation 
to any new vector control will be impacted by the ability to quantify its market share, 
and the main donors’ willingness to competitively procure the new tool. However, KI in 
the global analysis expressed a willingness to develop consolidated, longer term 
procurement plans which include multi country gap analysis and multi year donor 
funding commitments. The predisposition of major vector control funders (GFATM, PMI 
and UNICEF) to work together in this way indicates that this recommended course of 
action in relation to a new vector control tool is feasible. It is noteworthy that such 
willingness to commit to funding a new vector control tool in such large scales over 
multiple years will be dependent on the resolution of the evidence, global policy 
adoption and funding issues discussed in sections 7.3.1 and 7.3.2 above and is therefore 
unlikely to be as immediate as the other recommendations above.  
 
Access to new vector control tools may be impeded if high costs deter funders from 
investing; however, it was clear from the global case study and discussions around IRS 
and LLINs that donors are predisposed to taking into consideration the cost 
effectiveness the tool in question and not just the purchase price (257). Taking into 
account the impact of the new vector control tool will improve its cost-effectiveness, 
provided it is more effective in areas of insecticide resistance. 
 
If a new malaria control intervention is more effective there is precedent for 
establishing global subsidy mechanism such as the Affordable Medicines Facility–
malaria (AMFm). The AMFm was designed to increase access to ACTs by subsidising 
their costs, increasing demand and ensuring a sustainable predictable market. 
Evaluations of the AMFm mechanism have shown that the subsidy, along with 
initiatives such as pooled procurement, can be successful in improving ACT price and 
availability (224, 267). With regards to vector control, a promising example is the 
UNITAID and IVCC initiative, which has established a partnership (NgenIRS) to provide 
co-payments to bring down the cost of the next generation IRS insecticides, such as 
Actellic 300CS©, and make them available to countries at lower prices (58). 
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It is important to note that national adoption and affordability does not automatically 
translate into national availability. Lessons from ACTs show that, after national policy 
adoption and financing, it took up to 2 years to import drugs due to procurement-
related delays (138). For example, there are 16 WHOPES-approved LLINs (235) and the 
lead-time from order to delivery is of approximately 6 months (199). The number of 
manufacturers with the capacity to manufacture and supply PBO LLINs will (at least in 
the early stages) be significantly less than those supplying standard LLINs, thus severely 
limiting the available quantities at least until more manufacturers develop new or 
equivalent products. Once PBO LLINs are recommended, the benefits of the WHOPES 
equivalence process arguably come into play by allowing manufactures of generic LLINs 
(seen to be equivalent to an approved LLIN) a shorter path to market, thereby 
accelerating access. For new malaria vector control paradigms, where only one or two 
products are being tested, it is clear that the ability to meet global demand if the tools 
demonstrate effectiveness will be a factor that has a significant impact on the 
availability of the tools and, therefore, access. Again technology transfer for these new 
paradigms, particularly those with simple technological requirements, will be a 
significant, albeit, longer term strategy for accelerating their sustained access. 
 
7.3.5 Strengthened Coordination among a Network of Global, Regional 
and National Actors 
 
7.3.5.1 Coordinated Network of Policy Champions for Insecticide 
Resistance and Malaria Elimination 
There are numerous studies in the health policy and access to health interventions 
fields that demonstrate the central role that actors, particularly policy champions, play 
in facilitating policy change and access to new health interventions. For example, the 
results of the global case study along with malaria literature show the pivotal role that 
policy champions played in artemisinin resistance (Professor Nick White (247)), the roll 
out of rapid diagnostic tests (the Foundation for Innovative New Diagnostics (120)), and 
the scale-up of ITNs (Professor Christian Lengeler) (120).  
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However, the need to develop new vector control tools, as shown in Figure 1, goes 
beyond addressing insecticide resistance as it encompasses the need for a 
comprehensive vector control response that will contribute to the elimination of 
malaria. This requires an access architecture that involves a coalition of individuals and 
organisations at the global, regional and national levels with technical competence, 
knowledge of the context (i.e., the disease, the product and product market), 
energy/time and the ability to take strategic action to facilitate access (268). A model 
for these activities could mirror that used for coordinating access to rapid diagnostic 
tests, with a focal point based in WHO coordinating affiliations with relevant 
institutions (120). This coordinated architecture is akin to policy networks, which have 
the capacity to determine policy success (269) and would be instrumental to 
strengthening the four areas discussed above.  
 
The IVCC, a product development partnership aimed at developing innovative vector 
control tools to address insecticide resistance (270). The IVCC, UNITAID and other 
partners in the NgenIRS project have been supporting access to a new insecticide 
(Actellic 300CS©) for malaria control programmes (271). The IVCC is also involved in the 
I2I partnership, which is aimed at achieving appropriate use for health impact, i.e., 
beyond bringing a product to market (241). Within the limitations of I2I noted in 
Section 7.3.2, the partnership is potentially a very significant step towards a globally 
coordinated approach to facilitating accelerated access to new vector control tools. 
 
Partnerships like the IVCC, NgenIRS and I2I, along with manufacturers, researchers, 
funders and WHO and its advisory committees (such as MPAC, VCAG and VCTEG) are 
important global initiatives for facilitating access to new tools. However, clarity is 
needed on the relative roles of the WHO advisory committees in relation to new vector 
control tools. Furthermore, given the confusion expressed by specific categories of KIs 
in the global case study, the manner in which the various partnerships work with the 
WHO mechanisms in order to align and achieve objectives, needs to be clarified. This 
will result in strengthened coordination of the global actors and allow for: 
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i. A comprehensive view of the global architecture (actors and their roles in 
relation to new vector control tools) and mechanisms to coordinate activities. 
ii. A comprehensive understanding of how the activities of individual actors 
complement one another and contribute to the goal of access to new vector 
control tools in the context of both insecticide resistance and malaria 
elimination.  
iii. The joint priority setting for research, development, resource mobilisation and 
resource allocation in relation to facilitating access to new vector control tools 
in the context of both insecticide resistance and malaria elimination. 
 
7.3.5.2 Strengthened Coordination between the Global, Regional and 
National Levels 
In 2012, ECOWAS articulated the regional goal of malaria elimination. This goal is a 
potential vehicle to facilitate the national adoption and funding of new vector control 
tools, as in the Nigeria case study, where the national decision to scale-up larviciding 
was linked to the ECOWAS malaria elimination agenda (169). Demonstrating the 
centrality of new vector control tools to the wider malaria elimination agenda leverages 
a key lesson from the findings of the Nigeria case study, i.e., of the power of framing 
new vector control tools within wider goals as a means to unlocking resources and 
facilitating access. However, in relation to PBO LLINs, there is no evidence that regional 
engagement was or is taking place to facilitate access. Hence, there is a need to 
strengthen links between the global and regional architecture in relation to adoption of 
specific new vector control tools in the context of insecticide resistance and malaria 
elimination. 
 
The recent reorganisation of the RBM partnership is potentially a significant 
opportunity to facilitate increased global, regional and national coordination in relation 
to access to new vector control tools. The RBM maintains that its strength lays in its 
ability to form partnerships nationally and globally through networks at the global, 
regional and national levels (272). The strength of the RBM partnership was evident at 
the national level in Burkina Faso and Nigeria. However, the influence of its regional 
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structure was not observed particularly in relation to the contentious issue of larviciding 
promoted by another regional body, suggesting room for improved regional 
coordination and influence. The recent reorganisation of the RBM, which included the 
appointment of a new executive board, aims to provide more emphasis on providing 
country support, financing, advocacy and resource mobilisation (273). The 
reorganisation is nascent and its impact on the vector control policy architecture 
remains to be seen. A recommended priority for the new RBM would be the increased 
engagement with regional bodies like ECOWAS, which have made malaria elimination a 
priority.  
 
7.3.5.3 Increased Engagement of High-level National Policymakers 
Increased engagement of high-level national policymakers is the final component 
needed for strengthening the global, regional and national architecture Members of 
national vector control policy advisory committees provide a useful entry point for 
developing support at the national level to facilitate access to new vector control tools 
(131). In addition, as seen in the Nigeria case study high-level actors, who may not be 
readily identified may have significant power in effecting policy change that other 
traditional actors may be powerless to stop (222). This underscores the importance of 
increased engagement at the highest national and regional policymaking levels as a 
crucial strategy for facilitating access to new vector control tools. A caveat is that 
engaging high-level politicians will require the malaria community to actively frame the 
contributions of new vector control tools in the context of malaria elimination and the 
wider national socioeconomic goals.  
 
A potentially important vehicle for reaching high-level national politicians on the 
African continent is (currently) the African Leaders Malaria Alliance (ALMA). ALMA is 
the coalition of 49 African Heads of State and Government working together to 
eliminate malaria by 2030 (274). ALMA is currently the only organisation with the aim 
of actively engaging the highest level of policymakers in sub-Saharan Africa specifically 
in response to malaria control and elimination. The Nigeria case study shows how high-
level regional influence from ECOWAS set the context for the national adoption a vector 
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control tool for malaria elimination in advance of the WHO Action and Investment to 
Defeat Malaria in 2015. Despite this, regional bodies, such as ECOWAS, ALMA and the 
RBM, currently appear to be underutilised as they were not identified by the KIs in the 
national cases studies as being part of the normal policy actors; facilitating and 
sustaining access to new vector control tools in the context of malaria elimination will 
require engagement of such regional bodies to facilitate regional commitment and 
national action.  
 
Strengthened coordination among a network of global, regional and national actors in 
order to facilitate access to new vector control tools in the context of insecticide 
resistance and malaria elimination is not an easy recommendation to implement given 
the number of organisations and potentially diverse range of interests involved. 
Nevertheless, until such a network of actors takes a coordinated and prominent stand 
at the global, regional and national levels, progress towards access to new vector 
control tools will be slow. 
 
7.4 Conclusions 
This chapter reaffirms the notion that without concerted effort to accelerate access to 
new/innovative vector control tools it will be impossible to achieve the 2030 malaria 
elimination goals. A synthesises results from the three case studies are presented here. 
The chapter outlines the 8 key policy influencers identified from the three cases studies, 
that can facilitate policy adoption at the global and national level. The chapter 
concludes by presenting a discussion on the 5 areas that need to be addressed in order 
to leverage on the key policy influencers and accelerate access to new vector control 
tools.  
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8 Chapter 8: Conclusions and Future Research 
 
8.1 Thesis Conclusions 
The modified analytical framework used in this thesis, based on the Walt and Gilson 
(77) and Frost and Reich (120) frameworks, provides a novel way to examine and 
facilitate access to new health interventions. The case study results provide insight into 
the adoption of new vector control tools at both the global and national levels, 
addressing knowledge gaps regarding the need for robust policy analysis in relation to 
malaria control in general, and to new vector control tools in particular (124, 126). The 
research presents policy analyses that demonstrate the interrelation of global and 
national policymaking in relation to malaria vector control. The synthesis of the results 
of the case studies identify 8 key policy influencers that facilitate policy adoption and 
presents five areas that need to be strengthened in order to accelerate access to new 
vector control tools.  
 
The findings of this thesis are of particular importance given the pivotal role that vector 
control has played in malaria control and in the elimination goals set for 2030 (2), as 
well as the insights it provides regarding the routes to accelerate access to these tools. 
The synthesised findings of the three case studies show that the national and global 
level factors that facilitate access to new vector control tools include evidence, a 
transparent and timely global adoption process, a diversified funding base, price, and a 
coordinated group of policy champions. 
 
The importance of evidence in policymaking at the global and the national levels (108, 
109, 179) is demonstrated by the fact that five of the eight key findings in this thesis 
relate to evidence. It was demonstrated herein that, in relation to new vector control 
tools, evidence-based policies in the context of insecticide resistance are nuanced. 
Further, robust and appropriate evidence that demonstrates the problem as well as the 
solution is required to effect policy change; such evidence needs to be context specific 
and its use can be what Weiss (110) classifies as strategic, i.e., choosing evidence that 
supports pre-established positions or ignoring evidence in favour of other policy 
influencing factors such as economic development. These findings reaffirm the view 
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that policymaking is a political exercise characterised by compromise (275). This thesis 
demonstrates that, even if the policy process in a given context is well defined, appears 
to be evidence based and is rational, it has the potential to be circumvented by the 
politics inherent in policymaking. In addition, that the policy process at the national 
level is linked to the global policy process and that weaknesses at the global level can 
significantly impact on national policy processes have also been shown.  
 
This thesis corroborates previous findings that highlight the centrality of financial 
considerations in the access to new vector control tools (128, 141, 142) and uniquely 
demonstrates how national decision-making powers are constrained by global funding 
and policy mechanisms, an interconnectedness that was underemphasized in the 
literature on malaria vector control. Furthermore, it shows that, at the national level, 
price rather than cost-effectiveness is the determining financial variable, thus affirming 
the need for interventions that facilitate price reductions, including innovative 
procurement mechanisms and global subsidies (74, 142). The potential for national 
funding for malaria control, facilitated by initiatives such as technology transfer, is 
demonstrated herein to be a powerful factor in determining access to new vector 
control tools. 
 
Finally, the present work demonstrates that a well-coordinated community of 
champions is needed to respond to the multi-faceted issue of facilitating accelerated 
access to new vector control tools in the context of insecticide resistance, thereby 
echoing political analyses and studies that highlight the importance of a group of actors 
involved in policymaking to share decision-making and exchange resources in order to 
achieve a common policy objective (75, 128).  
 
8.2 Future Research 
This research reiterates that robust evidence is key to the adoption of new vector 
control tools and poses a number of critical questions that need to be addressed. 
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i. What is the feasibility of developing and using regional level evidence to 
influence national vector control policymaking, taking into account the multiple 
malaria transmission settings? 
ii. What factors facilitate increased levels of national funding for malaria control 
interventions? 
iii. What role can regional bodies like RBM, ECOWAS and ALMA play in coordinating 
research, resource mobilisation and national policy adoption for malaria 
elimination?  
iv. What is the feasibility of long-term national vector control procurement plans in 
reducing the cost of vector control interventions?  
 
These questions will progress from the findings of this thesis by further investigating 
the economic and policy-related questions required to facilitate access to new vector 
control tools and ultimately malaria elimination.  
 
8.3 Study Limitations 
The study focused on national and global policy adoption, thereby missing the 
important perspectives of healthcare providers and beneficiaries, which may have 
added an important angle and provided particularly valuable community-level insight, 
potentially supporting elements of the decision to scale-up larviciding in Nigeria. 
However, as stated in the introductory chapter, data on community perspectives have 
been collected through other aspects of the AvecNet project.  
 
Another potential limitation is the absence of the perspective of regional policymaking 
institutions and actors who emerged as influential at the KI interview stage. However, 
the regional perspective was provided during interviews at the national and global level 
and this was supplemented with document reviews of the relevant regional bodies, 
including ECOWAS, RBM and ALMA. 
 
For the Nigeria case study, a number of potential limitations must be noted. Firstly, as 
only 14 people were interviewed, inevitably some categories of stakeholders were 
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under-represented. Secondly, the study had limited access to what Shiffman terms 
policy elites, a recognised limitation of policy analysis at this level (276). The 
researcher’s inability to gain access to representatives from ECOWAS, the office of the 
presidency, and the Minister of Health, all of whom were identified as key actors in the 
decision to scale-up larviciding but not in the desk review of normal policy actors, 
denies the study a perspective that would have been valuable and enriching. 
 
The researcher had spent time working closely with the NMCP and therefore had some 
insider status, potentially allowing for greater insight into the policy analysis (75). In this 
instance, it allowed the researcher increased access to respondents, the opportunity to 
investigate a sensitive issue, and an in-depth knowledge and understanding of the 
culture aiding in the interpretation of non-verbal cues. 
 
In Burkina Faso, participants did not identify the private sector as key to national 
decision-making. However, it may have been beneficial to have included a perspective 
from a manufacturer of a next generation LLIN as opposed to directing specific 
questions to a representative of this sector after the interviews had been completed. 
The problem of counterfeit nets in Burkina Faso, confirmed after the interviews had 
been conducted, could have limited the willingness of respondents to openly discuss 
LLIN procurement; however, some respondents alluded to this and hence these 
perspectives were captured. Finally, the main researcher’s ability to be the primary data 
collector was limited due to language barriers and the reduced access given to 
researchers considered outsiders (75). However, this limitation provided an advantage 
in the data analysis process, where an outsider status conferred objectivity in the 
interpretation of results. Mr Traore is a Burkinabe working at CNRFP and therefore has 
some level of insider status (75), allowing for additional insight into the cultural context 
and helping establish rapport with KIs during data collection. 
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8.4 Researcher Reflexivity and Positionality 
Researcher reflexivity involves “laying open pre-conceptions and becoming aware of 
situational dynamics” (277) in the research process. The section below reports (in the 
first person) on researcher pre-conceptions that may have shaped the research results. 
 
8.4.1  Nigeria 
There was a mutuality of understanding that was inherent in the interviews in Nigeria 
born by the fact that I am Nigerian and had spent a number of years working as an 
advisor within the NMCP. A quote by Johnson-Bailey (278) resonates with my 
experience of conducting the interviews in Nigeria, “There were silent understandings, 
culture-bound phrases that did not need interpretation, and non-verbalized answers 
conveyed with culture-specific hand gestures and facial expressions laced throughout 
the dialogue”. 
 
This insider status also allowed me access to KIs that may not have been as open with 
an outsider. Even in situations where an individual was approached and declined to 
formally take part in the study, they spent considerable time providing background 
information that was then followed up through independent sources. 
 
Having worked with the majority of the KIs, I had pre-conceptions of their positions and 
their bias and their technical orientation, i.e., in many instances I was aware of the 
underlining organisational dynamics that influenced a KI’s responses. In analysing the 
interviews from Nigeria, I approached the data by analysing every single line of the 
interviews, suspending judgement, i.e., not drawing any conclusions based on previous 
knowledge, but constantly asking myself ‘what is this person saying in relation to the 
research question at hand?’ A comprehensive record of methods used, triangulation of 
KI data with document review and review of findings with my supervisors were 
strategies used to mitigated bias (279). A possible limitation of my insider position, was 
the preconceptions held by the interviewees in providing responses based on 
assumptions they had in relation to my views as a result of my work history with the 
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interviewees. In order to reduce this bias information elicited was triangulated across 
interviewee categories and through document reviews. 
 
 
8.4.2  Burkina Faso 
My role as a researcher in Burkina Faso was perhaps the inverse of my role in Nigeria. I 
was in a foreign country, with limited language skills and was, for all intents and 
purposes, an outsider. For example, when one of the organisations declined to 
participate in the interviews, unlike in Nigeria where they gave off the record 
comments, in Burkina Faso I was directed to the organisation’s website for information. 
 
Mr Traore (my Burkinabe colleague), a social scientist from the AvecNet project, 
conducted the majority of the interviews in French, thereby overcoming the language 
barrier. Mr Traore is an insider to the Burkinabe system and was cognisant of cultural 
norms and protocols that facilitated the introduction of the research to KIs. However, 
he was relatively new to the malaria vector policymaking field and his role was largely 
limited to data collection. What I lacked in insider status in Burkina Faso, I gained in 
added objectivity when analysing the data captured, indexed and charted as described 
in the data analysis section. 
 
8.4.3  Global  
My position in the global study was based on a mix of being both an insider and an 
outsider. I had met most of the KIs and had a fair amount of access – aided by 
introductions from my supervisors. The common ground at the global level was not 
cultural but rather recognition by the KIs that the research question was important and 
timely. Furthermore, there was a general desire to find evidence-based solutions to the 
vector control challenges collectively faced by the global community that has invested 
heavily in fighting malaria. This made people generous with their time and open with 
their responses – as a contribution to finding solutions to the problem of access to new 
vector control tools. 
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In general, I believe that my thoughts and preconceptions have evolved over the course 
of the research, lending credence to views that argue the fluidity of a researcher’s 
positionality in relation to research (280). As a result, the preconceptions I held when I 
conducted the Nigeria study had somewhat evolved by the time I carried out the global 
study 18 months later. Initially, I leaned quite heavily toward rational model of 
policymaking, unwittingly believing in the pre-eminence of evidence-based 
policymaking. However, over the course of the research, I became more aware of the 
politics involved in policymaking and the reality that other factors, can be, whether I 
like it or not, considered more important than evidence. As Walt and Gilson put it, the 
reality of what policymaking is, as opposed to the aspiration of what it should be (75). 
 
I believe that my status in each context, as well as my intellectual evolution as a 
product of the research, lends credibility to the discussions and recommendations I 
provide in Chapter 7. This is because the synthesis and recommendations of the case 
studies provide novel and nuanced insight into five areas that can bridge the gap 
between the development of new vector control tools and their adoption into policy by 
capitalising on both the rational (evidence based) and political nature of policymaking. 
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Annex 1 WHOPES Recommended LLINs 
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Annex 2 WHOPES Recommended LLINs 
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Annex 3 WHOPES Recommended Compound for Mosquito Larvae 
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Annex 4: New Paradigms for Malaria Vector Control 
Parameter* New Paradigms for Malaria Vector Control 
       
 Insecticide-treated bednets 
against resistant vector 
populations 
Insecticide-treated 
walls against resistant 
vector populations 
Attract 
and kill 
baits 
Spatial 
repellents 
interrupting 
human-vector 
contact 
Insecticide-
treated 
materials for 
specific risk 
groups 
Vector traps for 
disease 
management  
Lethal house 
lures 
Generic 
exemplars 
LLINs controlling IR 
populations for defined IR 
mechanism 
IRS/ wall hanging 
controlling IR 
populations for 
defined IR mechanism 
Attractive 
toxic sugar 
bait 
Passive 
emanator 
Insecticide –
treated material 
Traps with lures Eave tubes 
Prototype PermaNet® 3.0, Interceptor® 
G2 
To date, no valid 
prototype with an 
explicit claim for IR 
populations has been 
reviewed 
Bait 
station 
Metofluthrin or 
transfluthrin 
emanators 
Blanket clothes ALOT IN2TRAP Eave tubes 
Indoor 
against 
adult 
mosquitoes 
 
√ 
 
√ 
√ √ √ √ √ 
Outdoors 
against 
adult 
mosquitoes 
CP and PP CP √ √ √ √ √ 
Outdoors 
against 
immature 
mosquito 
stages 
WHOPES for long lasting 
effect 
VCAG for IR claims 
WHOPES for long 
lasting effect 
VCAG for IR claims 
   √  
CLAIM: 
personal 
protection  
PP and/or CP; see notes 1 
and 2 below 
CP NO YES YES for specific 
risk groups 
NO NO 
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CLAIM: 
community 
protection 
Review and assessment of 
public health value 
TBD YES YES NO YES YES 
WHOPES/V
CAG 
  VCAG VCAG VCAG VCAG VCAG 
VCAG 
epidemiolo
gical end-
point 
-personal 
protection 
(PP) 
-community 
protection  
  CP PP & CP PP CP CP 
Progress of 
paradigm 
(VCAG step) 
  Initial 
interaction 
on data 
needs. 
Review and 
assessment of 
public health 
value 
Early 
notification of 
intervention 
concepts 
Review and 
assessment of 
public health 
value 
Initial 
interaction on 
data needs. 
*CP, community protection; IR, insecticide-resistant; IRS, indoor residual spraying; LLIN, long-lasting insecticide-treated net; PP, personal 
protection; TBD, to be determined; VCAG, Vector Control Advisory Group; WHOPES, WHO Pesticide Evaluation Scheme 
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Annex 5 – Search Strategy 
A: Policy analysis Search Strategy 
Databases Underlying 
Questions  
First review – 
March-November 
2012 
Second review 
August - 
October 2015 
Inclusions 
PubMed-
Medline  
Google 
Scholar 
Google 
Organisational 
Websites 
 
What is health 
policy? 
How is health 
policy made? 
What factors 
influence its 
development 
and adoption? 
What is the role 
of evidence in 
policymaking 
What facilitates 
the use of 
evidence in 
policymaking? 
What are the 
barriers to the 
use of evidence 
in policymaking? 
 
Policy 
Policymaking 
Policy Analysis 
Policy 
Development 
Policy process 
Health Policy 
Health 
Policymaking 
Health policy 
analysis 
Health policy 
development 
Health policy 
process 
Decision-making 
Evidence-based 
policy 
Barriers Evidence 
and policy 
Policy framework 
Policymaking 
theories 
Evidence and the 
policy process 
Evidence-based 
health policy 
Evidence-informed 
health policy 
 
 
Policy 
Policymaking 
Policy Analysis 
Policy 
Development 
Policy process 
Health Policy 
Health 
Policymaking 
Health policy 
analysis 
Health policy 
development 
Health policy 
process 
Decision-making 
Evidence-based 
policy 
Barriers 
Evidence and 
policy 
Policy 
framework 
Policymaking 
theories 
Evidence and 
the policy 
process 
 
Titles and abstract 
were read all 
articles related to:  
 
Published in 
English  
Full article 
accessible  
Health policy 
focus  
Policy processes  
Policy change  
Factors 
influencing policy 
processes  
Frameworks and 
theories on 
policymaking 
Studies in 
developed and 
developing 
countries 
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Annex 5B: Nigeria Search Strategy 
Database
s 
Underlying 
Questions 
First review – February 
2013 
Second review April 2016 Inclusions 
Pubmed-
Medline  
Google 
Scholar 
  
What is the 
national 
policymakin
g context in 
Nigeria? 
 
What is 
malaria 
vector 
control 
policy in 
Nigeria? 
 
Who are the 
key malaria 
vector 
control 
policy actors 
in Nigeria? 
 
Search Terms – using a 
combination of AND/OR 
1. Malaria  
2. Malaria Control  
3. Malaria 
Prevention 
4. Vector Control  
5. Integrated 
Vector 
Management 
6. Insecticide 
Resistance 
7. 1 or 2 or 3 or 4 
or 5 or 6 
8. Policy 
9. Policymaking 
10. Policy analysis 
11. Policy 
development 
12. Policy process 
13. Decision-making 
14. 8 or 9 or 10 or 11 
or 12 or 13 
15. Evidence-based 
health policy 
16. Evidence-based 
health policy –
Nigeria 
17. 15 or 16 
18. Evidence-
informed health 
policy 
19. Evidence-
informed health 
policy- Nigeria  
20. 18 or 19 
21. Access to vector 
control tools  
22. 21 AND 14 
23. Larviciding  
24. Malaria Control 
in Nigeria 
25. Vector control in 
Nigeria 
26. Policymaking in 
Nigeria 
27. 7 AND 14 
28. 7 AND 17 
29. 7 AND 21 
 
Search Terms – using a 
combination of AND/OR 
 
1. ECOWAS Malaria 
Elimination 
2. Larviciding 
3. Onchocerciasis 
elimination 
4. 1 and 2 
 
 
 
Titles and 
abstract were 
read and articles 
were included 
that were 
published 
between 1990-
2016 and related 
to:  
 
Published 
between 1990-
2016  
Published in 
English  
Full article 
accessible  
Policy adoption 
of malaria vector 
control tools 
Policy adoption 
and/or 
recommendatio
n of malaria 
control tools 
(drugs, 
diagnostics and 
vaccines) 
Policy adoption 
of vaccines (not 
restricted to 
malaria) 
Availability of 
new vector 
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control tools 
The 
development of 
new malaria 
vector control 
tools 
The 
procurement of 
new malaria 
vector control 
tools 
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Annex 5 C: Burkina Faso Search Strategy 
 
Databases Underlying 
Questions 
First review - March 2014 Second review March 
2015 
Inclusions 
PubMed-
Medline  
Google 
Scholar 
Web of 
Science 
Global 
Health  
Jstor,  
Taylor & 
Francis  
What is the 
national 
policymaking 
context in 
Burkina 
Faso? 
 
What is 
malaria 
vector 
control 
policy in 
Burkina 
Faso? 
 
Who are the 
key malaria 
vector 
control 
policy actors 
in Burkina 
Faso 
Search Terms – using a 
combination of AND/OR 
1. Malaria  
2. Malaria Control  
3. Malaria Prevention 
4. Vector Control  
5. Integrated Vector 
Management 
6. 1 or 2 or 3 or 4 or 5 
7. Insecticide 
Resistance 
8. 6 AND 7 
9. Policymaking 
10. Policy Analysis 
11. Policy 
Development 
12. Policy process 
13. 9 or 10 or 11 or 12  
14. Decision-making 
15. Evidence-based 
health policy 
16. Evidence-based 
health policy –
Burkina Faso 
17. Evidence-informed 
health policy 
18. Evidence-informed 
health policy- 
Burkina Faso 
19. Burkina Faso 
20. 14 or 15 or 16 or 
17 or 18 
21. 6 AND 19 
22. Access to vector 
control tools  
23. 19 AND 22 AND 6 
24. PBO LLINs 
25. PermaNet® 3.0 
26. Malaria Control in 
Burkina Faso 
27. 26 AND 13  
28. Vector control in 
Burkina Faso 
29. 28 AND 13 
Search Terms – using a 
combination of AND/OR 
 
1. PBO LLINs 
2. PermaNet® 3.0 
3. 1 or 2 
4. Actellic® 3CS 
5. VCAG 
Recommendati
ons 
6. 3 AND 5 
7. WHO 
Recommendati
on PBO LLINs 
8. 3 AND 7 
9. Innovation to 
Impact 
10. Artemisinin 
Resistance 
11. ACT 
policy/introduc
tion 
 
 
 
Titles and 
abstract were 
read and articles 
were included 
that were 
published 
between 1990-
2016 and related 
to:  
 
Published 
between 1990-
2016  
Full article 
accessible  
Policy adoption 
of malaria vector 
control tools 
Policy adoption 
and/or 
recommendation 
of malaria 
control tools 
(drugs, 
diagnostics and 
vaccines) 
Policy adoption 
of vaccines (not 
restricted to 
malaria) 
Availability of 
new vector 
control tools 
The development 
of new malaria 
vector control 
tools 
The procurement 
of new malaria 
vector control 
tools 
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Annex 5D: Global Search Strategy  
Databases Underlying 
Questions 
First review - March 
2014 
Second review May 
2015 
Inclusions 
Pubmed-
Medline  
Google 
Scholar 
Google 
Organisation
al Websites 
 
What is the 
global 
policymakin
g context? 
 
What are 
the global 
malaria 
vector 
control 
policies? 
 
Who are 
the key 
malaria 
vector 
control 
policy 
actors at 
the global 
level? 
Search Terms – using a 
combination of 
AND/OR 
 
1. Malaria  
2. Malaria 
Control  
3. Malaria 
Prevention 
4. Vector Control  
5. 1 or 2 or 3 or 4 
6. Bednets 
7. Long-lasting 
insecticidal 
nets LLINs 
8. Insecticide-
treated nets 
9. 6 or 7 or 8 
10. Integrated 
vector 
management 
11. Insecticide 
resistance 
12. Policy 
13. Policymaking 
14. Policy analysis 
15. Policy 
Development 
16. Policy process 
17. 12 or 13 or 14 
or 15 or 16 
18. Decision-
making 
19. Evidence-
based health 
policy 
20. Evidence-
informed 
health policy 
21. 18 or 19 or 20 
22. Access to 
vector control 
tools  
23. PBO LLINs 
24. PermaNet® 3.0 
Search Terms – using 
a combination of 
AND/OR 
 
1. PBO LLINs 
2. PermaNet® 
3.0 
3. 1 or 2 
4. Actellic® 3CS 
5. VCAG 
Recommend
ations 
6. WHO 
Recommend
ation PBO 
LLINs 
7. Innovation to 
Impact 
8. Artemisinin 
Resistance 
9. ACTs 
policy/introd
uction 
 
 
 
Titles and 
abstract were 
read and 
articles were 
included  
 
Published 
between 1990-
2016  
Published in 
English  
Full article 
accessible  
Policy adoption 
of malaria 
vector control 
tools 
Policy adoption 
and/or 
recommendati
on of malaria 
control tools 
(drugs, 
diagnostics and 
vaccines) 
Policy adoption 
of vaccines (not 
restricted to 
malaria) 
Availability of 
new vector 
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25. 5 AND 9 
26. 17 AND 9 AND 
5 
27. 21 AND 5 
28. 22 AND 17 
 
control tools 
The 
development of 
new malaria 
vector control 
tools 
The 
procurement of 
new malaria 
vector control 
tools 
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Annex 6: Sample – Framework for Organisation Identification 
Framework 
Theme 
Definition  Rationale  Organisations 
identified through 
document review 
Availability  Involves the logistics of 
making, ordering, 
shipping, storing, 
distributing, and 
delivering 
a new health 
technology to ensure it 
reaches the hands (or 
mouth) of the end-user. 
Availability and those organisations who are 
central to determining the availability of vector 
control tools are a set of critical set of 
stakeholders who form part of the network of 
organisations who facilitate access. These 
include, researchers that contribute to the 
product development and testing process, 
manufacturers and public private partnerships 
that facilitate the availability of new vector 
control tools.  
Vesteergaard, 
Sumitomo, 
Innovative Vector 
Control Consortium 
(IVCC),  
Insecticide Resistance 
Action Committee,  
Researchers with 
vector control and 
insecticide resistance 
expertise  
Affordability  Affordability depends 
on the technology’s 
price, cost of services 
(such as user fees) 
related to accessing the 
technology, and 
the availability of funds 
for purchasing (which 
depends on the 
purchaser’s available 
resources and 
perceptions of expected 
benefits and costs, 
including side effects, 
and other factors such 
as social acceptance).  
Given that vector control tools are primarily 
funded by international donors and to a lesser 
extent national governments. The concept of 
affordability in this study will focus on resources 
and perceptions of expected benefits and costs 
of international donors. For example according 
to the World Malaria report 2013 the Global 
Fund to fight AIDS, Tuberculosis and malaria 
funds 40% of malaria control globally. Other 
major funders include DfID, PMI/USAID, World 
Bank CIDA, AUSAID, etc. UNICEF is also cited as 
a major procurer of LLINs.  
Global Fund,  
DfID,  
PMI/USAID,  
UNICEF 
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Adoption Involves gaining 
acceptance and creating 
demand for IRMS by 
global organizations, 
government actors 
The WHO – Global Malaria Programme (GMP) is 
being responsible for setting, communicating 
and promoting the adoption of evidence based 
norms, standards, policies, and guidelines. To 
fulfil this policymaking function WHO GMP 
relies on structures such as the Malaria Policy 
Advisory Committee (MPAC), Vector Control 
Advisory Group (VCAG), the Vector control 
Technical Expert Group (VCTEG) and the WHO 
Pesticide Evaluation Scheme (WHOPES) whose 
key mandate is to ‘collect, consolidate, evaluate 
and disseminate information on the use of 
pesticides for public health. In prominent 
umbrella group is the African Leaders Malaria 
Alliance (ALMA) which was set up by African 
Heads of State to utilize their individual and 
collective power across country and regional 
borders. One of the mandates of the 
organisation is the Provide a forum for high-
level, collective advocacy to ensure an timely 
global procurement system with an emphasis 
on funding manufacturing and distribution; and 
provide a forum to share best practices and to 
review progress and address challenges in 
meeting the malaria targets. The perspective of 
stakeholders within this organisation will be 
pertinent in understanding some of the factors 
that contribute to national governments 
adoption of new vector control tools. 
WHO-GMP.  
MPAC,  
VCAG,  
VCTEG,  
WHOPES,  
ALMA 
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Annex 6B: Sample – Framework for Key Informant Identification 
Potential 
perspectives 
Name KII 
NAME 
Institution Area Expertise Thesis 
perspective 
Adoption/Researcher Left blank to 
preserve 
anonymity 
Left blank to 
preserve 
anonymity 
Vector Control 
Insecticide 
resistance 
Researcher 
Donor Left blank to 
preserve 
anonymity 
Left blank to 
preserve 
anonymity 
Vector control Donor 
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Annex 7: Glossary of Research Terms 
SN Term Definition  
1 Access For the purposes of this study - the ability to consistently obtain and appropriately 
deploy/ use good quality vector control tools when and where they are needed 
2 Adoption Involves gaining acceptance and creating demand for Insecticide resistance 
management strategies (IRMS). These constitute global organizations and national 
government actors. While providers/ dispensers, and individual patients are a 
crucial stakeholder group to consider in the adoption of a new tool, this study is 
restricting its scope to adoption (policy endorsement and demand for tools) by 
global organisations and national governments 
3 Affordability Affordability depends on the technology’s 
price, cost of services (such as user fees) related to accessing the technology, and 
the availability of funds for purchasing (which depends on the purchaser’s available 
resources and perceptions of expected benefits and costs, including side effects, 
and other factors such as social acceptance). Given that vector control tools are 
primarily funded by international donors and to a lesser extent national 
governments. The concept of affordability in this study will focus on resources and 
perceptions of expected benefits and costs of international donors 
4 Architecture The organizational structure and relationships that coordinates availability, 
affordability, and adoption activities, i.e., the network of stakeholders involved in 
ensuring the availability, affordability and adoption of IRMS 
5 Availability Involves the logistics of making, ordering, shipping, storing, distributing, and 
delivering new/novel vector control tools 
6 Combination 
LLIN 
Long lasting insecticidal nets that use a combination of two insecticides (for the 
purposes of this study these do not include LLINs that utilize an insecticide and a 
synergist) 
7 Funders Actors involved in the financing vector control, e.g., GFATM, DfID, USAID 
8 Implementers Actors involved in the deployment of vector control tools, e.g., Malaria consortium 
9 Insecticide 
resistance 
monitoring 
programmes 
(IRMP) 
National insecticide resistance monitoring programmes that seek to collect routine 
data to inform decisions on the resistance management strategies 
10 Insecticide 
resistance 
management 
strategies 
(IRMS) 
The deployment of a set of strategies (vector control tools and complementary 
practices such as IRMPs) to tackle insecticide resistance 
 Insecticide 
resistance 
management? 
tools (IRMT) 
Vector control tools deployed in order to/in a manner that addresses insecticide 
resistance, e.g., the rotation of insecticides in Insecticide spraying programmes 
11 LLIN LLINs with a single insecticide 
12 Policymakers Actors/bodies involved in the making Vector, e.g., WHO, MPAC control policy 
13 Private sector Commercial for profit organisations/ groups of involved in the development and 
manufacture of vector control tools, e.g., Sumitomo, vestergaard. Product 
development partnerships such as IVCC whose mandate is to accelerate the 
development and delivery of new vector control products and tools will also be 
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considered as providing perspectives on private sector issues 
14 Researcher Actors involved in carrying out scientific research on Vector control, e.g., academics, 
research organisations 
15 Translation The ‘translation’ of a new/novel tool is said to be achieved once a product 
demonstrates both efficacy in the research environment as well as demonstrated 
sustainable effectiveness in implementation settings, i.e., turning early-stage 
innovations into new deliverable health products 
Components of the translation pathway include basic science, intervention concept, 
target product profile, proof of concept, product development and implementation 
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Annex 8: Semi-structured interview guide – Burkina Faso 
Framework Themesa SSI questions in English SSI questions in French  
National architecture for coordinating 
access to combination LLINs (Themes: 
actors, power and processes) 
National architecture for coordinating access to 
combination LLINs  
  
Actors Who are the key actors involved in coordinating access to 
insecticide resistance management tools like combination 
LLINs? (Prompt: key policymakers, financers, 
manufacturers) 
Qui sont les principaux acteurs impliqués dans la coordination de 
l'accès aux outils de gestion de la résistance aux insecticides comme 
combinaison MILDA (: les principaux décideurs, les financiers, les 
fabricants) 
Power  Which player / players would you say carries the most 
influence? Why? 
Quel joueur/joueurs diriez-vous porte le plus d'influence? Pourquoi? 
Process Please describe the process of making policies in vector 
control 
S'il vous plaît décrire le processus de rendre les politiques dans la 
lutte antivectorielle 
National availability of combination LLINs 
(Theme Availability) 
National availability of combination LLINs    
   Please describe the factors that led to the 
adoption/distribution of PermaNet® 3) 
Prompts for factors: Solution to a perceived problem, 
availability of funding, evidence (local/international) of 
efficacy), political will from superior officers. 
S'il vous plaît décrire les facteurs qui ont conduit à l'adoption / 
distribution de PermaNet 3 
Aller facteurs: Solution à un problème perçu, la disponibilité du 
financement, la preuve (local / international) de l'efficacité), la 
volonté politique des officiers supérieurs. 
  What would you describe as barriers to the availability of 
IRMT like combination LLINs? 
Que feriez-vous décrire comme des obstacles à la disponibilité de la 
combinaison de MILDA 
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a Information on the 7th framework theme (context) is gathered from desk review 
  What/if any opportunities exist for overcoming the barriers 
you described? 
Qu'est / si des possibilités existent pour surmonter les obstacles que 
vous avez décrits? 
National affordability of combination LLINs 
(Themes: Affordability)  
National affordability of combination LLINs    
  What factors in your view positively influenced the 
affordability of PermaNet® 3.0 
Quels sont les facteurs dans votre vue influence positive sur 
l'abordabilité des Permanet 3.0 
  What would you describe as barriers to the affordability of 
LLINs that seek to tackle resistance (prompts: 
budget/finance constraints, competing demands/priorities, 
perceived value compared to alternative 
products/interventions)  
Que feriez-vous décrire comme des obstacles à l'accessibilité des 
moustiquaires imprégnées qui cherchent à lutter contre la 
résistance (invites: contraintes de budget / finances, des demandes 
concurrentes / priorités, la valeur perçue par rapport aux produits / 
interventions alternatives) 
  What/if any opportunities existing for overcoming the 
barriers you described? 
  
National adoption of Combination LLINs 
(Theme: Adoption) 
National adoption of combination LLINs    
  What would you describe as barriers to the adoption of 
LLINs that seek to tackle resistance 
Que feriez-vous décrire comme des obstacles à l'adoption de MILDA 
qui cherchent à attaquer la résistance 
  What/if any opportunities existing for overcoming the 
barriers you described? 
Qu'est / si des opportunités existantes pour surmonter les obstacles 
que vous avez décrits? 
  Could you prioritize the top 3 issues which in your view 
need to be addressed in order to accelerate access to IRMT 
like combination LLINs at the national level 
Pourriez-vous prioriser le top 3 des questions qui, à votre avis, 
doivent être abordés afin d'accélérer l'accès de combinaison de 
MILDA au niveau national 
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Annex 9: Stakeholder Interview Guide Nigeria 
 
Name: 
Gender: 
Position: 
Type of institution you work for? 
Tell me a bit about your background and the work you do in malaria control 
What is your role in policymaking processes in malaria vector control? 
 
Vector Control Policymaking in General 
 
Can you describe to me the process by which national vector control policies are meant 
to be developed and agreed?  
Can you describe to me how you are engaged in the policymaking process? 
Do you see any barriers to things being taken up as policy?  
Which institutions/individuals play the biggest role and, in general who carries the most 
weight in influencing the decision making process? 
 
Thinking now about the role of evidence in the policymaking process….. 
 
The Role of Evidence in the Process 
In what ways, if any, do you use the outputs of research to engage in the policy 
process? 
What kind of evidence do you find useful or most likely to influence policy? 
Aside from these sources of evidence, what other factors do you think come into play in 
decision about a new policy (e.g., donations from foreign governments, lobbying from 
interest groups (e.g., farmers), concerns about community 
acceptability/implementability etc.). How? 
If you think there is an important research finding that needs to get into policy, what 
institution would you speak to? 
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 What individuals/institutions ask you for information when they need to make 
decisions? 
 
 
Thinking now about a recent change in policy relating to a malaria vector control tool …. 
 
Recent Malaria Vector Control Policy Change 
Can we use the example of larviciding to discuss why policy changes?  
In your view, which of these factors played the most important role in  
(i) prompting the policy change discussion and  
Did the evidence for scientific research play and role and, if so, then in what way? 
Which institutions/individuals were instrumental/influential in the policy change 
process larviciding,? 
Overall which three factors do you think have the greatest influence on decisions to 
change policy and adopt a new intervention strategy? 
 
Thank you for your time and do you have any questions to ask me?  
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Annex 10: Stakeholder Interview Guide: Global  
 
Name: 
Gender: 
Position: 
Inter start time:   Interview end time: 
Type of institution you work for? 
 
Global Architecture for Coordinating Access to Insecticide Resistance Management 
Tools (IRMT) like Next Generation LLINs  
 
Who are the key actors involved in coordinating access to insecticide resistance 
management tools like combination LLINs? (Prompt: key policymakers, financers, 
manufacturers) 
Which player / players would you say carries the most influence? Why? 
What would be the process for obtaining policy adoption to a new insecticide resistance 
management tool like combination LLINs?  
 
Global Availability of IRMTs like PBO LLINs 
 What factors in your view positively influence the availability of IRMT like combination 
LLINs? (prompts: Product development pipeline, manufacturing, forecasting, 
procurement, distribution, delivery) 
What would you describe as barriers to the availability of IRMT like combination LLINs? 
What/if any opportunities exist for overcoming the barriers you described? 
 
Global Affordability of IRMTs like PBO LLINs 
What factors in your view positively influence the global affordability of IRMT like 
combination LLINs? 
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What would you describe as barriers to the global affordability of IRMT like 
combination LLINs? (prompts: budget/finance constraints, competing 
demands/priorities, perceived value compared to alternative products/interventions)  
What/if any opportunities existing for overcoming the barriers you described? 
 
Global Adoption of IRMTs like PBO LLINs 
What factors in your view positively influence the global adoption (policy endorsement 
and generating demand for the tools) of IRMT like combination LLINs? (prompts: what 
kind of evidence base, standards, policies, guidelines) 
What would you describe as barriers to the global adoption of IRMT like combination 
LLINs? 
What/if any opportunities existing for overcoming the barriers you described? 
Could you prioritize the top 3 issues which in your view need to be addressed in order 
to accelerate access to IRMT like combination LLINs at the global level? 
 
Insecticide Resistance Management Programmes 
What factors are likely to facilitate increased availability of IRMP at national level? 
(prompts: Capacity and scientific know-how, infrastructure) 
What factors do you think positively influence the affordability of IRMPs? (prompts: 
budget/finance constraints, competing demands/priorities, perceived value compared 
to alternative products/interventions, perceived threat) 
What in your view are the top 3 barriers to the implementation of national IRMPs? 
What opportunities exist at the global level, in your view, for increasing access to 
national IRMPs?
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Annex 11: Sample Coding Matrix- Data Analysis 
Coding 
Reference  2 
2.1 2.2 2.3 
  Availability of PBO 
LLINs 
Positive influencers Barriers to availability Opportunities for acceleration 
  001 Reference 1 - 0.90% Coverage 
 
Okay, so I think the availability will be 
very much influenced by the 
manufacturers and they can be quite 
aggressive in marketing their nets and 
especially where there are known 
pockets of high resistance. I’ve heard of 
cases where the manufacturers will in 
and really persuade people that this is 
the only solution and go in and 
manufacture it that way. So, the 
manufacturers can positively influence, 
(well I don’t know if this is positive), but 
they can influence availability by making 
them available,  
 
Reference 2 - 0.95% Coverage 
 
And again availability will be affected by 
how much, what the pricing mechanism 
is; if you’ve got fixed budgets, does that 
mean lower coverage targets, so, those 
sorts of decision should be taken by 
donors but presumably in the case of 
Global fund, the countries will have to be 
making those recommendations as part 
of their Global fund application that they 
Reference 1 - 0.72% Coverage 
 
but then also there may be issues in the 
other direction in that they are not 
manufacturing these at scale at the moment 
because there is no agreed process on which 
they are adopted. So if all of a sudden 
countries did want to or funders did decide 
to adopt this on a large scale, would they be 
available? So, I think the manufacturing side 
is a big challenge there; supply and demand. 
And again availability 
 
Reference 2 - 0.17% Coverage 
 
So I can start with the manufacturer’s side, 
they’ve got to see that there is a demand for 
these, 
 
Reference 3 - 0.15% Coverage 
 
they’ve got to see that there are processes 
in place for global level endorsement. 
 
Reference 4 - 0.80% Coverage 
 
And they also have to have some sort of 
protection for their innovation; which seems 
Reference 1 - 0.80% Coverage 
 
And, I mean if we are thinking about this as a 
long term solution, we need much more 
innovation because the two nets that actually 
you can go off and order now are both nets that 
have pyrethroids and a synergist in. And they 
work okay, but even the manufacturers would 
acknowledge that these are sort of stop gap, so 
we need more new nets coming forward so the 
people trying to accelerate the development of 
the market, and I think its gained momentum; 
 
Reference 2 - 0.68% Coverage 
 
I received before and I think this is something 
where they could play a major role is helping 
with overcoming these issues of protecting 
intellectual property and all these sorts of 
things may be barriers to getting new nets. But I 
think actually perhaps a bigger barrier is we’ve 
spent years now trying to convince countries 
and it’s deep in to documents to put a 
combination of these; 
 
Reference 3 - 1.01% Coverage 
 
it’s really important to monitor for resistance. 
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want to put these nets in these areas. So, 
the countries will also influence (I’m not 
sure they’ll influence the availability), but 
they will influence the demand for these. 
 
 
to be a major issue that’s coming up now 
that what if they develop these nets, 
especially for something quite innovative, 
spend millions developing and then 
marketing them, and then the generic 
comes along and has the same idea and 
then they’ve lost all their market; I have no 
idea how you tackle that, but that is 
something that’s been raised by the industry 
partners 
 
 
We tell everybody to monitor resistance using a 
very standard methodology and then we offer 
no interpretation of what the results of that 
mean in terms of what strategy you should 
adopt. So I think where we could really 
accelerate things now is by saying okay if we 
accept that these nets are going to be 
developed and are going to be evaluated, there 
will be evidence that they work better against 
resistant mosquitoes, let’s work with the 
countries for them to be able to map out where 
they’ve got problems with resistance 
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Annex 12: Nigeria Ethic Approval 
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Annex 13: Ethics Approval Burkina Faso  
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Annex 14: Ethics Approval Burkina Faso  
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Annex 15: Ethics Approval Liverpool School of Tropical Medicine for Nigeria and 
Burkina Faso Case Studies 
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Annex 15B: Ethics Approval Liverpool School of Tropical Medicine for Global Case 
Study 
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Annex 16: Participant Information Sheet for all Case Studies  
Adoption and support for combination long lasting insecticidal net: Process, barriers and 
opportunities for accelerated access 
 
Information Sheet for In-depth interviews (APPENDIX 2) 
 
Institution  Individuals  
Liverpool School of Tropical Medicine 
Pembroke Place, Liverpool 
L3 5QA  
Ms Kemi Tesfazghi  
o.tesfazghi@liv.ac.uk  
+44 785 2175 820 
 
 
What is this research about? 
My PhD project is part of an EU funded project AvecNet and seeks to accelerate the availability of 
new Insecticide Resistance Management Strategies (IRMS). This qualitative study forms part of my 
PhD and aims to contribute to accelerated access to IRMS (which comprises of Insecticide Resistance 
Management Tools (IRMT) and Insecticide Resistance Management Programmes (IRMPs)) by 
understanding the process for the global policy adoption of IRMTs such as combination Long lasting 
insecticidal nets (CLLINs) and IRMPs, the potential barriers in the identified process and 
opportunities to accelerate access. This will be achieved by obtaining KI’s perspectives on five areas: 
global organizations and structures important for ensuring access to new IRMS; availability, 
affordability and adoption6 as well as opportunities and threats to accelerated access. 
 
How will the information be collected? 
Documents have been reviewed to identify institutions involved in ensuring the availability, 
affordability and adoption of IRMS, elicit policymaking processes and structures, as well as to 
identify key stakeholders. In addition to the document reviews, key informant interviews will be 
carried out with global level stakeholders involved in malaria vector control policy making, research, 
financing and implementation.  
 
Why do you want to talk to us and what does it involve? 
I would like to talk to you in order to gain your perspective on the global adoption of IRMS, the 
process, barriers and opportunities for accelerated access. 
                                                 
6 Adoption encompasses policy adoption and generating global demand 
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What will you be talking to us about? 
I would like to talk to you about the process of adopting new IRMS: the key stakeholders involved 
and factors that influence issues like their availability and affordability. I would also like to talk to 
you about potential opportunities to accelerate access to these new tools.  
If you would like to see a copy of the topic guide in advance of the interview please feel free to 
contact Ms Tesfazghi on the address provided above. 
 
Are there any advantages or disadvantages to me of taking part?  
The interview should take a maximum of 90 minutes, however you can halt the process at any point 
in time. There are no individual benefits to taking part, but in answering our questions you will help 
us improve our understanding accelerating the access to life saving IRMS. 
 
Who will have access to the information I give? 
We will not share individual information about you with anyone beyond myself and the study team 
at LSTM, who are closely concerned with the research. Information shared with funders will be 
anonymized. All of our documents/recordings are stored securely in locked cabinets and on 
password protected computers. Tapes will be destroyed as soon as they have been transcribed 
(usually within two weeks) and the transcripts will contain no information that will allow for the 
identification of individual participants.   
 
The knowledge gained from this research will be shared in summary form, without revealing 
individuals’ identities. With your agreement, anonymous quotes may be used to illustrate general 
points, but if they are used they will not contain any information that will allow identification of 
individuals. 
 
What will happen if I refuse to participate?  
All participation in research is voluntary. You are free to decide if you want to take part or not. If you 
do agree you can change your mind at any time without any consequences.  
 
What if I have any questions? 
You are free to ask me any question about this research. If you have any further information or 
points for clarification regarding the interview at a later date or if you have any further questions 
about the study, you are free to contact the research team using the contacts provided above.  
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Annex 17: Interview Consent Form for all Case Studies: Accelerating Access to New 
Vector Control Tools: Policy Analysis  
 
Study title: Global adoption and support for combination Long lasting insecticidal nets: Process, barriers 
and opportunities for accelerated access 
 
CONFIDENTIAL 
 
Participant Identification Number for this Study: 
 
 
The purpose of this form is to allow the use of your interview for research purposes. Please sign below if 
you have read the information sheet and agree to take part in this research study. 
 
I have been read the information sheet dated __________ that explains the reasons for this study [or 
have understood the verbal explanation] and I understand what will be required of me and what will 
happen to me if I take part in it. 
 
All the questions I had about this study have been answered.    
 
I understand that at any time I may withdraw from this study without giving a reason. 
 
I hereby declare that I have not been subjected to any form of coercion in giving this consent.  
 
I am aware that all the information that I give will be kept confidential, and will only be seen by the study 
investigators.               
 
I agree to quotes arising from my participation in the study being included anonymously the study report.
  Yes/No 
 
If yes:  
I would like to see and approve the use of any such quote before submission of the report to (name of 
host organization) or any other third party.   Yes/No 
 
I do not need to see and approve the use of any such quote before submission of the report to (name of 
host organization) or any other third party.   Yes/No 
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I agree to take part in this study         Yes/No 
 
 
Signing this declaration does not affect your right to decline to take part in any future study. 
I permit the interview to be tape-recorded     
 
 
                 
Name of participant    Date   Signature 
 
                
Name of person taking     Date   Signature 
Consent  
When complete: 1 copy for participant; 1 copy (original) for research file. 
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Annex 18: Chapter 6 Global Analysis Supplementary Quotes 
 Analytical 
Framework  
Subtheme Theme Additional illustrative quote 
1 Global Adoption 
Process 
Data on failure of 
current tools  
 
 
‘I think everyone understands that resistance has 
become more of a challenge but as of yet there is 
really not a lot of documented data on the 
[operational] impact of resistance.’ (Funder) 
 
 ‘The main limitation is of course the national 
capacity to do this [insecticide resistance 
monitoring]. The resources I think are available in 
almost every country through PMI, through Global 
fund … So, the question is do they have the human 
capacity and lab capacity to look up all these 
things…The question is not resources, it’s (1) to see 
the importance of it, (2) to have the resources, 
human and technical resources to do it.’ (Researcher) 
 
2 Global Adoption 
Process 
Evidence of 
effectiveness of new 
tool 
That if you see a significant difference in disease 
impact with the combination LLIN in comparison with 
the pyrethroid, that’s the thing that will motivate 
people and drive people in that direction (Private 
sector TM) 
 
3 Global Adoption 
Process 
Lengthy and unclear 
global policy 
adoption process 
 
‘…because there is not one final approval agency like 
there is for drugs. In drugs, when you develop a drug 
it’s very clear who in the end is going to make a final 
decision. And by and large only that agency is 
relevant for the decision you want to make. In vector 
control, there are at least three different players, you 
have the national approval agencies, there’s 
WHOPES and there’s VCAG. And how they interact, 
what the prerogatives are etc is absolutely not 
defined and that’s part of the problem.’ (Researcher) 
 
4 Global Adoption 
Process 
Developing an 
effective tool  
 
‘I think it depends on which, generation of the 
combinations LLINs cause there are going to be 
several different generations. I think my current view, 
.…. is that the LLINs that are on the immediate 
horizon that are likely to be approved in the next 3 or 
4 years as combination LLINs are not ideal and I 
would use them as effectively emergency response; if 
you have some problem with the pyrethroid LLINs in 
a particular place.’ (Researcher) 
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6 Availability Forecasting the size 
of the market 
‘ So, there isn’t a clear market today, you can’t point 
to a clear market today and say 30% of the bed net 
market is combinations nets and it’s going to grow to 
50% in five years, there’s just no data that would 
support anything like that. And it would be very 
interesting to understand of the two PBO nets, … just 
how much market share they were taking. I suspect 
it’s really not very much. So there isn’t an established 
market that we can point the manufacturers to and 
say ‘there it is, that’s what you ought to go after’, 
there are still some really substantial policy and 
regulatory risks attached to these manufacturers, so 
they’re trying to work out what the right way to 
approach it is.’ (Private sector ) 
7 Availability The ability to predict 
market share 
‘I think nowadays you can at the same time while 
looking at the product obviously a shift in the way 
people are thinking about distributions, away from 
just campaigns to continuous distributions and 
potentially with campaigns at such a time when the 
campaigns are needed so that would perhaps or 
could be an enabler for increasing access because if 
It meant that the demand was steady all over the 
year, rather than intermittent very large 
requirements then that would help to make it 
available.’ (Policy advisor)  
8 Availability Affordability of PBO 
LLINs  
‘I think, is the predictability of a market for the 
manufacturer, otherwise the manufacturer would be 
reluctant to invest into a new product and we’ve 
seen that ...I think already. And so knowing about the 
demand for....or potential demand for a specific 
product from the key donors, I think is going to be a 
huge catalytic factor in this process.’ (Donor) 
9 Availability Fostering innovation  ‘The other piece I think is definitely the intellectual 
property protection for some of this new nets, I’ve 
heard that some of the manufacturers are not going 
to be submitting products until the intellectual 
property issues that WHOPES has, are sorted … 
unless that gets sorted out that also touches our 
getting new products into the market place.’ (Donor)  
10 Availability Ability to meet 
global demand 
 
If all of a sudden countries did want to or funders did 
decide to adopt this [next generation LLINs] on a 
large scale, would they be available? So, I think the 
manufacturing side is a big challenge there. 
(Researcher) 
11 Availability WHO 
recommendation  
 
‘I mean if I was a manufacturer, which obviously I’m 
not, I wouldn’t scale up significantly of course until 
I’ve got my WHOPES approval and the WHO policy 
position in place.’ (Policy advisor ) 
12 Availability Clarity on the 
process and the 
‘I think there needs to be a clear process for 
evaluating the products. A clear understanding of 
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evidence base 
required to convince 
policymakers 
 
how you measure if one of these products is better 
than a current standard LLIN and then be able to 
communicate with people who are procuring this net 
that this is better than a normal net by some 
standardized level and therefore it is worth paying an 
extra however much the net is going to be. 
Otherwise, it will just look like a more expensive net 
to people who are going to procuring the net without 
that standard measure of how much better it is 
against resistant mosquitoes or for resistance 
prevention.’ (Donor)  
13 Affordability Price ‘I think the other big chunk is getting the funders 
happy with the idea that they’re going to have to pay 
more for the nets. It’s unrealistic to expect these 
products to arrive at the same price that the 
pyrethroid bed nets are today and the intervention 
funders need to get their minds around that.’ (Private 
sector) 
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Annex 19: Chapter 5 Burkina Faso Analysis Supplementary Quotes 
SN Research Finding Supplementary illustrative quote 
1 The PNLP drafts the policy 
document and politicians at the 
highest level endorse it 
“To summarise, … it is up to the politicians to decide, 
especially those who are at the ministry level, at the 
National Assembly (Parliament), it is up to them to 
decide; yes we are going for a particular strategy, no 
we do not go.” (NGO) 
2 Policies are developed by PNLP 
with input from partners 
“It is at the development stage that the technical 
department in charge of the issue will consult the 
other partners like us, the WHO, the UNICEF, all these 
partners are already involved in the development of 
the draft.” (NGO) 
3 Policymakers as technicians “There are technicians first who work in the shade. I 
mean the national program for malaria control (PNLP). 
These technicians draft all... strategies about malaria 
control.” (NGO) 
4 Power as to influence opinion In different countries they [WHO] act as a Special 
Advisor to the Ministry of Health, and most of the 
strategies put into practice to counter lots of diseases 
are, to a certain extent, dictated by the WHO, who 
conducts countless studies and offers solutions to 
countries….And in general, WHO is also the 
organisation that provides guidance to various 
donors.” (Donor) 
5 Financial power Global Fund is providing a very significant financial 
support, [compared to] the other partners provide 
[who provide] very little financial support.” 
(Multilateral) 
6 Financial resources influence 
policy adoption 
“When it [research] is confirmed at the international 
level, now the funding bodies now adopt that strategy 
and now come to the country and suggest activities to 
the country saying ‘these are the new strategy that we 
have resources to support…if you are interested’. So 
based on that also, the Comité de Pilotage decides to 
go with that new strategy” (Researcher) 
7 National research indirectly 
influences national policymaking 
“I say that this is nice, you need to produce nice result, 
but you will change the situation not directly but 
indirectly.” (Researcher)  
8 The decision to procure PBO LLINs 
was not made nationally. 
‘I didn’t buy myself…. when they [the procurement 
agency] buy, they come with PermaNet 3.0’ 
(Policymaker) 
9 Individual interests can affect 
choice of vector control tool 
“Do you think this decision maker will let you 
popularise your new technique that will prevent him 
from importing mosquito nets and therefore lose his 
contract percentage” (NGO) 
 10 WHO recommendations 
influences donor  
“Donors will fund, if you use a method that has been 
proven, which has been recognised by the WHO as a 
valid mandate’ (Donor) 
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11 The need to meet set target is 
jeopardised if the new tool is 
more expensive and the resource 
envelope is fixed. 
“I think the first priority should be letting everybody 
have access first of all as a minimum and now start 
improving it.” (Researcher)  
12 National funding is a way to 
improve affordability and 
availability of new tools. 
“Poor availability of nets can be caused by the political 
commitment. It is also the absence of a national 
budget line; if we count only on the partners to acquire 
it.” (NGO) 
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Annex 20: Publication – Nigeria Analysis 
 
